

# The Androgen Excess and PCOS Society criteria for the complete task force report

Fertility and Sterility

91, 456-488

DOI: [10.1016/j.fertnstert.2008.06.035](https://doi.org/10.1016/j.fertnstert.2008.06.035)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Frequency and outcome of treatment in polycystic ovaries related infertility. Pakistan Journal of Medical Sciences, 1969, 31, 694-9.	0.6	4
2	Influence of pesticides on male fertility. Scandinavian Journal of Work, Environment and Health, 2007, 33, 13-28.	3.4	83
3	Role of Haptoglobin in Polycystic Ovary Syndrome (PCOS), Obesity and Disorders of Glucose Tolerance in Premenopausal Women. PLoS ONE, 2009, 4, e5606.	2.5	31
4	Metabolic syndrome and polycystic ovary syndrome... and vice versa. Arquivos Brasileiros De Endocrinologia E Metabologia, 2009, 53, 227-237.	1.3	48
5	Polycystic Ovary Syndrome â€” â€œA Riddle Wrapped in a Mystery inside an Enigmaâ€•. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1883-1885.	3.6	30
6	Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Human Reproduction Update, 2009, 15, 477-488.	10.8	284
7	Comparison of Simvastatin and Metformin in Treatment of Polycystic Ovary Syndrome: Prospective Randomized Trial. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4938-4945.	3.6	85
8	Early Origins of Polycystic Ovary Syndrome: Hypotheses May Change without Notice. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3682-3685.	3.6	28
9	Asymptomatic Volunteers with a Polycystic Ovary Are a Functionally Distinct but Heterogeneous Population. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1579-1586.	3.6	56
10	Polycystic Ovarian Syndrome and the Risk of Cardiovascular Disease and Thrombosis. Seminars in Thrombosis and Hemostasis, 2009, 35, 613-620.	2.7	44
11	Pharmacogenomics of ovulation induction: facilitating decisions on who, when and how to treat. Pharmacogenomics, 2009, 10, 1377-1379.	1.3	7
12	Female Infertility: A Systematic Approach to Radiologic Imaging and Diagnosis. Radiographics, 2009, 29, 1353-1370.	3.3	145
13	Dissociation of endothelial function and arterial stiffness in nonobese women with polycystic ovary syndrome (PCOS). Clinical Endocrinology, 2009, 71, 808-814.	2.4	33
14	Adiponectin levels in adolescent girls with polycystic ovary syndrome (PCOS). Clinical Endocrinology, 2009, 71, 823-827.	2.4	20
15	Expression of 11 $\beta$ -hydroxysteroid dehydrogenase 1 and 2 in subcutaneous adipose tissue of lean and obese women with and without polycystic ovary syndrome. International Journal of Obesity, 2009, 33, 1249-1256.	3.4	26
16	The Mammalian Ovary from Genesis to Revelation. Endocrine Reviews, 2009, 30, 624-712.	20.1	630
17	Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndrome. Fertility and Sterility, 2009, 91, e2-e2.	1.0	0
18	Criteria for the polycystic ovary syndrome. Fertility and Sterility, 2009, 92, e14.	1.0	0

#	ARTICLE	IF	CITATIONS
19	Reply of the Authors: Criteria for the polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2009, 92, e15.	1.0	2
20	Reduced serum ghrelin in a putative postmenopausal polycystic ovary syndrome phenotype. <i>Fertility and Sterility</i> , 2009, 92, 1753-1754.	1.0	3
21	Adiponectin levels reflect the different phenotypes of polycystic ovary syndrome: study in normal weight, normoinsulinemic patients. <i>Fertility and Sterility</i> , 2009, 92, 2078-2081.	1.0	14
22	Adipose tissue expandability and the early origins of PCOS. <i>Trends in Endocrinology and Metabolism</i> , 2009, 20, 418-423.	7.1	88
23	Evaluation and Management of Polycystic Ovary Syndrome. <i>Journal of Pediatric Health Care</i> , 2009, 23, 337-343.	1.2	5
24	Dietary intakes in infertile women a pilot study. <i>Nutrition Journal</i> , 2009, 8, 53.	3.4	18
25	Omega-3 Fatty Acid Supplementation Decreases Liver Fat Content in Polycystic Ovary Syndrome: A Randomized Controlled Trial Employing Proton Magnetic Resonance Spectroscopy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3842-3848.	3.6	164
26	The biology of gonadotroph regulation. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2009, 16, 321-327.	2.3	73
27	Polycystic Ovary Syndrome in Adolescents. <i>Current Women's Health Reviews</i> , 2010, 6, 108-122.	0.2	0
28	Role of Oxidative Stress in Polycystic Ovary Syndrome. <i>Current Women's Health Reviews</i> , 2010, 6, 96-107.	0.2	69
30	Overview and definitions of polycystic ovary syndrome and the polycystic ovary. , 0, , 1-12.		0
31	Risk of impaired glucose tolerance in normal weight hirsute women during four years observation. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2010, 89, 1091-1095.	2.8	4
32	Polycystic ovary syndrome. <i>Frontiers of Medicine in China</i> , 2010, 4, 280-284.	0.1	14
33	An algorithm for treatment of infertile women with polycystic ovary syndrome. <i>Middle East Fertility Society Journal</i> , 2010, 15, 231-239.	1.5	7
34	Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. <i>BMC Medicine</i> , 2010, 8, 41.	5.5	950
35	Current knowledge of obesity's effects in the pre- and periconceptional periods and avenues for future research. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 203, 525-530.	1.3	158
36	Evidence that obesity and androgens have independent and opposing effects on gonadotropin production from puberty to maturity. <i>Brain Research</i> , 2010, 1364, 186-197.	2.2	74
37	Direct measurement of serum free testosterone by ultrafiltration followed by liquid chromatography tandem mass spectrometry. <i>Clinical Biochemistry</i> , 2010, 43, 490-496.	1.9	37

#	ARTICLE	IF	CITATIONS
38	Report of the international symposium: polycystic ovary syndrome: first Latin-American consensus. International Journal of Clinical Practice, 2010, 64, 544-557.	1.7	10
39	Androgenetic alopecia in the paediatric population: a retrospective review of 57 patients. British Journal of Dermatology, 2010, 163, 378-385.	1.5	57
40	Obesity impairs general health-related quality of life (HR&QoL) in premenopausal women to a greater extent than polycystic ovary syndrome (PCOS). Clinical Endocrinology, 2010, 73, 595-601.	2.4	19
41	Ethnic differences in Rotterdam criteria and metabolic risk factors in a multiethnic group of women with PCOS studied in Denmark. Clinical Endocrinology, 2010, 73, 732-738.	2.4	58
42	Interventional studies for polycystic ovarian syndrome in children and adolescents. Pediatric Health, 2010, 4, 59-73.	0.3	9
43	A Single Nucleotide Polymorphism in <i>STK11</i> Influences Insulin Sensitivity and Metformin Efficacy in Hyperinsulinemic Girls With Androgen Excess. Diabetes Care, 2010, 33, 1544-1548.	8.6	31
44	Live birth prediction in polycystic ovary syndrome. Nature Reviews Endocrinology, 2010, 6, 64-66.	9.6	3
45	Retrospective observational study on the effects and tolerability of flutamide in a large population of patients with various kinds of hirsutism over a 15-year period. European Journal of Endocrinology, 2010, 163, 139-147.	3.7	24
46	Fibrillins in Adult Human Ovary and Polycystic Ovary Syndrome: Is Fibrillin-3 Affected in PCOS?. Journal of Histochemistry and Cytochemistry, 2010, 58, 903-915.	2.5	38
47	LH Dynamics in Overweight Girls with Premature Adrenarche and Slowly Progressive Sexual Precocity. International Journal of Pediatric Endocrinology (Springer), 2010, 2010, 1-12.	1.6	10
48	Prevalence of Polycystic Ovary Syndrome and Related Disorders in Mexican Women. Gynecologic and Obstetric Investigation, 2010, 69, 274-280.	1.6	111
49	Endocrinology of hirsutism. International Journal of Trichology, 2010, 2, 30.	0.5	22
50	Thiazolidinedione treatment in PCOS – an update. Gynecological Endocrinology, 2010, 26, 791-803.	1.7	22
51	Polycystic Ovary Syndrome in the Pediatric Population. Metabolic Syndrome and Related Disorders, 2010, 8, 375-394.	1.3	70
52	Current evidence of acupuncture on polycystic ovarian syndrome. Gynecological Endocrinology, 2010, 26, 473-478.	1.7	30
53	Hirsutism: investigation and management. Expert Review of Endocrinology and Metabolism, 2010, 5, 189-195.	2.4	4
54	Hirsutism: from Brazil to a place near you. Expert Opinion on Pharmacotherapy, 2010, 11, 177-183.	1.8	1
55	Proteomic Analysis of Plasma in the Polycystic Ovary Syndrome Identifies Novel Markers Involved in Iron Metabolism, Acute-Phase Response, and Inflammation. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3863-3870.	3.6	60

#	ARTICLE	IF	CITATIONS
56	Polycystic ovary syndrome: steroid assessment for diagnosis. <i>Nature Reviews Endocrinology</i> , 2010, 6, 305-307.	9.6	3
57	Insulin resistance in polycystic ovary syndrome: maker or marker?. <i>Expert Review of Obstetrics and Gynecology</i> , 2010, 5, 67-75.	0.4	4
58	Defining hyperandrogenism in polycystic ovary syndrome: measurement of testosterone and androstenedione by liquid chromatography-tandem mass spectrometry and analysis by receiver operator characteristic plots. <i>European Journal of Endocrinology</i> , 2010, 162, 611-615.	3.7	60
59	Assessment of theca cell function prior to controlled ovarian stimulation: the predictive value of serum basal/stimulated steroid levels. <i>Human Reproduction</i> , 2010, 25, 228-234.	0.9	23
60	Is polycystic ovary syndrome an exception for reproductive aging?. <i>Human Reproduction</i> , 2010, 25, 1775-1781.	0.9	89
61	Apoptotic Markers Indicate Nonalcoholic Steatohepatitis in Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 343-348.	3.6	50
62	Treatment of Polycystic Ovary Syndrome (PCOS) with Metformin Ameliorates Insulin Resistance in Parallel with the Decrease of Serum Interleukin-6 Concentrations. <i>Hormone and Metabolic Research</i> , 2010, 42, 815-820.	1.5	34
63	Are There Any Sensitive and Specific Sex Steroid Markers for Polycystic Ovary Syndrome?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 810-819.	3.6	113
64	Anxiety and depression symptoms in women with polycystic ovary syndrome compared with controls matched for body mass index. <i>Human Reproduction</i> , 2010, 25, 450-456.	0.9	143
65	Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. <i>European Journal of Endocrinology</i> , 2010, 162, 193-212.	3.7	199
66	HbA1c levels for the diagnosis of diabetes mellitus in children. <i>Nature Reviews Endocrinology</i> , 2010, 6, 304-305.	9.6	1
67	Lack of association between CYP21 V281L variant and polycystic ovary syndrome in Italian women. <i>Gynecological Endocrinology</i> , 2010, 26, 596-599.	1.7	5
68	Polycystic Ovarian Syndrome in Taiwanese Women. <i>Journal of Experimental and Clinical Medicine</i> , 2010, 2, 218-223.	0.2	4
69	Intense electroacupuncture normalizes insulin sensitivity, increases muscle GLUT4 content, and improves lipid profile in a rat model of polycystic ovary syndrome. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2010, 299, E551-E559.	3.5	75
70	Visually scoring hirsutism. <i>Human Reproduction Update</i> , 2010, 16, 51-64.	10.8	272
71	Assessment of diagnostic competence of plasmatic androgens on polycystic ovary syndrome based on receiver operator characteristic curves. <i>Gynecological Endocrinology</i> , 2010, 26, 600-606.	1.7	8
72	Insulin and hyperandrogenism in women with polycystic ovary syndrome. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2010, 122, 42-52.	2.5	229
74	Not all women diagnosed with PCOS share the same cardiovascular risk profiles. <i>Fertility and Sterility</i> , 2010, 94, 826-832.	1.0	56

#	ARTICLE	IF	CITATIONS
75	Visfatin and leptin levels in women with polycystic ovaries undergoing ovarian stimulation. <i>Fertility and Sterility</i> , 2010, 94, 1451-1456.	1.0	51
76	Menstrual cycle irregularities and their relationship with HbA1c and insulin dose in adolescents with type 1 diabetes mellitus. <i>Fertility and Sterility</i> , 2010, 94, 1822-1826.	1.0	54
77	Re: Clinical and biochemical presentations of polycystic ovary syndrome among obese and nonobese women. <i>Fertility and Sterility</i> , 2010, 93, e27.	1.0	0
78	Variation in metabolic and cardiovascular risk in women with different polycystic ovary syndrome phenotypes. <i>Fertility and Sterility</i> , 2010, 94, 2493-2496.	1.0	78
79	Normal serum concentrations of anti-Müllerian hormone in women with regular menstrual cycles. <i>Reproductive BioMedicine Online</i> , 2010, 21, 463-469.	2.4	91
80	Assessment of Cardiovascular Risk and Prevention of Cardiovascular Disease in Women with the Polycystic Ovary Syndrome: A Consensus Statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2038-2049.	3.6	831
81	Case 20-2010. <i>New England Journal of Medicine</i> , 2010, 363, 178-186.	27.0	3
82	An update on the pathogenesis, inflammation, and metabolism in hirsutism and polycystic ovary syndrome. <i>Gynecological Endocrinology</i> , 2010, 26, 281-296.	1.7	133
83	Polycystic Ovary Syndrome and Weight Management. <i>Women's Health</i> , 2010, 6, 271-283.	1.5	54
84	Oocyte-thecal Cell Regulatory Loop in the Control of Preantral Follicle Development. <i>Journal of Mammalian Ova Research</i> , 2011, 28, 2-7.	0.1	0
85	Oral contraceptives in polycystic ovarian syndrome: the long and short of it. <i>Expert Review of Endocrinology and Metabolism</i> , 2011, 6, 129-133.	2.4	0
86	Diet composition and physical activity in overweight and obese premenopausal women with or without polycystic ovary syndrome. <i>Gynecological Endocrinology</i> , 2011, 27, 978-981.	1.7	31
87	Clinical, ultrasound and biochemical features of polycystic ovary syndrome in adolescents: implications for diagnosis. <i>Human Reproduction</i> , 2011, 26, 1469-1477.	0.9	133
88	Sex Steroid Hormones and Reproductive Disorders. <i>Reproductive Sciences</i> , 2011, 18, 702-712.	2.5	24
89	Depression, anxiety and cardiometabolic risk in polycystic ovary syndrome. <i>Human Reproduction</i> , 2011, 26, 3339-3345.	0.9	122
90	PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. <i>Human Reproduction Update</i> , 2011, 17, 495-500.	10.8	310
91	Endometrium in women with polycystic ovary syndrome during the window of implantation. <i>Revista Da Associação Médica Brasileira (English Edition)</i> , 2011, 57, 688-695.	0.1	17
92	Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. <i>Nature Reviews Endocrinology</i> , 2011, 7, 219-231.	9.6	1,062

#	ARTICLE	IF	CITATIONS
93	Acupuncture for polycystic ovarian syndrome. , 2011, , CD007689.		20
94	Effect of high-protein or normal-protein diet on weight loss, body composition, hormone, and metabolic profile in southern Brazilian women with polycystic ovary syndrome: a randomized study. Gynecological Endocrinology, 2011, 27, 925-930.	1.7	40
95	Retrospective, observational study on the effects and tolerability of flutamide in a large population of patients with acne and seborrhea over a 15-year period. Gynecological Endocrinology, 2011, 27, 823-829.	1.7	17
96	Ethinylestradiol/Chlormadinone Acetate for Use in Dermatological Disorders. American Journal of Clinical Dermatology, 2011, 12, 13-19.	6.7	5
97	Medical and Behavioral Evaluation of Patients with Obesity. Psychiatric Clinics of North America, 2011, 34, 797-812.	1.3	9
98	EndomÃ©trio na janela de implantaÃ§Ã£o em mulheres com sÃndrome dos ovÃrios policÃsticos. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2011, 57, 702-709.	0.7	33
100	Polycystic ovarian morphology in postmenarchal adolescents. Fertility and Sterility, 2011, 95, 702-706.e2.	1.0	86
101	Polycystic ovary syndrome and maternal obesity affect oocyte size in in vitro fertilization/intracytoplasmic sperm injection cycles. Fertility and Sterility, 2011, 95, 2146-2149.e1.	1.0	95
102	Racial influence on the polycystic ovary syndrome phenotype: a black and white case-control study. Fertility and Sterility, 2011, 96, 224-229.e2.	1.0	27
103	Polycystic ovary syndrome is associated with negatively variable impacts on domains of health-related quality of life: evidence from a meta-analysis. Fertility and Sterility, 2011, 96, 452-458.	1.0	73
104	Blood pressure regulation and resting heart rate abnormalities in adolescent girls with polycystic ovary syndrome. Fertility and Sterility, 2011, 96, 1519-1525.	1.0	16
105	Vocal Changes in Patients With Polycystic Ovary Syndrome. Journal of Voice, 2011, 25, 501-504.	1.5	15
106	Cardiovascular risk in postmenopausal women with the polycystic ovary syndrome. Maturitas, 2011, 68, 13-16.	2.4	45
107	Mutations of the hexose-6-phosphate dehydrogenase gene rarely cause hyperandrogenemic polycystic ovary syndrome. Steroids, 2011, 76, 135-139.	1.8	11
108	CYP19 gene expression in subcutaneous adipose tissue is associated with blood pressure in women with polycystic ovary syndrome. Steroids, 2011, 76, 1383-1388.	1.8	10
109	Metabolic syndrome and oocyte quality. Trends in Endocrinology and Metabolism, 2011, 22, 103-109.	7.1	100
110	Insulin resistance is not strictly associated with energy intake or dietary macronutrient composition in women with polycystic ovary syndrome. Nutrition Research, 2011, 31, 97-103.	2.9	33
111	Hirsutismo: diagnÃ³stico y conducta prÃ¡ctica. EMC - Tratado De Medicina, 2011, 15, 1-6.	0.0	0

#	ARTICLE	IF	CITATIONS
112	Low estradiol-to-testosterone ratio is associated with oligo-anovulatory cycles and atherogenic lipidic pattern in women with polycystic ovary syndrome. <i>Gynecological Endocrinology</i> , 2011, 27, 579-586.	1.7	18
113	Inappropriate gonadotropin secretion in polycystic ovary syndrome: The relationship with clinical, hormonal and metabolic characteristics. <i>Korean Journal of Obstetrics &amp; Gynecology</i> , 2011, 54, 659.	0.1	6
114	The Hirsute Woman: Challenges in Evaluation and Management. <i>Endocrine Practice</i> , 2011, 17, 807-818.	2.1	22
115	A rational approach to the diagnosis of polycystic ovarian syndrome during adolescence. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2011, 55, 590-598.	1.3	26
116	Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline. <i>Medical Journal of Australia</i> , 2011, 195, S65-112.	1.7	282
117	Secondary infertility in women: radiologic evaluation. <i>Reports in Medical Imaging</i> , 2011, , 1.	0.8	5
118	Management of Polycystic Ovary Syndrome in the Non-Infertility Patient. <i>Postgraduate Obstetrics &amp; Gynecology</i> , 2011, 31, 1-7.	0.1	0
119	Management of Polycystic Ovary Syndrome in the Non-Infertility Patient. <i>Postgraduate Obstetrics &amp; Gynecology</i> , 2011, 31, 8.	0.1	0
120	Insulin Resistance in Childhood and Adolescence. , 2011, , 294-309.		1
121	Assessing the Function of the Human Adrenal Cortex. , 2011, , 350-378.		4
122	S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. <i>British Journal of Dermatology</i> , 2011, 164, 5-15.	1.5	172
123	Prenatal Programming by Testosterone of Hypothalamic Metabolic Control Neurones in the Ewe. <i>Journal of Neuroendocrinology</i> , 2011, 23, 401-411.	2.6	40
124	Polycystic Ovary Syndrome: Evidence-based Strategies for Managing Symptoms and Preventing Long-term Sequelae. <i>Nursing for Women's Health</i> , 2011, 15, 402-411.	0.8	2
125	Distinctive Features of Female-to-Male Transsexualism and Prevalence of Gender Identity Disorder in Japan. <i>Journal of Sexual Medicine</i> , 2011, 8, 1686-1693.	0.6	56
126	Sexual differentiation of human behavior: Effects of prenatal and pubertal organizational hormones. <i>Frontiers in Neuroendocrinology</i> , 2011, 32, 183-200.	5.2	276
127	State of the Art Review: Emerging Therapies: The Use of Insulin Sensitizers in the Treatment of Adolescents with Polycystic Ovary Syndrome (PCOS). <i>International Journal of Pediatric Endocrinology (Springer)</i> , 2011, 2011, 9.	1.6	54
128	Pregnancy outcomes in women with polycystic ovary syndrome: a metaanalysis. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 204, 558.e1-558.e6.	1.3	216
129	Cardiovascular-Renal and Metabolic Characterization of a Rat Model of Polycystic Ovary Syndrome. <i>Gender Medicine</i> , 2011, 8, 103-115.	1.4	81



#	ARTICLE	IF	CITATIONS
130	The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study. <i>Journal of Assisted Reproduction and Genetics</i> , 2011, 28, 591-596.	2.5	34
131	Cardiovascular disease risk characteristics of the main polycystic ovary syndrome phenotypes. <i>Endocrine</i> , 2011, 39, 272-277.	2.3	32
132	The prevalence of idiopathic hirsutism and polycystic ovary syndrome in the Tehran Lipid and Glucose Study. <i>Reproductive Biology and Endocrinology</i> , 2011, 9, 144.	3.3	54
133	The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study. <i>Reproductive Biology and Endocrinology</i> , 2011, 9, 39.	3.3	204
134	Early Metformin Therapy (Age 8–12 Years) in Girls with Precocious Pubarche to Reduce Hirsutism, Androgen Excess, and Oligomenorrhea in Adolescence. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E1262-E1267.	3.6	104
135	Sonographic Measurement of Mesenteric Fat Predicts Presence of Fatty Liver among Subjects with Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 799-807.	3.6	36
136	Effects of Simvastatin and Metformin on Polycystic Ovary Syndrome after Six Months of Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 3493-3501.	3.6	98
137	Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome. <i>European Journal of Endocrinology</i> , 2011, 164, 53-60.	3.7	78
138	An Analysis of Online Resources for Women with Polycystic Ovary Syndrome. <i>Journal of Consumer Health on the Internet</i> , 2011, 15, 361-369.	0.4	4
139	Cushing's syndrome: Stepwise approach to diagnosis. <i>Indian Journal of Endocrinology and Metabolism</i> , 2011, 15, 317.	0.4	12
140	Polycystic Ovary Syndrome. <i>Clinical Obstetrics and Gynecology</i> , 2011, 54, 675-684.	1.1	16
141	Cholesterol, endocrine and metabolic disturbances in sporadic anovulatory women with regular menstruation. <i>Human Reproduction</i> , 2011, 26, 423-430.	0.9	17
142	Assessment of hirsutism among Korean women: results of a randomly selected sample of women seeking pre-employment physical check-up. <i>Human Reproduction</i> , 2011, 26, 214-220.	0.9	56
143	High serum dehydroepiandrosterone sulfate is associated with phenotypic acne and a reduced risk of abdominal obesity in women with polycystic ovary syndrome. <i>Human Reproduction</i> , 2011, 26, 227-234.	0.9	50
144	Polycystic ovarian morphology in adolescents with regular menstrual cycles is associated with elevated anti-Mullerian hormone. <i>Human Reproduction</i> , 2011, 26, 2861-2868.	0.9	76
145	The oligomenorrhoic phenotypes of polycystic ovary syndrome are characterized by a high visceral adiposity index: a likely condition of cardiometabolic risk. <i>Human Reproduction</i> , 2011, 26, 1486-1494.	0.9	82
146	Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgen-suppression test and a low-dose ACTH test. <i>Human Reproduction</i> , 2011, 26, 3138-3146.	0.9	53
147	Harmony and Compensation for Oocyte Providers. <i>American Journal of Bioethics</i> , 2011, 11, 39-41.	0.9	2

#	ARTICLE	IF	CITATIONS
148	Impact of electro-acupuncture and physical exercise on hyperandrogenism and oligo/amenorrhea in women with polycystic ovary syndrome: a randomized controlled trial. American Journal of Physiology - Endocrinology and Metabolism, 2011, 300, E37-E45.	3.5	165
149	Reproduction in females: the role of the early life environment. Human Reproduction Update, 2011, 17, 210-227.	10.8	81
150	Cryptotanshinone reverses reproductive and metabolic disturbances in prenatally androgenized rats via regulation of ovarian signaling mechanisms and androgen synthesis. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2011, 300, R869-R875.	1.8	24
151	Uterine Morphology and Peristalsis in Women with Polycystic Ovary Syndrome. Acta Radiologica, 2012, 53, 1195-1201.	1.1	22
152	Polycystic Ovarian Syndrome: Metformin or Thiazolidinediones for Cardiovascular Risk Reduction?. Diabetes Spectrum, 2012, 25, 229-237.	1.0	3
153	Maternal androgen excess reduces placental and fetal weights, increases placental steroidogenesis, and leads to long-term health effects in their female offspring. American Journal of Physiology - Endocrinology and Metabolism, 2012, 303, E1373-E1385.	3.5	90
154	Association of polycystic ovary syndrome and Graves's disease: Is autoimmunity the link between the two diseases. Indian Journal of Endocrinology and Metabolism, 2012, 16, 982.	0.4	20
155	Hyperandrogenism Does Not Influence Metabolic Parameters in Adolescent Girls with PCOS. International Journal of Endocrinology, 2012, 2012, 1-5.	1.5	19
156	Polycystic Ovary Syndrome with Hyperandrogenism Is Characterized by an Increased Risk of Hepatic Steatosis Compared to Nonhyperandrogenic PCOS Phenotypes and Healthy Controls, Independent of Obesity and Insulin Resistance. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3709-3716.	3.6	198
157	Polycystic ovary syndrome in adolescents. Current Opinion in Obstetrics and Gynecology, 2012, 24, 281-287.	2.0	20
158	Adolescent Gynecology. Clinical Obstetrics and Gynecology, 2012, 55, 651-661.	1.1	8
159	Diagnosis and treatment of polycystic ovarian syndrome in adolescents. Current Opinion in Endocrinology, Diabetes and Obesity, 2012, 19, 497-504.	2.3	30
160	Clinical update on screening, diagnosis and management of metabolic disorders and cardiovascular risk factors associated with polycystic ovary syndrome. Current Opinion in Endocrinology, Diabetes and Obesity, 2012, 19, 512-519.	2.3	27
161	Reproductive impact of polycystic ovary syndrome. Current Opinion in Endocrinology, Diabetes and Obesity, 2012, 19, 505-511.	2.3	31
162	Effects of increased dietary protein-to-carbohydrate ratios in women with polycystic ovary syndrome. American Journal of Clinical Nutrition, 2012, 95, 39-48.	4.7	55
163	Hyperandrogenism in Adolescent Girls. Endocrine Development, 2012, 22, 181-193.	1.3	18
164	Polycystic Ovary Syndrome Is Associated with Higher Left Ventricular Mass Index: The CARDIA Women's Study. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4656-4662.	3.6	35
165	Insulin Resistance and Polycystic Ovary Syndrome Through Life. Current Pharmaceutical Design, 2012, 18, 5569-5576.	1.9	40

#	ARTICLE	IF	CITATIONS
166	Common variants in the sex hormone-binding globulin gene (SHBG) and polycystic ovary syndrome (PCOS) in Mediterranean women. <i>Human Reproduction</i> , 2012, 27, 3569-3576.	0.9	39
167	Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study. <i>Human Reproduction</i> , 2012, 27, 541-549.	0.9	117
168	Relative Contributions of Oligomenorrhea and Hyperandrogenemia to the Risk of Metabolic Syndrome in Midlife Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E868-E877.	3.6	39
169	Therapeutic implications of vitamin D and calcium in overweight women with polycystic ovary syndrome. <i>Gynecological Endocrinology</i> , 2012, 28, 965-968.	1.7	108
170	Comparison of the phenotype of Chinese versus Dutch Caucasian women presenting with polycystic ovary syndrome and oligo/amenorrhoea. <i>Human Reproduction</i> , 2012, 27, 1481-1488.	0.9	38
171	Infertility Treatment in Polycystic Ovary Syndrome: Lifestyle Interventions, Medications and Surgery. <i>Frontiers of Hormone Research</i> , 2013, 40, 128-141.	1.0	17
172	Hirsutism “ From Diagnosis to Use of Antiandrogens. <i>Frontiers of Hormone Research</i> , 2013, 40, 103-114.	1.0	6
173	MECHANISMS IN ENDOCRINOLOGY: Recent advances in cardiovascular aspects of polycystic ovary syndrome. <i>European Journal of Endocrinology</i> , 2012, 166, 575-583.	3.7	51
174	Increased frequency of the DI genotype of the angiotensin-I converting enzyme and association of the II genotype with insulin resistance in polycystic ovary syndrome. <i>European Journal of Endocrinology</i> , 2012, 166, 695-702.	3.7	15
175	Higher ghrelin and lower leptin secretion are associated with lower LH secretion in young amenorrheic athletes compared with eumenorrheic athletes and controls. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2012, 302, E800-E806.	3.5	91
176	Subfertility and risk of later life maternal cardiovascular disease. <i>Human Reproduction</i> , 2012, 27, 568-575.	0.9	79
177	Prevalence of functional disorders of androgen excess in unselected premenopausal women: a study in blood donors. <i>Human Reproduction</i> , 2012, 27, 1209-1216.	0.9	72
178	Phenotypes and Enviromental Factors: Their Influence in PCOS. <i>Current Pharmaceutical Design</i> , 2012, 18, 270-282.	1.9	78
179	Androgens and polycystic ovary syndrome. <i>Expert Review of Endocrinology and Metabolism</i> , 2012, 7, 91-102.	2.4	9
180	Call for Papers: Geriatric Medicine and End-of-Life Care Deadline June 1, 2013. <i>Linacre quarterly</i> , The, 2012, 79, 505-505.	0.2	0
181	The Importance of Fertility Awareness in the Assessment of a Woman's Health a Review. <i>Linacre quarterly</i> , The, 2012, 79, 426-450.	0.2	19
182	Serum Levels of Angiopoietin-Related Growth Factor (AGF) Are Increased in Polycystic Ovary Syndrome. <i>Journal of Investigative Medicine</i> , 2012, 60, 813-817.	1.6	10
183	The prevalence of endometrial hyperplasia and endometrial cancer in women with polycystic ovary syndrome or hyperandrogenism. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2012, 91, 1173-1176.	2.8	29

#	ARTICLE	IF	CITATIONS
184	Ovarian stromal vessels assessed by spatiotemporal image correlation—high definition flow in women with polycystic ovary syndrome: a case—control study. <i>Ultrasound in Obstetrics and Gynecology</i> , 2012, 40, 470-475.	1.7	27
185	Polycystic Ovarian Syndrome Management Options. <i>Obstetrics and Gynecology Clinics of North America</i> , 2012, 39, 495-506.	1.9	16
186	Management of Postmenopausal Virilization. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2584-2588.	3.6	66
187	Therapeutic effects of calcium & vitamin D supplementation in women with PCOS. <i>Complementary Therapies in Clinical Practice</i> , 2012, 18, 85-88.	1.7	93
188	Metformin Inhibits Human Androgen Production by Regulating Steroidogenic Enzymes HSD3B2 and CYP17A1 and Complex I Activity of the Respiratory Chain. <i>Endocrinology</i> , 2012, 153, 4354-4366.	2.8	73
189	Different diagnostic power of anti-Mullerian hormone in evaluating women with polycystic ovaries with and without hyperandrogenism. <i>Journal of Assisted Reproduction and Genetics</i> , 2012, 29, 1147-1151.	2.5	19
190	Adipose tissue insulin resistance in peripubertal girls with first-degree family history of polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2012, 98, 1627-1634.	1.0	31
191	The Female Athlete Triad. <i>Sports Health</i> , 2012, 4, 302-311.	2.7	109
192	Malignant Ovarian Sertoli-Leydig Cell Tumor Localized With Selective Ovarian Vein Sampling. <i>Journal of Minimally Invasive Gynecology</i> , 2012, 19, 789-793.	0.6	4
193	Severe Hyperandrogenemia and Insulin Resistance in a 12-Year-Old Girl. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2012, 25, e99-e101.	0.7	2
194	Síndrome de ovario poliquístico en adolescentes. <i>Anales De Pediatría Continuada</i> , 2012, 10, 257-263.	0.1	1
195	Clinical Variability in Approaches to Polycystic Ovary Syndrome. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2012, 25, 259-261.	0.7	32
196	Rodent Models for Human Polycystic Ovary Syndrome1. <i>Biology of Reproduction</i> , 2012, 86, 149, 1-12.	2.7	227
197	Inflammation in Polycystic Ovary Syndrome: Underpinning of insulin resistance and ovarian dysfunction. <i>Steroids</i> , 2012, 77, 300-305.	1.8	328
198	Surgical management of metabolic dysfunction in PCOS. <i>Steroids</i> , 2012, 77, 312-316.	1.8	23
199	Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. <i>Human Reproduction Update</i> , 2012, 18, 146-170.	10.8	367
200	Metabolic manifestations of polycystic ovary syndrome in obese adolescents: retinol-binding protein 4 and ectopic fat deposition. <i>Fertility and Sterility</i> , 2012, 97, 1009-1015.	1.0	10
201	Anti-Müllerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries. <i>Fertility and Sterility</i> , 2012, 98, 242-249.e4.	1.0	71

#	ARTICLE	IF	CITATIONS
202	Animal models of polycystic ovary syndrome: a focused review of rodent models in relationship to clinical phenotypes and cardiometabolic risk. <i>Fertility and Sterility</i> , 2012, 98, 185-193.e2.	1.0	103
203	The R453Q and D151A polymorphisms of Hexose-6-Phosphate Dehydrogenase Gene (H6PD) influence the polycystic ovary syndrome (PCOS) and obesity. <i>Gene</i> , 2012, 497, 38-44.	2.2	14
204	Insulin Resistance and the Polycystic Ovary Syndrome Revisited: An Update on Mechanisms and Implications. <i>Endocrine Reviews</i> , 2012, 33, 981-1030.	20.1	1,301
205	Menstrual pattern and menstrual disorders among adolescents: an update of the Italian data. <i>Italian Journal of Pediatrics</i> , 2012, 38, 38.	2.6	84
206	The effects of treatment with drospirenone/ethinyl oestradiol alone or in combination with metformin on elastic properties of aorta in women with polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2012, 77, 885-892.	2.4	16
207	Pervasive developmental disorders in children of hyperandrogenic women with polycystic ovary syndrome: a longitudinal case-control study. <i>Clinical Endocrinology</i> , 2012, 77, 898-904.	2.4	116
208	Metabolic Heterogeneity in Polycystic Ovary Syndrome Is Determined by Obesity: Plasma Metabolomic Approach Using GC-MS. <i>Clinical Chemistry</i> , 2012, 58, 999-1009.	3.2	94
209	Serum Anti-Müllerian Hormone Levels in Healthy Females: A Nomogram Ranging from Infancy to Adulthood. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 4650-4655.	3.6	203
210	The Link between Polycystic Ovary Syndrome and both Type 1 and Type 2 Diabetes Mellitus: What Do we Know Today?. <i>Women's Health</i> , 2012, 8, 147-154.	1.5	19
211	Demystifying Ovarian Cysts. <i>Ultrasound Clinics</i> , 2012, 7, 75-91.	0.2	2
212	Abnormal Expression of Genes Involved in Inflammation, Lipid Metabolism, and Wnt Signaling in the Adipose Tissue of Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E765-E770.	3.6	67
213	Iron metabolism and the polycystic ovary syndrome. <i>Trends in Endocrinology and Metabolism</i> , 2012, 23, 509-515.	7.1	61
214	Analysis of mitochondrial DNA sequence variants in patients with polycystic ovary syndrome. <i>Archives of Gynecology and Obstetrics</i> , 2012, 286, 653-659.	1.7	35
215	Polycystic Ovarian Syndrome: Role of Imaging in Diagnosis. <i>Radiographics</i> , 2012, 32, 1643-1657.	3.3	45
216	A macrophage activation marker chitotriosidase in women with PCOS: does low-grade chronic inflammation in PCOS relate to PCOS itself or obesity?. <i>Archives of Gynecology and Obstetrics</i> , 2012, 286, 1065-1071.	1.7	35
217	Adipocytokine profiles in a putative novel postmenopausal polycystic ovary syndrome (PCOS) phenotype parallel those in premenopausal PCOS: the Rancho Bernardo Study. <i>Metabolism: Clinical and Experimental</i> , 2012, 61, 1238-1241.	3.4	9
218	Polycystic Ovary Syndrome: Definitions, Phenotypes and Diagnostic Approach. <i>Frontiers of Hormone Research</i> , 2013, 40, 1-21.	1.0	60
219	Aromatase Gene Polymorphism Does Not Influence Clinical Phenotype and Response to Oral Contraceptive Pills in Polycystic Ovary Syndrome Women. <i>Gynecologic and Obstetric Investigation</i> , 2012, 74, 136-142.	1.6	10

#	ARTICLE	IF	CITATIONS
220	17-hydroxysteroid dehydrogenase type 5 gene polymorphism (-71A/G HSD17B5 SNP) and treatment with oral contraceptive pills in PCOS women without metabolic comorbidities. Gynecological Endocrinology, 2012, 28, 606-610.	1.7	11
221	Prenatal Hyperandrogenization Induces Metabolic and Endocrine Alterations Which Depend on the Levels of Testosterone Exposure. PLoS ONE, 2012, 7, e37658.	2.5	47
222	Early-to-Mid Gestation Fetal Testosterone Increases Right Hand 2D~4D Finger Length Ratio in Polycystic Ovary Syndrome-Like Monkeys. PLoS ONE, 2012, 7, e42372.	2.5	63
224	Polycystic Ovary Syndrome in the Non-Gynaecological Practice â€œ Can We Use a Common Medical Approach?. , 0, , .		0
225	Incorporating patient preference into the management of infertility in women with polycystic ovary syndrome. Patient Preference and Adherence, 2012, 6, 407.	1.8	1
226	Effect of hCG priming on embryonic development of immature oocytes collected from unstimulated women with polycystic ovarian syndrome. Reproductive Biology and Endocrinology, 2012, 10, 40.	3.3	34
227	Clinical outcomes in the management of congenital adrenal hyperplasia. Endocrine, 2012, 41, 355-373.	2.3	87
228	Contraception, and pregnancy in adolescents with type 1 diabetes: a review. Pediatric Diabetes, 2012, 13, 108-123.	2.9	29
229	Non polycystic ovary syndromeâ€related endocrine disorders associated with hirsutism. European Journal of Clinical Investigation, 2012, 42, 86-94.	3.4	36
230	Ovarian failure and polycystic ovary syndrome. Autoimmunity Reviews, 2012, 11, A471-A478.	5.8	50
231	Polycystic Ovary Syndrome: A Common But Often Unrecognized Condition. Journal of Midwifery and Women's Health, 2012, 57, 221-230.	1.3	47
232	Ovulation induction in women with polycystic ovary syndrome. Steroids, 2013, 78, 767-772.	1.8	46
233	General Characteristics of Hair in Eating Disorders. , 2013, , 71-77.		0
234	Eating Disorders and the Skin. , 2013, , .		27
235	Dietary glycemic index is associated with less favorable anthropometric and metabolic profiles in polycystic ovary syndrome women with different phenotypes. Fertility and Sterility, 2013, 100, 1081-1088.	1.0	62
236	The clinical ramifications of polycystic ovarian morphology in oocyte donors. Journal of Assisted Reproduction and Genetics, 2013, 30, 233-238.	2.5	4
237	Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility. Endocrine, 2013, 44, 583-590.	2.3	72
238	Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis. Reproductive Biology and Endocrinology, 2013, 11, 56.	3.3	212



#	ARTICLE	IF	CITATIONS
239	Elevated serum levels of anti-AMH/4llarian hormone can be introduced as a new diagnostic marker for polycystic ovary syndrome. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2013, 92, 1369-1374.	2.8	56
240	Diagnosis of adolescent polycystic ovary syndrome. <i>Steroids</i> , 2013, 78, 751-754.	1.8	45
241	miRNA-93 Inhibits GLUT4 and Is Overexpressed in Adipose Tissue of Polycystic Ovary Syndrome Patients and Women With Insulin Resistance. <i>Diabetes</i> , 2013, 62, 2278-2286.	0.6	231
242	Adolescent Anovulation: Maturational Mechanisms and Implications. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3572-3583.	3.6	111
243	Gynecologic and Reproductive Health Concerns of Adolescents Using Selected Psychotropic Medications. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2013, 26, 7-15.	0.7	9
244	Menstrual dysfunction. <i>Obstetrics, Gynaecology and Reproductive Medicine</i> , 2013, 23, 307-311.	0.3	1
245	The Severity of Menstrual Dysfunction as a Predictor of Insulin Resistance in PCOS. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1967-E1971.	3.6	57
246	Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4565-4592.	3.6	1,380
247	Genetic polymorphism of vitamin D receptor gene affects the phenotype of PCOS. <i>Gene</i> , 2013, 515, 193-196.	2.2	44
248	Hypothetical physiological and molecular basis for the effect of acupuncture in the treatment of polycystic ovary syndrome. <i>Molecular and Cellular Endocrinology</i> , 2013, 373, 83-90.	3.2	23
249	Metabolically healthy polycystic ovary syndrome (MH-PCOS) and metabolically unhealthy polycystic ovary syndrome (MU-PCOS): a comparative analysis of four simple methods useful for metabolic assessment. <i>Human Reproduction</i> , 2013, 28, 1919-1928.	0.9	29
250	Management of female infertility from hormonal causes. <i>International Journal of Gynecology and Obstetrics</i> , 2013, 123, S9-17.	2.3	17
251	Using the Androgen Excess-PCOS Society Criteria to Diagnose Polycystic Ovary Syndrome and the Risk of Metabolic Syndrome in Adolescents. <i>Journal of Pediatrics</i> , 2013, 162, 937-941.	1.8	53
252	Microsatellite polymorphism in the fibrillin 3 gene and susceptibility to PCOS: a case-control study and meta-analysis. <i>Reproductive BioMedicine Online</i> , 2013, 26, 168-174.	2.4	21
253	Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. <i>Human Reproduction Update</i> , 2013, 19, 268-288.	10.8	399
254	Circulating levels and subcutaneous adipose tissue gene expression of pigment epithelium-derived factor in polycystic ovary syndrome and normal women: a case control study. <i>Reproductive Biology and Endocrinology</i> , 2013, 11, 77.	3.3	11
255	Phenotypic comparison of Caucasian and Asian women with polycystic ovary syndrome: a cross-sectional study. <i>Fertility and Sterility</i> , 2013, 100, 214-218.	1.0	32
256	Differences in the Management of Adolescents with Polycystic Ovary Syndrome across Pediatric Specialties. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2013, 26, 234-238.	0.7	32

#	ARTICLE	IF	CITATIONS
257	Ovulatory effects of flutamide in the polycystic ovary syndrome. <i>Gynecological Endocrinology</i> , 2013, 29, 391-395.	1.7	53
258	Diabetes advice for women with polycystic ovary syndrome: prevention, prevention, prevention. <i>Diabetes Management</i> , 2013, 3, 467-480.	0.5	3
259	Metabolic syndrome in patients with the polycystic ovary syndrome. <i>Expert Review of Endocrinology and Metabolism</i> , 2013, 8, 559-568.	2.4	2
260	Androgen receptor gene polymorphism and polycystic ovary syndrome. <i>International Journal of Gynecology and Obstetrics</i> , 2013, 120, 115-118.	2.3	45
261	Acupuncture in Polycystic Ovary Syndrome: Potential and Challenge. , 2013, , 487-515.		1
262	Cardiac autonomic modulation in polycystic ovary syndrome: does the phenotype matter?. <i>Fertility and Sterility</i> , 2013, 99, 286-292.	1.0	39
263	Faster thrombin generation in women with polycystic ovary syndrome compared with healthy controls matched for age and body mass index. <i>Fertility and Sterility</i> , 2013, 99, 1786-1790.	1.0	10
264	Androgens inhibit adipogenesis during human adipose stem cell commitment to preadipocyte formation. <i>Steroids</i> , 2013, 78, 920-926.	1.8	122
265	Neuroendocrine considerations in the treatment of men and women with epilepsy. <i>Lancet Neurology</i> , The, 2013, 12, 72-83.	10.2	111
266	Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20â€year retrospective cohort study. <i>Clinical Endocrinology</i> , 2013, 78, 926-934.	2.4	156
267	Divergences in Insulin Resistance Between the Different Phenotypes of the Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E628-E637.	3.6	186
268	Ontogeny of the ovary in polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2013, 100, 23-38.	1.0	95
269	Global Adiposity and Thickness of Intraperitoneal and Mesenteric Adipose Tissue Depots Are Increased in Women With Polycystic Ovary Syndrome (PCOS). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1254-1263.	3.6	103
270	Referral Bias in Defining the Phenotype and Prevalence of Obesity in Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1088-E1096.	3.6	139
271	Prevalence of metabolic syndrome in women with polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2013, 78, 586-592.	2.4	54
272	Changes in the PCOS phenotype with age. <i>Steroids</i> , 2013, 78, 761-766.	1.8	65
273	Metabolic Inflexibility Is a Feature of Women With Polycystic Ovary Syndrome and Is Associated With Both Insulin Resistance and Hyperandrogenism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2581-2588.	3.6	36
274	Polycystic ovarian syndrome during puberty and adolescence. <i>Molecular and Cellular Endocrinology</i> , 2013, 373, 61-67.	3.2	37



#	ARTICLE	IF	CITATIONS
275	Can Anti-Müllerian Hormone Predict the Diagnosis of Polycystic Ovary Syndrome? A Systematic Review and Meta-Analysis of Extracted Data. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3332-3340.	3.6	230
276	How to recognize PCOS: results of a web-based survey at IVF-worldwide.com. Reproductive BioMedicine Online, 2013, 26, 500-505.	2.4	11
277	Menstrual Disorders and Hyperandrogenism in Adolescence. , 2013, , 441-464.		0
278	Prenatal androgen excess programs metabolic derangements in pubertal female rats. Journal of Endocrinology, 2013, 217, 119-129.	2.6	41
279	I tumori androgeno-secermenti nella donna: dal sospetto clinico alla diagnosi. L Endocrinologo, 2013, 14, 243-249.	0.0	0
282	Atherogenic changes in low-density lipoprotein particle profiles were not observed in non-obese women with polycystic ovary syndrome. Human Reproduction, 2013, 28, 1354-1360.	0.9	20
283	Effects of the FSH- $\beta$ -Subunit Promoter Polymorphism $\alpha^{211G \rightarrow T}$ on the Hypothalamic-Pituitary-Ovarian Axis in Normally Cycling Women Indicate a Gender-Specific Regulation of Gonadotropin Secretion. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E82-E86.	3.6	36
284	Effects of Endogenous Androgens and Abdominal Fat Distribution on the Interrelationship Between Insulin and Non-Insulin-Mediated Glucose Uptake in Females. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1541-1548.	3.6	34
285	Ovarian Cycle-Specific Regulation of Adipose Tissue Lipid Storage by Testosterone in Female Nonhuman Primates. Endocrinology, 2013, 154, 4126-4135.	2.8	39
286	Testosterone exposure in childhood: discerning pathology from physiology. Expert Opinion on Drug Safety, 2013, 12, 375-388.	2.4	12
287	Thyroid disorders in polycystic ovarian syndrome subjects: A tertiary hospital based cross-sectional study from Eastern India. Indian Journal of Endocrinology and Metabolism, 2013, 17, 304.	0.4	72
288	Lack of Association between C385A Functional Polymorphism of the Fatty Acid Amide Hydrolase Gene and Polycystic Ovary Syndrome. Experimental and Clinical Endocrinology and Diabetes, 2013, 121, 338-342.	1.2	7
289	Bone mineral density and vitamin D in PCOS and hirsutism. Expert Review of Endocrinology and Metabolism, 2013, 8, 449-459.	2.4	13
290	Serum anti-carbonic anhydrase I and II antibodies and polycystic ovary syndrome. Turkish Journal of Biochemistry, 2013, 38, 43-48.	0.5	4
291	Pregnancy, Epilepsy, and Women's Issues. CONTINUUM Lifelong Learning in Neurology, 2013, 19, 697-714.	0.8	15
292	Association of angiotensin-converting enzyme gene insertion/deletion polymorphism with polycystic ovary syndrome: a meta-analysis. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2013, 14, 255-262.	1.7	18
293	Estradiol Negative and Positive Feedback in a Prenatal Androgen-Induced Mouse Model of Polycystic Ovarian Syndrome. Endocrinology, 2013, 154, 796-806.	2.8	99
294	Body composition of lean women with polycystic ovary syndrome. Anthropological Review, 2013, 76, 183-198.	0.3	3

#	ARTICLE	IF	CITATIONS
295	Anti-androgenic effect of <i>Symplocos racemosa</i> Roxb. against letrozole induced polycystic ovary using rat model. <i>Journal of Coastal Life Medicine</i> , 2013, , .	0.2	4
296	Polymorphisms of TCF7L2 gene in South Brazilian women with polycystic ovary syndrome: a cross-sectional study. <i>European Journal of Endocrinology</i> , 2013, 169, 569-576.	3.7	12
298	Favourable metabolic effects of a eucaloric lower carbohydrate diet in women with <scp>PCOS</scp>. <i>Clinical Endocrinology</i> , 2013, 79, 550-557.	2.4	84
299	Obesity in Adolescence. , 2013, , 53-65.		0
300	Evaluation and treatment of acne from infancy to preadolescence. <i>Dermatologic Therapy</i> , 2013, 26, 462-466.	1.7	15
301	Obesity in PCOS and Infertility. , 2013, , 99-116.		1
302	Ethnic-specific polycystic ovary syndrome: epidemiology, significance and implications. <i>Expert Review of Endocrinology and Metabolism</i> , 2013, 8, 71-79.	2.4	33
303	Updated ultrasound criteria for polycystic ovary syndrome: reliable thresholds for elevated follicle population and ovarian volume. <i>Human Reproduction</i> , 2013, 28, 1361-1368.	0.9	406
304	Glucose metabolism in obese and lean adolescents with polycystic ovary syndrome. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2013, 26, 319-24.	0.9	5
305	Polycystic Ovary Syndrome in Adolescents. <i>Southern Medical Journal</i> , 2013, 106, 570-576.	0.7	6
306	Supporting young women with oligomenorrhea. <i>British Journal of School Nursing</i> , 2013, 8, 124-128.	0.1	0
307	Clomiphene Citrate, Metformin or Both for Ovulation Induction in Therapy Naïve Women with Polycystic Ovary Syndrome (PCOS)? A Descriptive Review. <i>Current Drug Therapy</i> , 2013, 8, 30-37.	0.3	1
309	Metabolic Disturbance in PCOS: Clinical and Molecular Effects on Skeletal Muscle Tissue. <i>Scientific World Journal</i> , The, 2013, 2013, 1-7.	2.1	13
310	Metabolic and other effects of pioglitazone as an add-on therapy to metformin in the treatment of polycystic ovary syndrome (PCOS). <i>Hormones</i> , 2013, 12, 363-378.	1.9	21
311	Clues to ovarian tumors: new concepts of symptoms, signs, syndromes, and paraneoplastic syndromes. , 0, , 325-348.		0
312	Chronic anovulation and the polycystic ovary syndrome. , 0, , 151-188.		1
313	Oligomenorrhoea: looking at the treatment options. <i>Practice Nursing</i> , 2013, 24, 165-168.	0.1	1
316	Polycystic Ovary Syndrome, Insulin Resistance, and Obesity: Navigating the Pathophysiologic Labyrinth. <i>International Journal of Reproductive Medicine</i> , 2014, 2014, 1-17.	1.1	247

#	ARTICLE	IF	CITATIONS
317	Clomiphene Citrate, Metformin or Aromatase Inhibitors for Anovulatory Infertility in Women with Polycystic Ovary Syndrome (PCOS): A Systematic Review of Meta-analyses and Randomized Controlled Trials. <i>Clinical Immunology, Endocrine and Metabolic Drugs</i> , 2014, 1, 2-10.	0.3	0
318	Optimal management of subfertility in polycystic ovary syndrome. <i>International Journal of Women's Health</i> , 2014, 6, 613.	2.6	16
319	Acupuncture and women's health: an overview of the role of acupuncture and its clinical management in women's reproductive health. <i>International Journal of Women's Health</i> , 2014, 6, 313.	2.6	28
321	Elevated serum androstenedione is associated with a more severe phenotype in women with polycystic ovary syndrome (PCOS). <i>Hormones</i> , 2014, 13, 213-221.	1.9	29
322	Immunohistochemical evaluation of proliferation, apoptosis and steroidogenic enzymes in the ovary of rats with polycystic ovary. <i>Revista Da Associação Médica Brasileira</i> , 2014, 60, 349-356.	0.7	24
323	Does Polycystic Ovarian Syndrome Increase Insulin Resistance Above and Beyond Obesity?. <i>Endocrinology &amp; Metabolic Syndrome: Current Research</i> , 2014, 03, .	0.7	0
324	Screening for glucose intolerance in polycystic ovary syndrome: hemoglobin A1C, fasting blood glucose or oral glucose tolerance test?. <i>Expert Review of Endocrinology and Metabolism</i> , 2014, 9, 671-683.	2.4	0
325	What do we know about metabolic syndrome in adolescents with PCOS?. <i>Journal of the Turkish German Gynecology Association</i> , 2014, 15, 49-55.	0.6	29
327	The influence of combined oral contraceptives containing drospirenone on hypothalamic-pituitary-adrenocortical axis activity and glucocorticoid receptor expression and function in women with polycystic ovary syndrome. <i>Hormones</i> , 2014, 14, 109-17.	1.9	7
328	Puberty and its disorders in the female. , 2014, , 569-663.e1.		22
329	Anti-Mullerian hormone may be a useful adjunct in the diagnosis of polycystic ovary syndrome in nonobese adolescents. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2014, 27, 1175-9.	0.9	35
331	Correlation of visfatin levels and lipoprotein lipid profiles in women with polycystic ovary syndrome undergoing ovarian stimulation. <i>Gynecological Endocrinology</i> , 2014, 30, 516-519.	1.7	19
332	Histomorphometric Analysis and Markers of Endometrial Receptivity Embryonic Implantation in Women With Polycystic Ovary Syndrome During the Treatment With Progesterone. <i>Reproductive Sciences</i> , 2014, 21, 930-938.	2.5	29
333	THERAPY OF ENDOCRINE DISEASE: Treatment of hirsutism in the polycystic ovary syndrome. <i>European Journal of Endocrinology</i> , 2014, 170, R75-R90.	3.7	30
334	Hypoxanthine Guanine Phosphoribosyl Transferase Is the Most Stable Reference Gene for Gene Expression Analysis by Quantitative PCR in Peripheral Blood Mononuclear Cells from Women with the Polycystic Ovary Syndrome. <i>Journal of Medical Biochemistry</i> , 2014, 33, 356-363.	1.7	1
335	Changes in Coagulation and Fibrinolytic Indices in Women with Polycystic Ovarian Syndrome Undergoing Controlled Ovarian Hyperstimulation. <i>International Journal of Endocrinology</i> , 2014, 2014, 1-6.	1.5	5
336	Endothelial dysfunction in hyperandrogenic polycystic ovary syndrome is not explained by either obesity or ectopic fat deposition. <i>Clinical Science</i> , 2014, 126, 67-74.	4.3	32
337	Polycystic ovarian syndrome: A review. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2014, 80, 154.	0.6	5

#	ARTICLE	IF	CITATIONS
338	Personality and Psychiatric Disorders in Women Affected by Polycystic Ovary Syndrome. <i>Frontiers in Endocrinology</i> , 2014, 5, 185.	3.5	46
339	Spironolactone and Dimethylsulfoxide Effect on Glucose Metabolism and Oxidative Stress Markers in Polycystic Ovarian Syndrome Rat Model. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2014, 122, 154-162.	1.2	13
340	Phenotypic variability of hyperandrogenemia in females heterozygous for CYP21A2 mutations. <i>Indian Journal of Endocrinology and Metabolism</i> , 2014, 18, 72.	0.4	17
341	Polycystic Ovary Syndrome in Young Women: Issues and Consequences. <i>Nestle Nutrition Institute Workshop Series</i> , 2014, , 87-94.	0.1	0
343	Circulating Irisin and Glucose-Dependent Insulinotropic Peptide Are Associated With the Development of Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E2539-E2548.	3.6	49
344	Easy Bruising in a Patient with Secondary Amenorrhea. <i>Clinical Chemistry</i> , 2014, 60, 1047-1050.	3.2	0
345	Tumor Necrosis Factor-Alpha and Polycystic Ovarian Syndrome: A Clinical, Biochemical, and Molecular Genetic Study. <i>Genetic Testing and Molecular Biomarkers</i> , 2014, 18, 605-609.	0.7	28
346	Prospective Association of Polycystic Ovary Syndrome With Coronary Artery Calcification and Carotid-Intima-Media Thickness. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 2688-2694.	2.4	83
347	Polycystic ovary syndrome in Iranian adolescents. <i>International Journal of Adolescent Medicine and Health</i> , 2014, 26, 559-565.	1.3	18
348	Ovulation induction in nonobese polycystic ovary syndrome women supplemented with Doppler studies. <i>Evidence Based Women S Health Journal</i> , 2014, 4, 211-213.	0.0	0
350	Polycystic ovary syndrome: clinical implication in perimenopause. <i>Przegląd Menopauzalny</i> , 2014, 6, 348-351.	1.3	2
351	Polycystic Ovary Syndrome: Do Endocrine-Disrupting Chemicals Play a Role?. <i>Seminars in Reproductive Medicine</i> , 2014, 32, 166-176.	1.1	51
352	Characterization of Serum MicroRNAs Profile of PCOS and Identification of Novel Non-Invasive Biomarkers. <i>Cellular Physiology and Biochemistry</i> , 2014, 33, 1304-1315.	1.6	115
353	Specificity and predictive value of circulating testosterone assessed by tandem mass spectrometry for the diagnosis of polycystic ovary syndrome by the National Institutes of Health 1990 criteria. <i>Fertility and Sterility</i> , 2014, 101, 1135-1141.e2.	1.0	53
354	Gastric bypass surgery in women with or without polycystic ovary syndromeâ€”A comparative observational cohort analysis. <i>European Journal of Internal Medicine</i> , 2014, 25, e23-e24.	2.2	10
355	Prevalence of androgenic alopecia in patients with polycystic ovary syndrome and characterization of associated clinical and biochemical features. <i>Fertility and Sterility</i> , 2014, 101, 1129-1134.	1.0	58
356	Follicle number, not assessments of the ovarian stroma, represents the best ultrasonographic marker of polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2014, 101, 280-287.e1.	1.0	41
357	Complete phenotypic and metabolic profiles of a large consecutive cohort of untreated Korean women with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2014, 101, 1424-1430.e3.	1.0	35

#	ARTICLE	IF	CITATIONS
358	Metabolic profile of the different phenotypes of polycystic ovary syndrome in two Latin American populations. <i>Fertility and Sterility</i> , 2014, 101, 1732-1739.e2.	1.0	26
359	Modeling Endocrine Control of the Pituitaryâ€“Ovarian Axis: Androgenic Influence and Chaotic Dynamics. <i>Bulletin of Mathematical Biology</i> , 2014, 76, 136-156.	1.9	13
360	Are Young Adult Women With Polycystic Ovary Syndrome Slipping Through the Healthcare Cracks?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 1583-1585.	3.6	31
361	New guidelines for the diagnosis and treatment of PCOS. <i>Nature Reviews Endocrinology</i> , 2014, 10, 130-132.	9.6	48
362	Ultra-short term clomiphene citrate in high responder women with polycystic ovary syndrome: a case series. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2014, 175, 191-193.	1.1	1
363	Dihydrotestosterone deteriorates cardiac insulin signaling and glucose transport in the rat model of polycystic ovary syndrome. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014, 141, 71-76.	2.5	14
364	Influence of oral contraceptives on anthropomorphometric, endocrine, and metabolic profiles of anovulatory polycystic ovary syndrome patients. <i>Fertility and Sterility</i> , 2014, 101, 1757-1765.e1.	1.0	25
365	Endogenous Sex Hormones, Metabolic Syndrome, and Diabetes in Men and Women. <i>Current Cardiology Reports</i> , 2014, 16, 467.	2.9	62
366	Diagnosis of Polycystic Ovary Syndrome: AMH in combination with clinical symptoms. <i>Journal of Assisted Reproduction and Genetics</i> , 2014, 31, 213-220.	2.5	47
367	Polycystic Ovary Syndrome. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 123-147.	3.2	82
368	Polycystic Ovary Syndrome: What's in a Name?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 1142-1145.	3.6	25
369	High-intensity focused ultrasound for potential treatment of polycystic ovary syndrome: toward a noninvasive surgery. <i>Fertility and Sterility</i> , 2014, 101, 545-551.e2.	1.0	8
370	No Phenotypic Differences for Polycystic Ovary Syndrome (PCOS) Between Women With and Without Type 1 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 203-211.	3.6	27
371	Hyperandrogenemia Predicts Metabolic Phenotype in Polycystic Ovary Syndrome: The Utility of Serum Androstenedione. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 1027-1036.	3.6	231
372	Association of fat to lean mass ratio with metabolic dysfunction in women with polycystic ovary syndrome. <i>Human Reproduction</i> , 2014, 29, 1508-1517.	0.9	49
373	Prevalence and impact of hyperandrogenemia in 1,218 women with polycystic ovary syndrome. <i>Endocrine</i> , 2014, 47, 631-638.	2.3	68
374	Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. <i>Human Reproduction Update</i> , 2014, 20, 334-352.	10.8	389
375	Imaging female infertility. <i>Abdominal Imaging</i> , 2014, 39, 92-107.	2.0	14

#	ARTICLE	IF	CITATIONS
376	The effects of being overweight and obese on female reproduction: a review. <i>Gynecological Endocrinology</i> , 2014, 30, 90-94.	1.7	71
377	Managing the PCOS-Related Symptoms of Hirsutism, Acne, and Hair Loss. , 2014, , 223-242.		1
378	Polymorphisms of transcription factor-7-like 2 (TCF7L2) gene in Tunisian women with polycystic ovary syndrome (PCOS). <i>Gene</i> , 2014, 533, 554-557.	2.2	19
380	Metabolomics in polycystic ovary syndrome. <i>Clinica Chimica Acta</i> , 2014, 429, 181-188.	1.1	41
381	The physiology and clinical utility of anti-M $\mu$ llerian hormone in women. <i>Human Reproduction Update</i> , 2014, 20, 370-385.	10.8	722
382	Altered microRNA and gene expression in the follicular fluid of women with polycystic ovary syndrome. <i>Journal of Assisted Reproduction and Genetics</i> , 2014, 31, 355-362.	2.5	149
383	Acneiform Eruptions in Dermatology. , 2014, , .		3
384	Potential benefits of adlay on hyperandrogenism in human chorionic gonadotropin-treated theca cells and a rodent model of polycystic ovary syndrome. <i>Journal of Functional Foods</i> , 2014, 11, 393-406.	3.4	6
385	Common polymorphisms of calpain-10 and the risk of polycystic ovary syndrome in Tunisian population: a caseâ€“control study. <i>Molecular Biology Reports</i> , 2014, 41, 6569-6574.	2.3	10
386	Focus on metabolic and nutritional correlates of polycystic ovary syndrome and update on nutritional management of these critical phenomena. <i>Archives of Gynecology and Obstetrics</i> , 2014, 290, 1079-1092.	1.7	24
387	Serum leptin level in obese women with polycystic ovary syndrome, and its relation to insulin resistance. <i>Asian Pacific Journal of Reproduction</i> , 2014, 3, 288-294.	0.4	3
388	The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. <i>European Journal of Endocrinology</i> , 2014, 171, P1-P29.	3.7	502
389	Increased Expression of Kindlin 2 in Luteinized Granulosa Cells Correlates With Androgen Receptor Level in Patients With Polycystic Ovary Syndrome Having Hyperandrogenemia. <i>Reproductive Sciences</i> , 2014, 21, 696-703.	2.5	13
390	M30 Does Not Predict the Severity of Hepatosteatorsis, Whereas Adiponectin Level Declined With Increase of ALT and the Severity of Hepatic Steatorsis. <i>Journal of Clinical Laboratory Analysis</i> , 2014, 28, 381-385.	2.1	3
391	Menstrual dysfunctionâ€“a proxy for insulin resistance in PCOS?. <i>Nature Reviews Endocrinology</i> , 2014, 10, 10-11.	9.6	12
392	Plasma levels of pentraxin-3, an inflammatory protein involved in fertility, are reduced in women with polycystic ovary syndrome. <i>European Journal of Endocrinology</i> , 2014, 170, 401-409.	3.7	20
393	GC-MS analysis of Cocus nucifera flower extract and its effects on heterogeneous symptoms of polycystic ovarian disease in female Wistar rats. <i>Chinese Journal of Natural Medicines</i> , 2014, 12, 677-684.	1.3	23
394	Incidence of hypertension, stroke, coronary heart disease, and diabetes in women who have delivered afterÂ“inÂ“vitro fertilization: aÂ“population-based cohort study from Sweden. <i>Fertility and Sterility</i> , 2014, 102, 1096-1102.	1.0	45



#	ARTICLE	IF	CITATIONS
395	Hyperinsulinaemic androgen excess in adolescent girls. <i>Nature Reviews Endocrinology</i> , 2014, 10, 499-508.	9.6	46
396	Utility of ultrasound in the diagnosis of polycystic ovary syndrome in adolescents. <i>Fertility and Sterility</i> , 2014, 102, 1432-1438.	1.0	23
397	Effects of a eucaloric reduced-carbohydrate diet on body composition and fat distribution in women with PCOS. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 1257-1264.	3.4	62
398	Prolactin is associated with metabolic risk and cortisol in 1007 women with polycystic ovary syndrome. <i>Human Reproduction</i> , 2014, 29, 1773-1779.	0.9	43
399	Treatment of the Obese Patient. , 2014, , .		3
400	The role of androst-5-ene-3 $\beta$ ,17 $\beta$ -diol (androstenediol) in cell proliferation in endometrium of women with polycystic ovary syndrome. <i>Steroids</i> , 2014, 89, 11-19.	1.8	17
401	European survey of diagnosis and management of the polycystic ovary syndrome: results of the ESE PCOS Special Interest Group's Questionnaire. <i>European Journal of Endocrinology</i> , 2014, 171, 489-498.	3.7	76
402	Bifurcation analysis of a menstrual cycle model reveals multiple mechanisms linking testosterone and classical PCOS. <i>Journal of Theoretical Biology</i> , 2014, 361, 31-40.	1.7	7
403	The Expression of the miR-25/93/106b Family of Micro-RNAs in the Adipose Tissue of Women With Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E2754-E2761.	3.6	42
404	Bioengineering the Ovarian Follicle Microenvironment. <i>Annual Review of Biomedical Engineering</i> , 2014, 16, 29-52.	12.3	138
405	Irregular menstrual cycles in a young woman. <i>Cmaj</i> , 2014, 186, 850-852.	2.0	1
406	Genetic variants of the HSD11B1 gene promoter may be protective against polycystic ovary syndrome. <i>Molecular Biology Reports</i> , 2014, 41, 5961-5969.	2.3	5
407	Testosterone treatment increases androgen receptor and aromatase gene expression in myotubes from patients with PCOS and controls, but does not induce insulin resistance. <i>Biochemical and Biophysical Research Communications</i> , 2014, 451, 622-626.	2.1	17
408	Aromatase inhibitors for subfertile women with polycystic ovary syndrome. <i>The Cochrane Library</i> , 2014, , CD010287.	2.8	68
409	Adiponectin, interleukin-6, monocyte chemoattractant protein-1, and regional fat mass during 12-month randomized treatment with metformin and/or oral contraceptives in polycystic ovary syndrome. <i>Journal of Endocrinological Investigation</i> , 2014, 37, 757-764.	3.3	19
411	17-Hydroxyprogesterone in children, adolescents and adults. <i>Annals of Clinical Biochemistry</i> , 2014, 51, 424-440.	1.6	43
412	Insulin and body weight but not hyperandrogenism seem involved in seasonal serum 25-OH-vitamin D3 levels in subjects affected by PCOS. <i>Gynecological Endocrinology</i> , 2014, 30, 739-745.	1.7	13
413	Polycystic ovary syndrome – Phenotypes and diagnosis. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2014, 74, 18-22.	1.2	23

#	ARTICLE	IF	CITATIONS
414	Polycystic ovaries “beyond menopause. Climacteric, 2014, 17, 109-115.	2.4	14
415	Characterization of Reproductive, Metabolic, and Endocrine Features of Polycystic Ovary Syndrome in Female Hyperandrogenic Mouse Models. Endocrinology, 2014, 155, 3146-3159.	2.8	238
416	Polycystic Ovary Syndrome: Update on Diagnosis and Treatment. American Journal of Medicine, 2014, 127, 912-919.	1.5	97
417	Cluster analysis of cardiovascular and metabolic risk factors in women of reproductive age. Fertility and Sterility, 2014, 101, 1404-1410.e1.	1.0	40
418	Maternal characteristics and pregnancy outcomes after assisted reproductive technology by infertility diagnosis: ovulatory dysfunction versus tubal obstruction. Fertility and Sterility, 2014, 101, 1019-1025.	1.0	27
419	Characterizing plasma phospholipid fatty acid profiles of polycystic ovary syndrome patients with and without insulin resistance using GC-MS and chemometrics approach. Journal of Pharmaceutical and Biomedical Analysis, 2014, 95, 85-92.	2.8	32
420	Hyperandrogenemia is implicated in both the metabolic and reproductive morbidities of polycystic ovary syndrome. Fertility and Sterility, 2014, 101, 840-845.	1.0	35
421	Levetiracetam as alternative treatment in Jeavons syndrome. Journal of the Neurological Sciences, 2014, 341, 147-149.	0.6	15
422	Clustering of metabolic and cardiovascular risk factors in the polycystic ovary syndrome: a principal component analysis. Metabolism: Clinical and Experimental, 2014, 63, 1071-1077.	3.4	11
423	Ovarian morphology assessed by magnetic resonance imaging in women with and without polycystic ovary syndrome and associations with anti-Müllerian hormone, free testosterone, and glucose disposal rate. Fertility and Sterility, 2014, 101, 1747-1756.e3.	1.0	27
424	To what extent does the use of the Rotterdam criteria affect the prevalence of polycystic ovary syndrome? A community-based study from the Southwest of Iran. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2014, 174, 100-105.	1.1	42
425	How to manage an adolescent girl presenting with features of polycystic ovary syndrome (<sc>PCOS</sc>); an exemplar for adolescent health care in endocrinology. Clinical Endocrinology, 2014, 81, 652-656.	2.4	11
426	Effect of gastric bypass surgery on endocrine and metabolic abnormalities in polycystic ovary syndrome—preliminary findings and future challenges. Surgery for Obesity and Related Diseases, 2014, 10, 792-794.	1.2	1
428	MicroRNAs Related to Polycystic Ovary Syndrome (PCOS). Genes, 2014, 5, 684-708.	2.4	124
429	2014 Meet-The-Professor: Endocrine Case Management. , 2014, , .		0
430	33. Hypocaloric diets in overweight and obese patients with polycystic ovary syndrome. Human Health Handbooks, 2014, , 533-552.	0.1	0
432	A 26-year-old woman with secondary amenorrhea. , 0, , 203-206.		0
433	Irregular bleeding in a 25-year-old woman. , 0, , 207-210.		0



#	ARTICLE	IF	CITATIONS
434	Role of Anti-Müllerian Hormone in pathophysiology, diagnosis and treatment of Polycystic Ovary Syndrome: a review. Reproductive Biology and Endocrinology, 2015, 13, 137.	3.3	127
435	Autonomic dysfunction in patients with polycystic ovary syndrome. Taiwanese Journal of Obstetrics and Gynecology, 2015, 54, 381-384.	1.3	12
436	Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis. Scientific Reports, 2015, 5, 16890.	3.3	61
437	American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome - Part 1. Endocrine Practice, 2015, 21, 1291-1300.	2.1	387
438	2015 Meet-The-Professor: Endocrine Case Management. , 2015, , .		0
439	Diagnosis and management of polycystic ovary syndrome. Independent Nurse, 2015, 2015, 27-28.	0.1	1
440	Controversies of the assesment and management of polycystic ovary syndrome in adolescents. International Journal of Pediatric Endocrinology (Springer), 2015, 2015, .	1.6	0
442	Serum testosterone predicts cardiorespiratory fitness impairment in normalâ€weight women with polycystic ovary syndrome. Clinical Endocrinology, 2015, 83, 895-901.	2.4	7
443	The association between hyperandrogenemia and the metabolic syndrome in morbidly obese women. Diabetology and Metabolic Syndrome, 2015, 7, 46.	2.7	27
444	Genetics of insulin resistance in polycystic ovary syndrome. Current Opinion in Clinical Nutrition and Metabolic Care, 2015, 18, 401-406.	2.5	8
445	Polycystic ovary syndrome: managing the basics. , 0, , 25-37.		0
446	Diagnostic criteria of polycystic ovary syndrome. , 0, , 74-78.		0
447	Polycystic ovary syndrome and cardiovascular risk. , 0, , 89-96.		0
448	History and physical examination of polycystic ovary syndrome: Detecting too much or too little. , 0, , 161-179.		0
449	Ovulation induction in women with polycystic ovary syndrome. , 0, , 226-232.		0
450	Prevalence of conditions causing chronic anovulation and the proposed algorithm for anovulation evaluation. Journal of Obstetrics and Gynaecology Research, 2015, 41, 1074-1079.	1.3	13
451	Adolescence and polycystic ovary syndrome: current concepts on diagnosis and treatment. International Journal of Clinical Practice, 2015, 69, 1236-1246.	1.7	23
452	Body fat distribution and its associated factors in Korean women with polycystic ovary syndrome. Journal of Obstetrics and Gynaecology Research, 2015, 41, 1577-1583.	1.3	6

#	ARTICLE	IF	CITATIONS
453	Women with polycystic ovary syndrome have elevated serum concentrations of and altered GABA <sub>A</sub> receptor sensitivity to allopregnanolone. Clinical Endocrinology, 2015, 83, 643-650.	2.4	25
454	11.7 Dysmenorrhoe. , 2015, , .		0
455	Value of ultrasonography in the diagnosis of polycystic ovary syndrome – literature review. , 2015, 15, 410-422.		22
456	Hyperandrogenism in female athletes with functional hypothalamic amenorrhea: a distinct phenotype. International Journal of Women's Health, 2015, 7, 103.	2.6	11
457	Síndrome de ovario poliquístico y complicaciones metabólicas: más allá del exceso de andrógenos. Revista Chilena De Obstetricia Y Ginecología, 2015, 80, 515-519.	0.1	2
458	Treatment of infertility in women with polycystic ovary syndrome: approach to clinical practice. Clinics, 2015, 70, 765-769.	1.5	123
460	Clinical characteristics in Taiwanese women with polycystic ovary syndrome. Clinical and Experimental Reproductive Medicine, 2015, 42, 86.	1.5	17
461	MicroRNA-223 Expression Is Upregulated in Insulin Resistant Human Adipose Tissue. Journal of Diabetes Research, 2015, 2015, 1-8.	2.3	81
462	The Association of a Mediterranean-Style Diet Pattern with Polycystic Ovary Syndrome Status in a Community Cohort Study. Nutrients, 2015, 7, 8553-8564.	4.1	37
464	Comparing the Effect of Metformin and Acarbose Accompanying Clomiphene on the Successful Ovulation Induction in Infertile Women with Polycystic Ovary Syndrome. Global Journal of Health Science, 2015, 8, 281.	0.2	8
465	Association of oral contraceptive and metformin did not improve insulin resistance in women with polycystic ovary syndrome. Revista Da Associação Médica Brasileira, 2015, 61, 215-219.	0.7	7
466	Liraglutide Improves Hypertension and Metabolic Perturbation in a Rat Model of Polycystic Ovarian Syndrome. PLoS ONE, 2015, 10, e0126119.	2.5	23
467	Trend of Cardio-Metabolic Risk Factors in Polycystic Ovary Syndrome: A Population-Based Prospective Cohort Study. PLoS ONE, 2015, 10, e0137609.	2.5	52
468	Prenatal Exposure to Perfluoroalkyl Acids and Serum Testosterone Concentrations at 15 Years of Age in Female ALSPAC Study Participants. Environmental Health Perspectives, 2015, 123, 1325-1330.	6.0	46
469	Hyperandrogenism-Insulin Resistance-Acanthosis Nigricans Syndrome. Case Reports in Endocrinology, 2015, 2015, 1-4.	0.4	8
470	The role of anti-Mullerian hormone and inhibin B in the assessment of metformin therapy in women with polycystic ovarian syndrome. Journal of King Abdulaziz University, Islamic Economics, 2015, 36, 562-567.	1.1	14
471	A COMPARATIVE STUDY OF METABOLIC AND HORMONAL EFFECTS OF MYOINOSITOL VS METFORMIN IN WOMEN WITH POLYCYSTIC OVARY SYNDROME: A RANDOMISED CONTROLLED TRIAL. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 2015, , 1.	0.1	6
472	Adiponectin and leptin in overweight/obese and lean women with polycystic ovary syndrome. Gynecological Endocrinology, 2015, 31, 264-268.	1.7	37

#	ARTICLE	IF	CITATIONS
473	A caseâ€control observational study of insulin resistance and metabolic syndrome among the four phenotypes of polycystic ovary syndrome based on Rotterdam criteria. <i>Reproductive Health</i> , 2015, 12, 7.	3.1	49
474	Role of androgens in normal and pathological ovarian function. <i>Reproduction</i> , 2015, 149, R193-R218.	2.6	120
475	Metabolic profile of Diane-35 versus Diane-35 plus metformin in Chinese PCOS women under standardized life-style changes. <i>Gynecological Endocrinology</i> , 2015, 31, 548-551.	1.7	18
476	Polycystic ovary syndrome: chemical pharmacotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1369-1393.	1.8	31
478	Androgen Receptor CAG Repeat Length in Relation to Phenotype Among Females with Nonclassical 21-Hydroxylase Deficiency. <i>Hormone and Metabolic Research</i> , 2015, 47, 491-496.	1.5	8
479	Greater arousal in response to expansive female pubic hair is linked to more positive reactions to female sterility among heterosexual men. <i>Canadian Journal of Human Sexuality</i> , 2015, 24, 63-68.	1.6	0
480	Infertility in a young woman with Type 2 diabetes. <i>London Journal of Primary Care</i> , 2015, 7, 55-57.	0.9	9
481	Serum ferritin levels and polycystic ovary syndrome in obese and nonobese women. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2015, 54, 403-407.	1.3	16
482	Non-Hemodynamic Components of EVA. , 2015, , 181-194.		0
483	A population-based study of the relationship between idiopathic hirsutism and metabolic disturbances. <i>Journal of Endocrinological Investigation</i> , 2015, 38, 155-162.	3.3	4
484	Influence of adrenal hyperandrogenism on the clinical and metabolic phenotype of women with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2015, 103, 795-801.e2.	1.0	33
485	Ratio of ovarian stroma and total ovarian area by ultrasound in prediction of hyperandrogenemia in reproductiveâ€aged Thai women with polycystic ovary syndrome: A diagnostic test. <i>Journal of Obstetrics and Gynaecology Research</i> , 2015, 41, 248-253.	1.3	7
486	Metabolic risk in PCOS: phenotype and adiposity impact. <i>Trends in Endocrinology and Metabolism</i> , 2015, 26, 136-143.	7.1	181
487	Ultrasound features of polycystic ovaries relate to degreeÂof reproductive and metabolic disturbance in polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2015, 103, 787-794.	1.0	36
488	Association of Luteinizing Hormone Chorionic Gonadotropin Receptor Gene Polymorphism (rs2293275) with Polycystic Ovarian Syndrome. <i>Genetic Testing and Molecular Biomarkers</i> , 2015, 19, 128-132.	0.7	43
489	Total Body Fat and Central Fat Mass Independently Predict Insulin Resistance but Not Hyperandrogenemia In Women With Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 661-669.	3.6	54
490	Functional genomics of PCOS: from GWAS to molecular mechanisms. <i>Trends in Endocrinology and Metabolism</i> , 2015, 26, 118-124.	7.1	161
491	Association between rs7903146 and rs12255372 polymorphisms of transcription factor 7-like 2 gene and polycystic ovary syndrome: a systematic review and meta-analysis. <i>Endocrine</i> , 2015, 49, 635-642.	2.3	10

#	ARTICLE	IF	CITATIONS
492	Characteristics and contributions of hyperandrogenism to insulin resistance and other metabolic profiles in polycystic ovary syndrome. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2015, 94, 494-500.	2.8	23
493	MANAGEMENT OF ENDOCRINE DISEASE: Hyperandrogenism after menopause. <i>European Journal of Endocrinology</i> , 2015, 172, R79-R91.	3.7	86
494	Maternal and neonatal outcomes in pregnant women with PCOS: comparison of different diagnostic definitions. <i>Human Reproduction</i> , 2015, 30, 2396-2403.	0.9	53
495	Hiperandrogenismo por tumor ovárico de células de Leydig. <i>Revista Clinica Espanola</i> , 2015, 215, 340-342.	0.6	0
496	Phenotypic Characterization of Polycystic Ovary Syndrome in Adolescents Based on Menstrual Irregularity. <i>Hormone Research in Paediatrics</i> , 2015, 84, 223-230.	1.8	4
497	Proposed criteria for the identification of polycystic ovary syndrome following menopause: An ancillary study of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). <i>Maturitas</i> , 2015, 81, 398-405.	2.4	6
498	The Diagnosis of Polycystic Ovary Syndrome during Adolescence. <i>Hormone Research in Paediatrics</i> , 2015, 83, 376-389.	1.8	2,130
499	What is the Risk of Metabolic Syndrome in Adolescents with Normal BMI who have Polycystic Ovary Syndrome?. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2015, 28, 271-274.	0.7	15
500	Metformin improves endothelial function and carotid intima media thickness in patients with PCOS. <i>Gynecological Endocrinology</i> , 2015, 31, 401-405.	1.7	28
501	Obesity and inflammatory biomarkers in women with polycystic ovary syndrome. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2015, 192, 66-71.	1.1	23
502	Haplosufficient Genomic Androgen Receptor Signaling Is Adequate to Protect Female Mice From Induction of Polycystic Ovary Syndrome Features by Prenatal Hyperandrogenization. <i>Endocrinology</i> , 2015, 156, 1441-1452.	2.8	77
503	The evaluation of endometrial sulfate glycosaminoglycans in women with polycystic ovary syndrome. <i>Gynecological Endocrinology</i> , 2015, 31, 278-281.	1.7	17
504	Nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: clinical presentation, diagnosis, treatment, and outcome. <i>Endocrine</i> , 2015, 50, 32-50.	2.3	93
505	Evidence-based approach to cutaneous hyperandrogenism in women. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 672-690.	1.2	43
506	Optimal management of polycystic ovary syndrome in adolescence. <i>Archives of Disease in Childhood</i> , 2015, 100, 1076-1083.	1.9	19
507	Effects of Lifestyle on Female Reproductive Features and Success: Lessons from Animal Models. , 2015, , 191-202.		0
508	Personality profile in patients with polycystic ovary syndrome. <i>Gynecological Endocrinology</i> , 2015, 31, 540-542.	1.7	8
509	Female-Specific Factors for IHD: Across the Reproductive Lifespan. <i>Current Atherosclerosis Reports</i> , 2015, 17, 481.	4.8	5

#	ARTICLE	IF	CITATIONS
510	Cardiac fatty acid uptake and metabolism in the rat model of polycystic ovary syndrome. <i>Endocrine</i> , 2015, 50, 193-201.	2.3	7
511	The prevalence of metabolic syndrome in polycystic ovary syndrome in a South Indian population and the use of neck circumference in defining metabolic syndrome. <i>International Journal of Diabetes in Developing Countries</i> , 2015, 35, 469-475.	0.8	3
512	Roles for the sympathetic nervous system, renal nerves, and CNS melanocortin-4 receptor in the elevated blood pressure in hyperandrogenemic female rats. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2015, 308, R708-R713.	1.8	42
513	Diagnosis and Management of Polycystic Ovary Syndrome (PCOS). , 2015, , 99-113.		9
514	Combined metformin+clomiphene in clomiphene-resistant polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2015, 94, 921-930.	2.8	27
515	ACR Appropriateness Criteria® Infertility. <i>Ultrasound Quarterly</i> , 2015, 31, 37-44.	0.8	10
516	Clinical characteristics of polycystic ovary syndrome: investigating differences in White and South Asian women. <i>Clinical Endocrinology</i> , 2015, 83, 542-549.	2.4	32
517	Polycystic Ovary Syndrome and Insulin: Our Understanding in the Past, Present and Future. <i>Women's Health</i> , 2015, 11, 137-149.	1.5	29
518	Effects of female increased body mass index on in vitro fertilization cycles outcome. <i>Obesity Research and Clinical Practice</i> , 2015, 9, 382-388.	1.8	40
519	How to manage the reproductive issues of PCOS: a 2015 integrated endocrinological and gynecological consensus statement of the Italian Society of Endocrinology. <i>Journal of Endocrinological Investigation</i> , 2015, 38, 1025-1037.	3.3	18
520	Fasting Glucose Changes in Adolescents with Polycystic Ovary Syndrome Compared with Obese Controls: A Retrospective Cohort Study. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2015, 28, 451-456.	0.7	3
521	Increased Risk of Unfavorable Metabolic Outcome in Patients with Clinically Nonfunctioning Pituitary Adenomas. <i>Hormone and Metabolic Research</i> , 2015, 47, 652-655.	1.5	4
522	The effectiveness and safety of treatments used for polycystic ovarian syndrome management in adolescents: a systematic review and network meta-analysis protocol. <i>Systematic Reviews</i> , 2015, 4, 125.	5.3	12
523	Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome. <i>Endocrine Reviews</i> , 2015, 36, 487-525.	20.1	649
524	Insulin dynamics and biochemical markers for predicting impaired glucose tolerance in obese Thai youth. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2015, 28, 1039-45.	0.9	3
527	Hyperandrogenism and phenotypes of polycystic ovary syndrome are not associated with differences in obstetric outcomes. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2015, 94, 204-211.	2.8	38
528	Expression of steroid sulfated transporters and $\beta$ -HSD activity in endometrium of women having polycystic ovary syndrome. <i>Steroids</i> , 2015, 104, 189-195.	1.8	13
529	Referral bias in female functional hyperandrogenism and polycystic ovary syndrome. <i>European Journal of Endocrinology</i> , 2015, 173, 603-610.	3.7	26

#	ARTICLE	IF	CITATIONS
530	A Novel Letrozole Model Recapitulates Both the Reproductive and Metabolic Phenotypes of Polycystic Ovary Syndrome in Female Mice1. <i>Biology of Reproduction</i> , 2015, 93, 69.	2.7	145
531	Endogenous thrombin potential in polycystic ovary syndrome: the association to body mass index, insulin resistance, and inflammation. <i>Gynecological Endocrinology</i> , 2015, 31, 720-724.	1.7	9
532	Relative importance of AMH and androgens changes with aging among non-obese women with polycystic ovary syndrome. <i>Journal of Ovarian Research</i> , 2015, 8, 45.	3.0	14
533	Attention deficit-hyperactivity disorder symptoms in women with polycystic ovary syndrome. <i>International Journal of Psychiatry in Medicine</i> , 2015, 50, 317-325.	1.8	23
534	Polycystic ovarian syndrome is accompanied by repression of gene signatures associated with biosynthesis and metabolism of steroids, cholesterol and lipids. <i>Journal of Ovarian Research</i> , 2015, 8, 24.	3.0	46
535	Android fat distribution affects some hemostatic parameters in women with polycystic ovary syndrome compared with healthy control subjects matched for age and body mass index. <i>Fertility and Sterility</i> , 2015, 104, 467-473.	1.0	8
536	Cardiometabolic and reproductive benefits of early dietary energy restriction and voluntary exercise in an obese PCOS-prone rodent model. <i>Journal of Endocrinology</i> , 2015, 226, 193-206.	2.6	10
537	Biochemical and genetic diagnosis of 21-hydroxylase deficiency. <i>Endocrine</i> , 2015, 50, 306-314.	2.3	62
538	Pitfalls in Imaging of Female Infertility. <i>Seminars in Roentgenology</i> , 2015, 50, 273-283.	0.6	4
539	Putative role for insulin resistance in depression risk in polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2015, 104, 707-714.e1.	1.0	46
540	Clinical utility of magnetic resonance imaging and ultrasonography for diagnosis of polycystic ovary syndrome in adolescent girls. <i>Fertility and Sterility</i> , 2015, 104, 1302-1309.e4.	1.0	31
541	The Diagnosis of Polycystic Ovary Syndrome in Adolescents. <i>Pediatrics</i> , 2015, 136, 1154-1165.	2.1	151
542	Plasma Visfatin Levels in Adolescents with Polycystic Ovary Syndrome: A Prospective Case-Control Study. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2015, 28, 249-253.	0.7	9
543	The Effect of Chromium Supplementation on Polycystic Ovary Syndrome in Adolescents. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2015, 28, 114-118.	0.7	28
544	Serum zonulin is elevated in women with polycystic ovary syndrome and correlates with insulin resistance and severity of anovulation. <i>European Journal of Endocrinology</i> , 2015, 172, 29-36.	3.7	54
545	Measurement of Testosterone by Immunoassays and Mass Spectrometry in Mouse Serum, Testicular, and Ovarian Extracts. <i>Endocrinology</i> , 2015, 156, 400-405.	2.8	35
546	Visceral adiposity index and DHEAS are useful markers of diabetes risk in women with polycystic ovary syndrome. <i>European Journal of Endocrinology</i> , 2015, 172, 79-88.	3.7	33
547	Biochemical hyperandrogenism is associated with metabolic syndrome independently of adiposity and insulin resistance in Romanian polycystic ovary syndrome patients. <i>Endocrine</i> , 2015, 48, 696-704.	2.3	24



#	ARTICLE	IF	CITATIONS
548	The Polycystic Ovary Morphology-Polycystic Ovary Syndrome Spectrum. Journal of Pediatric and Adolescent Gynecology, 2015, 28, 412-419.	0.7	50
549	Further Investigation in Europeans of Susceptibility Variants for Polycystic Ovary Syndrome Discovered in Genome-Wide Association Studies of Chinese Individuals. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E182-E186.	3.6	57
550	Correlations of Insulin Resistance and Serum Testosterone Levels with LH:FSH Ratio and Oxidative Stress in Women with Functional Ovarian Hyperandrogenism. Indian Journal of Clinical Biochemistry, 2015, 30, 345-350.	1.9	23
551	Editorial (Thematic Issue: Advances in the Diagnosis and Treatment of Polycystic Ovarian Syndrome). Current Pharmaceutical Design, 2016, 22, 5505-5507.	1.9	2
552	Postmenopausal Hyperandrogenism in a Patient With an Adrenal Adenoma: How Should We Approach It?. AACE Clinical Case Reports, 2016, 2, e138-e142.	1.1	1
553	EFFECT OF SARGASSUM ILICIFOLIUM ON OVOGENESIS IN PCOS INDUCED RATS. Asian Journal of Pharmaceutical and Clinical Research, 2016, 9, 127.	0.3	6
554	The frequency of polycystic ovary syndrome in young reproductive females in Qatar. International Journal of Women's Health, 2017, Volume 9, 1-10.	2.6	27
555	The Gut Microbiome Is Altered in a Letrozole-Induced Mouse Model of Polycystic Ovary Syndrome. PLoS ONE, 2016, 11, e0146509.	2.5	145
556	Polycystic Ovary Syndrome May Be an Autoimmune Disorder. Scientifica, 2016, 2016, 1-7.	1.7	52
557	Metabolism and Ovarian Function in PCOS Women: A Therapeutic Approach with Inositols. International Journal of Endocrinology, 2016, 2016, 1-9.	1.5	75
558	Association between the angiotensin converting enzyme gene insertion/deletion polymorphism and metabolic disturbances in women with polycystic ovary syndrome. Molecular Medicine Reports, 2016, 14, 5401-5407.	2.4	16
559	Mechanisms of Comorbidities Associated With the Metabolic Syndrome: Insights from the JCR:LA-cp Corpulent Rat Strain. Frontiers in Nutrition, 2016, 3, 44.	3.7	12
560	Poly Cystic Ovarian Syndrome: An Updated Overview. Frontiers in Physiology, 2016, 7, 124.	2.8	180
561	Polycystic ovarian syndrome: clinical and biological diagnosis. Annales De Biologie Clinique, 2016, 74, 661-667.	0.1	22
562	SERUM IRISIN AND LEPTIN LEVELS IN OBESE AND NON-OBESE WOMEN WITH POLYCYSTIC OVARY SYNDROME WITH REFERENCE TO GLUCOSE HOMEOSTASIS. International Journal of Pharmacy and Pharmaceutical Sciences, 2016, 8, 276.	0.3	6
563	Antimüllerian hormone, antral follicle count and ovarian volume predict menstrual cycle length in healthy women. Clinical Endocrinology, 2016, 84, 870-877.	2.4	22
564	A randomized pilot study of dietary treatments for polycystic ovary syndrome in adolescents. Pediatric Obesity, 2016, 11, 210-220.	2.8	31
565	Strategies for improving outcome of assisted reproduction in women with polycystic ovary syndrome: systematic review and meta-analysis. Ultrasound in Obstetrics and Gynecology, 2016, 48, 709-718.	1.7	48

#	ARTICLE	IF	CITATIONS
566	Voice characteristics associated with polycystic ovary syndrome. Laryngoscope, 2016, 126, 2067-2072.	2.0	13
567	Correlation of clinical and biochemical hyperandrogenism in <scp>Thai</scp> women with polycystic ovary syndrome. Journal of Obstetrics and Gynaecology Research, 2016, 42, 678-683.	1.3	15
568	Polycystic Ovary Syndrome. New England Journal of Medicine, 2016, 375, 54-64.	27.0	366
569	Delayed diagnosis and a lack of information associated with dissatisfaction in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 2017, 102, jc.2016-2963.	3.6	188
570	The rules of acupoint-selection of acupuncture for polycystic ovary syndrome based on data mining. World Journal of Acupuncture-moxibustion, 2016, 26, 73-78.	0.5	10
571	Prenatal programming: adverse cardiac programming by gestational testosterone excess. Scientific Reports, 2016, 6, 28335.	3.3	35
572	Inositol for subfertile women with polycystic ovary syndrome. The Cochrane Library, 2016, , .	2.8	2
573	Impaired ApoB-Lipoprotein and Triglyceride Metabolism in Obese Adolescents with Polycystic Ovary Syndrome.. Journal of Clinical Endocrinology and Metabolism, 2016, 102, jc.2016-2854.	3.6	25
574	The effect of androgens on ovarian follicle maturation: Dihydrotestosterone suppress FSH-stimulated granulosa cell proliferation by upregulating PPAR $\beta$ -dependent PTEN expression.. Scientific Reports, 2016, 5, 18319.	3.3	55
576	Association of obesity and overweight with the prevalence of insulin resistance, pre-diabetes and clinicalâ€biochemical characteristics among infertile Mexican women with polycystic ovary syndrome: a cross-sectional study. BMJ Open, 2016, 6, e012107.	1.9	29
577	Diagnostic criteria for PCOS: Is there a need for a rethink?. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2016, 37, 5-11.	2.8	66
578	The clinical and biochemical characteristics associated with insulin resistance in non-obese young women. Gynecological Endocrinology, 2016, 32, 767-771.	1.7	2
579	Vitamin D Status Relates to Reproductive Outcome in Women With Polycystic Ovary Syndrome: Secondary Analysis of a Multicenter Randomized Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3027-3035.	3.6	66
580	Androgen excess: Investigations and management. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2016, 37, 98-118.	2.8	94
581	Challenges of diagnosing and managing the adolescent with heavy menstrual bleeding. Thrombosis Research, 2016, 143, 91-100.	1.7	30
582	Androgenic Disorders and Abnormal Pubertal Development. , 2016, , 109-125.		0
583	Ethnic differences: Is there an Asian phenotype for polycystic ovarian syndrome?. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2016, 37, 46-55.	2.8	47
584	Ovarian Physiology and GWAS: Biobanks, Biology, and Beyond. Trends in Endocrinology and Metabolism, 2016, 27, 516-528.	7.1	9



#	ARTICLE	IF	CITATIONS
585	Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertility and Sterility, 2016, 106, 6-15.	1.0	741
586	Polycystic Ovarian Syndrome: Is It Time to Rename PCOS to HA-PODS?. Journal of Obstetrics and Gynecology of India, 2016, 66, 81-87.	0.9	10
587	Abnormal Female Puberty. , 2016, , .		0
588	Are progranulin levels associated with polycystic ovary syndrome and its possible metabolic effects in adolescents and young women?. Archives of Gynecology and Obstetrics, 2016, 294, 403-409.	1.7	10
589	Focus on BMI and subclinical hypothyroidism in adolescent girls first examined for amenorrhea or oligomenorrhea. The emerging role of polycystic ovary syndrome. Journal of Pediatric Endocrinology and Metabolism, 2016, 29, 693-702.	0.9	11
590	Premenopausal Circulating Androgens and Risk of Endometrial Cancer: results of a Prospective Study. Hormones and Cancer, 2016, 7, 178-187.	4.9	20
591	Metformin or Oral Contraceptives for Adolescents With Polycystic Ovarian Syndrome: A Meta-analysis. Pediatrics, 2016, 137, .	2.1	67
592	Magnetic resonance imaging structured reporting in infertility. Fertility and Sterility, 2016, 105, 1421-1431.	1.0	14
593	Menstrual dysfunction. Obstetrics, Gynaecology and Reproductive Medicine, 2016, 26, 149-154.	0.3	1
594	Î²-endorphins Plasma Level is Higher in Lean Polycystic Ovary Syndrome (PCOS) Women. Experimental and Clinical Endocrinology and Diabetes, 2016, 124, 55-60.	1.2	11
595	Basic and Meal Stimulated Plasma GIP Levels are Higher in Lean PCOS Women with FAI over 5. Experimental and Clinical Endocrinology and Diabetes, 2016, 124, 77-81.	1.2	4
596	An evidence based approach for diagnosis of adolescent polycystic ovarian syndrome. Middle East Fertility Society Journal, 2016, 21, 194-195.	1.5	3
597	Polycystic Ovary Syndrome in Adolescent Girls. , 2016, , 229-245.		0
598	Metabolic implications of menstrual cycle length in non-hyperandrogenic women with polycystic ovarian morphology. Endocrine, 2016, 54, 798-807.	2.3	4
599	Raising threshold for diagnosis of polycystic ovary syndrome excludes population of patients with metabolic risk. Fertility and Sterility, 2016, 106, 1244-1251.	1.0	15
600	The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocrine Reviews, 2016, 37, 467-520.	20.1	863
601	What does a diagnostic label of "polycystic ovary syndrome"™ really mean in adolescence? a review of current practice recommendations. Clinical Obesity, 2016, 6, 1-18.	2.0	14
602	Effects of orlistat vs. metformin on weight loss-related clinical variables in women with PCOS: systematic review and meta-analysis. International Journal of Clinical Practice, 2016, 70, 450-461.	1.7	53

#	ARTICLE	IF	CITATIONS
604	Comparison of regional fat mass measurement by whole body <sup>1</sup>H DEXA scans and anthropometric measures to predict insulin resistance in women with polycystic ovary syndrome and controls. Acta Obstetrica Et Gynecologica Scandinavica, 2016, 95, 1235-1243.	2.8	34
605	The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Human Reproduction Update, 2016, 22, 687-708.	10.8	440
606	Phenotypes and body mass in women with polycystic ovary syndrome identified in referral versus unselected populations: systematic review and meta-analysis. Fertility and Sterility, 2016, 106, 1510-1520.e2.	1.0	112
607	Abnormally activated one-carbon metabolic pathway is associated with mtDNA hypermethylation and mitochondrial malfunction in the oocytes of polycystic ovary ovaries. Scientific Reports, 2016, 6, 19436.	3.3	63
608	Serum metabolomics of Indian women with polycystic ovary syndrome using <sup>1</sup>H NMR coupled with a pattern recognition approach. Molecular BioSystems, 2016, 12, 3407-3416.	2.9	34
609	Are There Benefits for Gestational Diabetes Mellitus in Treating Lower Levels of Hyperglycemia Than Standard Recommendations?. Canadian Journal of Diabetes, 2016, 40, 548-554.	0.8	8
610	Alternative splicing of DENND1A, a PCOS candidate gene, generates variant 2. Molecular and Cellular Endocrinology, 2016, 434, 25-35.	3.2	27
611	Polycystic ovary syndrome. Nature Reviews Disease Primers, 2016, 2, 16057.	30.5	1,004
612	Androgen Receptor in the Ovary Theca Cells Plays a Critical Role in Androgen-Induced Reproductive Dysfunction. Endocrinology, 2017, 158, en.2016-1608.	2.8	44
613	Cortisol-Metabolizing Enzymes in Polycystic Ovary Syndrome. Clinical Medicine Insights Reproductive Health, 2016, 10, CMRH.S35567.	3.9	18
614	The effect of home exercise on ovulation induction using clomiphene citrate in overweight underserved women with polycystic ovarian syndrome. Contraception and Reproductive Medicine, 2016, 1, 14.	1.9	10
615	Polycystic ovary syndrome in adolescents: a review of past year evidence. Current Opinion in Obstetrics and Gynecology, 2016, 28, 373-380.	2.0	9
616	Copy number variation analysis detects novel candidate genes involved in follicular growth and oocyte maturation in a cohort of premature ovarian failure cases. Human Reproduction, 2016, 31, 1913-1925.	0.9	41
617	Molecular signatures of ovarian diseases: Insights from network medicine perspective. Systems Biology in Reproductive Medicine, 2016, 62, 266-282.	2.1	47
618	The high-molecular weight multimer form of adiponectin is a useful marker of polycystic ovary syndrome in Bahraini Arab women. Clinical Nutrition ESPEN, 2016, 13, e33-e38.	1.2	6
619	Physiological Aspects of Female Fertility: Role of the Environment, Modern Lifestyle, and Genetics. Physiological Reviews, 2016, 96, 873-909.	28.8	143
620	Impact of Adolescent Gender Dysphoria on Treatment Uptake in an Obesity Management Program. Journal of Pediatrics, 2016, 176, 207-209.	1.8	3
621	MANAGEMENT OF ENDOCRINE DISEASE: Secondary polycystic ovary syndrome: theoretical and practical aspects. European Journal of Endocrinology, 2016, 175, R157-R169.	3.7	22

#	ARTICLE	IF	CITATIONS
622	Acupuncture for polycystic ovarian syndrome. The Cochrane Library, 2016, , CD007689.	2.8	39
623	Dietary intake, resting energy expenditure, and eating behavior in women with and without polycystic ovary syndrome. Clinical Nutrition, 2016, 35, 213-218.	5.0	54
624	MicroRNA Species in Follicular Fluid Associating With Polycystic Ovary Syndrome and Related Intermediary Phenotypes. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1579-1589.	3.6	58
625	Letrozole vs estradiol valerate induced PCOS in rats: glycemic, oxidative and inflammatory status assessment. Reproduction, 2016, 151, 401-409.	2.6	33
626	Stein and Leventhal: 80 years on. American Journal of Obstetrics and Gynecology, 2016, 214, 247.e1-247.e11.	1.3	66
627	Polycystic ovary syndrome and metabolic syndrome: the worrisome twosome?. Climacteric, 2016, 19, 7-16.	2.4	12
628	Maternal polycystic ovary syndrome and the risk of autism spectrum disorders in the offspring: a population-based nationwide study in Sweden. Molecular Psychiatry, 2016, 21, 1441-1448.	7.9	105
629	Defining Hyperandrogenism in Women With Polycystic Ovary Syndrome: A Challenging Perspective. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2013-2022.	3.6	84
630	Altered cardiorespiratory response to exercise in overweight and obese women with polycystic ovary syndrome. Physiological Reports, 2016, 4, e12719.	1.7	10
631	Effect of meal frequency on glucose and insulin levels in women with polycystic ovary syndrome: a randomised trial. European Journal of Clinical Nutrition, 2016, 70, 588-594.	2.9	22
632	Differential Expression of microRNAs in the Ovaries from Letrozole-Induced Rat Model of Polycystic Ovary Syndrome. DNA and Cell Biology, 2016, 35, 177-183.	1.9	23
633	Implications of Androgen Assay Accuracy in the Phenotyping of Women With Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 610-618.	3.6	51
634	Cutaneous Findings and Systemic Associations in Women With Polycystic Ovary Syndrome. JAMA Dermatology, 2016, 152, 391.	4.1	60
635	Anti-Müllerian hormone as a marker of ovarian reserve: What have we learned, and what should we know?. Reproductive Medicine and Biology, 2016, 15, 127-136.	2.4	52
636	A Dietary Medium-Chain Fatty Acid, Decanoic Acid, Inhibits Recruitment of Nur77 to the HSD3B2 Promoter In Vitro and Reverses Endocrine and Metabolic Abnormalities in a Rat Model of Polycystic Ovary Syndrome. Endocrinology, 2016, 157, 382-394.	2.8	29
637	The Role of Anti-Müllerian Hormone in the Characterization of the Different Polycystic Ovary Syndrome Phenotypes. Reproductive Sciences, 2016, 23, 655-661.	2.5	21
638	Association of serum glypican-4 levels with cardiovascular risk predictors in women with polycystic ovary syndrome – a pilot study. Gynecological Endocrinology, 2016, 32, 223-226.	1.7	9
639	Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria. Archives of Gynecology and Obstetrics, 2016, 293, 447-456.	1.7	44

#	ARTICLE	IF	CITATIONS
640	Association of TLR2 S450S and ICAM1 K469E polymorphisms with polycystic ovary syndrome (PCOS) and obesity. Journal of Reproductive Immunology, 2016, 113, 9-15.	1.9	13
641	Hyperandrogenism, Hirsutism, and Polycystic Ovary Syndrome. , 2016, , 2275-2296.e6.		2
642	Caring for women with polycystic ovary syndrome. Nurse Practitioner, 2017, 42, 39-47.	0.3	1
643	Western-style diet, sex steroids and metabolism. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 1147-1155.	3.8	49
644	Activity of LPO Processes in Women with Polycystic Ovarian Syndrome and Infertility. Bulletin of Experimental Biology and Medicine, 2017, 162, 320-322.	0.8	24
645	Is acne a sign of androgen excess disorder or not?. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2017, 211, 21-25.	1.1	23
646	Parallel diurnal fluctuation of testosterone, androstenedione, dehydroepiandrosterone and 17OHprogesterone as assessed in serum and saliva: validation of a novel liquid chromatography-tandem mass spectrometry method for salivary steroid profiling. Clinical Chemistry and Laboratory Medicine, 2017, 55, 1315-1323.	2.3	27
647	Vitamin D receptor polymorphisms and the polycystic ovary syndrome: A systematic review. Journal of Obstetrics and Gynaecology Research, 2017, 43, 436-446.	1.3	40
648	Role of vitamin E and D3 supplementation in Intra-Cytoplasmic Sperm Injection outcomes of women with polycystic ovarian syndrome: A double blinded randomized placebo-controlled trial. Clinical Nutrition ESPEN, 2017, 18, 23-30.	1.2	40
649	Evaluation of tumor necrosis factor alpha serum level in obese and lean women with clomiphene citrate resistant polycystic ovary disease. Middle East Fertility Society Journal, 2017, 22, 193-200.	1.5	0
651	Enhanced Inflammation without Impairment of Insulin Signaling in the Visceral Adipose Tissue of 5 $\alpha$ -Dihydrotestosterone-Induced Animal Model of Polycystic Ovary Syndrome. Experimental and Clinical Endocrinology and Diabetes, 2017, 125, 522-529.	1.2	11
652	Asthma in reproductive-aged women with polycystic ovary syndrome and association with obesity. European Respiratory Journal, 2017, 49, 1601334.	6.7	24
654	Prevalence of "obesity-associated gonadal dysfunction"™ in severely obese men and women and its resolution after bariatric surgery: a systematic review and meta-analysis. Human Reproduction Update, 2017, 23, 390-408.	10.8	166
655	Are women with polycystic ovary syndrome at increased cardiovascular disease risk later in life?. Climacteric, 2017, 20, 222-227.	2.4	54
656	Assessing Energy Requirements in Women With Polycystic Ovary Syndrome: A Comparison Against Doubly Labeled Water. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1951-1959.	3.6	4
657	Worldwide Dissatisfaction With the Diagnostic Process and Initial Treatment of PCOS. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 375-378.	3.6	12
658	The role of a pulse-based diet on infertility measures and metabolic syndrome risk: protocol of a randomized clinical trial in women with polycystic ovary syndrome. BMC Nutrition, 2017, 3, 23.	1.6	8
659	The evaluation of temperament and quality of life in patients with polycystic ovary syndrome. Gynecological Endocrinology, 2017, 33, 250-253.	1.7	20

#	ARTICLE	IF	CITATIONS
660	Insulin and the polycystic ovary syndrome. Diabetes Research and Clinical Practice, 2017, 130, 163-170.	2.8	150
661	Competing Factors Link to Bone Health in Polycystic Ovary Syndrome: Chronic Low-Grade Inflammation Takes a Toll. Scientific Reports, 2017, 7, 3432.	3.3	34
662	Association between biochemical hyperandrogenism parameters and Ferrimanâ€¢Gallwey score in patients with polycystic ovary syndrome: A systematic review and metaâ€¢regression analysis. Clinical Endocrinology, 2017, 87, 217-230.	2.4	40
663	Which origin for polycystic ovaries syndrome: Genetic, environmental or both?. Annales D'Endocrinologie, 2017, 78, 176-185.	1.4	34
664	MicroRNAâ€¢141â€¢3p targets DAPK1 and inhibits apoptosis in rat ovarian granulosa cells. Cell Biochemistry and Function, 2017, 35, 197-201.	2.9	38
665	Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women. Human Reproduction Update, 2017, 23, 580-599.	10.8	136
667	Testosterone and Women. , 2017, , 319-351.		0
668	The Effect of Vitamin D Supplementation on the Androgenic Profile in Patients with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Clinical Trials. Hormone and Metabolic Research, 2017, 49, 174-179.	1.5	41
669	Chinese Herbal Medicine for the Optimal Management of Polycystic Ovary Syndrome. The American Journal of Chinese Medicine, 2017, 45, 405-422.	3.8	62
670	Serum complexed and free prostate-specific antigen (PSA) for the diagnosis of the polycystic ovarian syndrome (PCOS). Clinical Chemistry and Laboratory Medicine, 2017, 55, 1789-1797.	2.3	14
672	Is cardiorespiratory fitness impaired in PCOS women? A review of the literature. Journal of Endocrinological Investigation, 2017, 40, 463-469.	3.3	13
673	Clinical perspectives in congenital adrenal hyperplasia due to 11âˆ²-hydroxylase deficiency. Endocrine, 2017, 55, 19-36.	2.3	99
674	Potential role of microRNAs in mammalian female fertility. Reproduction, Fertility and Development, 2017, 29, 8.	0.4	31
675	Polycystic ovary syndrome: early diagnosis and intervention are necessary for fertility preservation in young women with endometrial cancer under 35Âyears of age. Reproductive Medicine and Biology, 2017, 16, 67-71.	2.4	28
676	High salivary testosteroneâ€¢toâ€¢androstenedione ratio and adverse metabolic phenotypes in women with polycystic ovary syndrome. Clinical Endocrinology, 2017, 86, 567-575.	2.4	16
677	The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections, 2017, 6, 811-816.	1.9	5
678	Women with Polycystic Ovary Syndrome and Risk of Cardiovascular Disease. Journal of Medical Biochemistry, 2017, 36, 259-269.	1.7	21
679	Endometrium and steroids, a pathologic overview. Steroids, 2017, 126, 85-91.	1.8	30

#	ARTICLE	IF	CITATIONS
680	Polycystic ovary syndrome in Indian women: a mass spectrometry based serum metabolomics approach. <i>Metabolomics</i> , 2017, 13, 1.	3.0	8
681	Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial. <i>European Journal of Endocrinology</i> , 2017, 177, 399-408.	3.7	23
682	A Machine Learning Algorithm for Identifying Atopic Dermatitis in Adults from Electronic Health Records. , 2017, 2017, 83-90.		42
683	Are expanding disease definitions unnecessarily labelling women with polycystic ovary syndrome?. <i>BMJ: British Medical Journal</i> , 2017, 358, j3694.	2.3	36
684	Insulin resistance and obesity among infertile women with different polycystic ovary syndrome phenotypes. <i>Scientific Reports</i> , 2017, 7, 5339.	3.3	46
685	Polycystic Ovary Syndrome in Adolescents: Which MR Imagingâ€‘based Diagnostic Criteria?. <i>Radiology</i> , 2017, 285, 961-970.	7.3	15
686	Ageâ€‘stratified thresholds of antiâ€‘MÃ¼llerian hormone improve prediction of polycystic ovary syndrome over a populationâ€‘based threshold. <i>Clinical Endocrinology</i> , 2017, 87, 733-740.	2.4	26
687	Combined androgen excess and Western-style diet accelerates adipose tissue dysfunction in young adult, female nonhuman primates. <i>Human Reproduction</i> , 2017, 32, 1892-1902.	0.9	32
688	The Role of Androgen Excess in Metabolic Dysfunction in Women. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1043, 597-608.	1.6	8
689	An International Consortium Update: Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome in Adolescence. <i>Hormone Research in Paediatrics</i> , 2017, 88, 371-395.	1.8	282
690	Polycystic ovary syndrome, adipose tissue and metabolic syndrome. <i>Archives of Gynecology and Obstetrics</i> , 2017, 296, 405-419.	1.7	106
691	The Complex Interaction Between Polycystic Ovary Syndrome and Hereditary Angioedema: Case Reports and Review of the Literature. <i>Obstetrical and Gynecological Survey</i> , 2017, 72, 417-424.	0.4	2
692	Î² cell function and insulin resistance in lean cases with polycystic ovary syndrome. <i>Gynecological Endocrinology</i> , 2017, 33, 877-881.	1.7	7
693	Association of polycystic ovary syndrome with metabolic syndrome and gestational diabetes: Aggravated complication of pregnancy. <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 1271-1276.	1.8	35
694	Can the source of hyperandrogenism in adolescents with polycystic ovary syndrome predict metabolic phenotype?. <i>Gynecological Endocrinology</i> , 2017, 33, 882-887.	1.7	3
695	Ovarian morphology is associated with insulin resistance in women with polycystic ovary syndrome: a cross sectional study. <i>Fertility Research and Practice</i> , 2017, 3, 8.	4.2	20
696	Impact of the opioid system onâ€‘theâ€‘reproductive axis. <i>Fertility and Sterility</i> , 2017, 108, 207-213.	1.0	44
697	Effects of Dietary Approach to Stop Hypertension diet on androgens, antioxidant status and body composition in overweight and obese women with polycystic ovary syndrome: a randomised controlled trial. <i>Journal of Human Nutrition and Dietetics</i> , 2017, 30, 275-283.	2.5	48



#	ARTICLE	IF	CITATIONS
698	Apparent diffusion coefficient measurement of ovarian stroma: A potential tool for the diagnosis of polycystic ovary syndrome. Diagnostic and Interventional Imaging, 2017, 98, 57-61.	3.2	5
699	Endocrine and cardiometabolic cord blood characteristics of offspring born to mothers with and without polycystic ovary syndrome. Fertility and Sterility, 2017, 107, 261-268.e3.	1.0	40
700	Effects of Exercise Intervention on Preventing Letrozole-Exposed Rats From Polycystic Ovary Syndrome. Reproductive Sciences, 2017, 24, 456-462.	2.5	9
701	MANAGEMENT OF ENDOCRINE DISEASE: Morbidity in polycystic ovary syndrome. European Journal of Endocrinology, 2017, 176, R53-R65.	3.7	37
702	Long and irregular menstrual cycles, polycystic ovary syndrome, and ovarian cancer risk in a population-based case-control study. International Journal of Cancer, 2017, 140, 285-291.	5.1	63
703	Maternal Polycystic Ovary Syndrome and Risk for Attention-Deficit/Hyperactivity Disorder in the Offspring. Biological Psychiatry, 2017, 82, 651-659.	1.3	53
704	Evaluation of cardiac risk marker levels in obese and non-obese patients with polycystic ovaries. Gynecological Endocrinology, 2017, 33, 43-47.	1.7	24
705	Molecular Mechanisms of Androstenediol in the Regulation of the Proliferative Process of Human Endometrial Cells. Reproductive Sciences, 2017, 24, 1079-1087.	2.5	7
706	A potential determinant role of adiponectin and receptors for the early embryo development in PCOS patients with obesity hinted by quantitative profiling. Gynecological Endocrinology, 2017, 33, 113-118.	1.7	5
708	Perspectives on Polycystic Ovary Syndrome: Is Polycystic Ovary Syndrome Research Underfunded?. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4421-4427.	3.6	43
709	Effectiveness of acupoint catgut embedding therapy for polycystic ovary syndrome: a systematic review and meta-analysis. World Journal of Acupuncture-moxibustion, 2017, 27, 41-51.	0.5	5
710	Increased Adrenal Androgens in Overweight Peripubertal Girls. Journal of the Endocrine Society, 2017, 1, 538-552.	0.2	13
711	Association of Exon 10A and 10B inactivating mutation of follicle stimulating hormone receptor gene (FSHR) and Polycystic Ovarian Syndrome in Vellore cohort. IOP Conference Series: Materials Science and Engineering, 2017, 263, 022036.	0.6	1
712	The prevalence of polycystic ovary syndrome in reproductive-aged women of different ethnicity: a systematic review and meta-analysis. Oncotarget, 2017, 8, 96351-96358.	1.8	203
713	Nutritional support and dietary interventions for women with polycystic ovary syndrome. Nutrition and Dietary Supplements, 0, Volume 9, 63-85.	0.7	10
714	Intrauterine Reprogramming of the Polycystic Ovary Syndrome: Evidence from a Pilot Study of Cord Blood Global Methylation Analysis. Frontiers in Endocrinology, 2017, 8, 352.	3.5	35
715	Diagnosis, Pathogenesis and Management of Polycystic Ovary Syndrome. , 0, , .		3
716	Urinary bisphenol A and pubertal development in Chinese school-aged girls: a cross-sectional study. Environmental Health, 2017, 16, 80.	4.0	20

#	ARTICLE	IF	CITATIONS
717	Evolution of metabolic alterations 5ÂYears after early puberty in a cohort of girls predisposed to polycystic ovary syndrome. <i>Reproductive Biology and Endocrinology</i> , 2017, 15, 56.	3.3	6
718	Nutritional supplements and herbal medicines for women with polycystic ovary syndrome; a systematic review and meta-analysis. <i>BMC Complementary and Alternative Medicine</i> , 2017, 17, 500.	3.7	37
719	Evaluation of vitamin D3 in patients of polycystic ovary syndrome and their correlation. <i>International Journal of Reproduction, Contraception, Obstetrics and Gynecology</i> , 2017, 6, 2010.	0.1	0
720	New Therapeutic Approaches in Obesity and Metabolic Syndrome Associated with Polycystic Ovary Syndrome. <i>Cureus</i> , 2017, 9, e1844.	0.5	29
721	The effects of combined therapy of myo-inositol and D-chiro inositol in reduction of the individual components of metabolic syndrome in overweight PCOS patients compared to myo-inositol supplementation alone: a prospective randomised controlled trial. <i>International Journal of Reproduction, Contraception, Obstetrics and Gynecology</i> , 2017, 6, 2939.	0.1	3
722	Impact of metformin on C-reactive protein levels in women with polycystic ovary syndrome: a meta-analysis. <i>Oncotarget</i> , 2017, 8, 35425-35434.	1.8	7
723	Polycystic Ovary Syndrome: Implications for Cardiovascular, Endometrial, and Breast Disease. , 2017, , 456-457.		0
724	Effects of combined oral contraceptives on the clinical and biochemical parameters of hyperandrogenism in patients with polycystic ovary syndrome: a systematic review and meta-analysis. <i>European Journal of Contraception and Reproductive Health Care</i> , 2018, 23, 64-77.	1.5	29
725	Expression profiles of mRNA and long noncoding RNA in the ovaries of letrozole-induced polycystic ovary syndrome rat model through deep sequencing. <i>Gene</i> , 2018, 657, 19-29.	2.2	24
726	Insulin resistance in an animal model of polycystic ovary disease is aggravated by vitamin D deficiency: Vascular consequences. <i>Diabetes and Vascular Disease Research</i> , 2018, 15, 294-301.	2.0	24
727	Clinical application of serum antiâ€MÃ¼llerian hormone as an ovarian reserve marker: A review of recent studies. <i>Journal of Obstetrics and Gynaecology Research</i> , 2018, 44, 998-1006.	1.3	39
728	Obesity and Polycystic Ovary Syndrome. , 2018, , 59-70.		0
729	Does Metformin Treatment During Pregnancy Modify the Future Metabolic Profile in Women With PCOS?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2408-2413.	3.6	15
730	The role of rs267606943 polymorphism in the prolidase gene and plasma prolidase in polycystic ovary syndrome. <i>British Journal of Biomedical Science</i> , 2018, 75, 153-155.	1.3	1
731	Reproductive health, obesity, and cardiometabolic risk factors among Samoan women. <i>American Journal of Human Biology</i> , 2018, 30, e23106.	1.6	1
732	Menstrual Disorders and Hyperandrogenism in Adolescence. , 2018, , 641-667.		2
733	Association between Th1/Th2 immune imbalance and obesity in women with or without polycystic ovary syndrome. <i>Gynecological Endocrinology</i> , 2018, 34, 709-714.	1.7	28
734	MANAGEMENT OF ENDOCRINE DISEASE Hyperandrogenic states in women: pitfalls in laboratory diagnosis. <i>European Journal of Endocrinology</i> , 2018, 178, R141-R154.	3.7	19



#	ARTICLE	IF	CITATIONS
735	Relationship of Polycystic Ovarian Syndrome with Cardiovascular Risk Factors. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2018, 12, 375-380.	3.6	17
736	Non-targeted profiling of circulating microRNAs in women with polycystic ovary syndrome (PCOS): effects of obesity and sex hormones. Metabolism: Clinical and Experimental, 2018, 86, 49-60.	3.4	63
737	Differential rate in decline in ovarian reserve markers in women with polycystic ovary syndrome compared with control subjects: results of a longitudinal study. Fertility and Sterility, 2018, 109, 526-531.	1.0	18
738	Contemporary approaches to the management of polycystic ovary syndrome. Therapeutic Advances in Endocrinology and Metabolism, 2018, 9, 123-134.	3.2	21
739	Unilateral or bilateral laparoscopic ovarian drilling in polycystic ovary syndrome: a meta-analysis of randomized trials. Archives of Gynecology and Obstetrics, 2018, 297, 859-870.	1.7	25
740	Ovarian markers and irregular menses among women with type 1 diabetes in the Epidemiology of Diabetes Interventions and Complications study. Clinical Endocrinology, 2018, 88, 453-459.	2.4	5
741	Differential insulin and steroidogenic signaling in insulin resistant and non-insulin resistant human luteinized granulosa cellsâ€”A study in PCOS patients. Journal of Steroid Biochemistry and Molecular Biology, 2018, 178, 283-292.	2.5	39
742	Infertility in Women with Polycystic Ovary Syndrome. , 2018, , .		6
743	PCOS Phenotypes: Impact on Fertility. , 2018, , 81-87.		1
744	Follicle Excess and Abnormalities in Women with PCOS: Pathophysiology, Assessment and Clinical Role. , 2018, , 89-105.		0
745	New perspectives on the definition and management of polycystic ovary syndrome. Journal of Endocrinological Investigation, 2018, 41, 1123-1135.	3.3	42
746	A review of diagnosis and treatment of acne in adult female patients. International Journal of Women's Dermatology, 2018, 4, 56-71.	2.0	123
747	What is adolescent polycystic ovary syndrome?. Journal of Paediatrics and Child Health, 2018, 54, 351-355.	0.8	16
748	Prevalence, clinical characteristics, and reproductive outcomes of polycystic ovary syndrome in older women referred for tertiary fertility care. Archives of Gynecology and Obstetrics, 2018, 297, 1037-1042.	1.7	12
749	Evaluation of the correlation between insulin like factor 3, polycystic ovary syndrome, and ovarian maldevelopment. Gynecological Endocrinology, 2018, 34, 481-488.	1.7	8
750	Anogenital distance in newborn daughters of women with polycystic ovary syndrome indicates fetal testosterone exposure. Journal of Developmental Origins of Health and Disease, 2018, 9, 307-314.	1.4	99
751	Suspected ontogeny of a recently described hypo-androgenic PCOS-like phenotype with advancing age. Endocrine, 2018, 59, 661-676.	2.3	14
752	Combined oral contraceptives and/or antiandrogens versus insulin sensitizers for polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update, 2018, 24, 225-241.	10.8	36

#	ARTICLE	IF	CITATIONS
753	Effectiveness of Omega-3 fatty acid for polycystic ovary syndrome: a systematic review and meta-analysis. <i>Reproductive Biology and Endocrinology</i> , 2018, 16, 27.	3.3	63
754	Polycystic ovary syndrome: possible involvement of androgen-induced, chemerin-mediated ovarian recruitment of monocytes/macrophages. <i>Biology of Reproduction</i> , 2018, 99, 838-852.	2.7	71
755	High level of C-type natriuretic peptide induced by hyperandrogen-mediated anovulation in polycystic ovary syndrome mice. <i>Clinical Science</i> , 2018, 132, 759-776.	4.3	21
756	Serum AMH levels and insulin resistance in women with PCOS. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2018, 224, 159-164.	1.1	38
757	The Diagnostic Value of Anti-Müllerian Hormone in Early Post Menarche Adolescent Girls with Polycystic Ovarian Syndrome. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2018, 31, 362-366.	0.7	6
758	Antiandrogen Treatment Ameliorates Reproductive and Metabolic Phenotypes in the Letrozole-Induced Mouse Model of PCOS. <i>Endocrinology</i> , 2018, 159, 1734-1747.	2.8	56
759	Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. <i>Nature Reviews Endocrinology</i> , 2018, 14, 270-284.	9.6	1,013
760	Pregnancy outcomes in women with polycystic ovary syndrome in two Latin American populations. <i>Journal of Obstetrics and Gynaecology</i> , 2018, 38, 750-755.	0.9	7
761	Women With Polycystic Ovary Syndrome Have Comparable Hip Bone Geometry to Age-Matched Control Women. <i>Journal of Clinical Densitometry</i> , 2018, 21, 54-60.	1.2	10
762	Histomorphometric Comparison of Induction of Polycystic Ovary Syndrome by Exposure to Constant Light in Primiparous and Nulliparous Rats. <i>Iranian Journal of Science and Technology, Transaction A: Science</i> , 2018, 42, 421-430.	1.5	1
763	Polycystic Ovary Syndrome among Obese Adolescents. <i>Gynecological Endocrinology</i> , 2018, 34, 45-48.	1.7	10
764	Ovarian volume and PCOS: a controversial issue. <i>Gynecological Endocrinology</i> , 2018, 34, 229-232.	1.7	17
765	Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis. <i>Endocrine</i> , 2018, 59, 30-38.	2.3	39
766	Links Between Polycystic Ovary Syndrome and Gestational Diabetes Mellitus. , 2018, , 189-206.		0
767	Gynecologic and andrologic dermatology and the metabolic syndrome. <i>Clinics in Dermatology</i> , 2018, 36, 72-80.	1.6	15
768	Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences. <i>Metabolism: Clinical and Experimental</i> , 2018, 86, 33-43.	3.4	217
769	Prevalence of dermatologic manifestations and metabolic biomarkers in women with polycystic ovary syndrome in north China. <i>Journal of Cosmetic Dermatology</i> , 2018, 17, 511-517.	1.6	21
770	Adropin levels in women with polycystic ovaries undergoing ovarian stimulation: correlation with lipoprotein lipid profiles. <i>Gynecological Endocrinology</i> , 2018, 34, 153-156.	1.7	14

#	ARTICLE	IF	CITATIONS
771	Polycystic ovary syndrome throughout a woman's life. <i>Journal of Assisted Reproduction and Genetics</i> , 2018, 35, 25-39.	2.5	110
772	Polycystic ovary syndrome in adolescents. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2018, 48, 103-114.	2.8	48
773	Alopecia and the metabolic syndrome. <i>Clinics in Dermatology</i> , 2018, 36, 54-61.	1.6	34
774	Borderline personality disorder and polycystic ovary syndrome: A review of the literature. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 117-128.	2.3	8
776	Sex hormone binding globulin - an important biomarker for predicting PCOS risk: A systematic review and meta-analysis. <i>Systems Biology in Reproductive Medicine</i> , 2018, 64, 12-24.	2.1	99
777	High-fat diet exposure from pre-pubertal age induces polycystic ovary syndrome (PCOS) in rats. <i>Reproduction</i> , 2018, 155, 139-149.	2.6	50
778	The effect of vitamin D supplementation in combination with low-calorie diet on anthropometric indices and androgen hormones in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 597-607.	3.3	26
779	Anti-Müllerian hormone measurement for the diagnosis of polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2018, 88, 258-262.	2.4	28
780	Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 174-182.	2.5	20
781	“You Think You’re the Only One”: Comparing Descriptions and Lived Experiences of Polycystic Ovarian Syndrome. <i>Anthropologica</i> , 2018, 60, 507-522.	0.1	0
782	Prevalence, pathogenesis and management of prediabetes and type 2 diabetes mellitus in patients with polycystic ovary syndrome. <i>Hormones</i> , 2018, 16, 373-380.	1.9	11
783	Polycystic ovary syndrome: Impact of obesity and aging on the profile of gonadotrophin and adrenal hormones. <i>International Journal of Medicine and Medical Sciences</i> , 2018, 10, 79-85.	0.3	0
784	The Effect of Nutrient Supplementation in Management of Polycystic Ovary Syndrome Associated Metabolic Dysfunctions: A Critical Review. <i>Journal of the Turkish German Gynecology Association</i> , 2018, 19, 220-232.	0.6	32
785	A prospective analysis of polycystic ovarian syndrome in infertile women. <i>International Journal of Reproduction, Contraception, Obstetrics and Gynecology</i> , 2018, 8, 299.	0.1	1
786	Geographical Prevalence of Polycystic Ovary Syndrome as Determined by Region and Race/Ethnicity. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 2589.	2.6	224
787	An Improved Dehydroepiandrosterone-Induced Rat Model of Polycystic Ovary Syndrome (PCOS): Post-pubertal Improve PCOS's Features. <i>Frontiers in Endocrinology</i> , 2018, 9, 735.	3.5	39
788	Sexual function in women with polycystic ovary syndrome: a systematic review and meta-analysis. <i>Reproductive BioMedicine Online</i> , 2018, 37, 750-760.	2.4	55
789	Inositol for subfertile women with polycystic ovary syndrome. <i>The Cochrane Library</i> , 2018, 12, CD012378.	2.8	27

#	ARTICLE	IF	CITATIONS
790	Polycystic Ovarian Condition May Be a Risk Factor for Ovarian Tumor Development in the Laying Hen Model of Spontaneous Ovarian Cancer. <i>Journal of Immunology Research</i> , 2018, 2018, 1-13.	2.2	6
791	Future Implications of Using Registered Dietitians in Multidisciplinary Polycystic Ovary Syndrome Treatment. <i>Healthcare (Switzerland)</i> , 2018, 6, 144.	2.0	2
792	Serum bisphenol A concentrations correlate with serum testosterone levels in women with polycystic ovary syndrome. <i>Reproductive Toxicology</i> , 2018, 82, 32-37.	2.9	39
793	Certified testosterone immunoassays for hyperandrogenaemia. <i>European Journal of Clinical Investigation</i> , 2018, 48, e13029.	3.4	5
794	Menstrual Patterns in the First Gynecological Year: A Systematic Review. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2018, 31, 557-565.e6.	0.7	33
796	Methodological and reporting quality evaluation of systematic reviews on acupuncture in women with polycystic ovarian syndrome: A systematic review. <i>Complementary Therapies in Clinical Practice</i> , 2018, 33, 197-203.	1.7	12
797	Metabolic inflexibility in women with PCOS is similar to women with type 2 diabetes. <i>Nutrition and Metabolism</i> , 2018, 15, 75.	3.0	17
798	Urinary steroid profiling in women hints at a diagnostic signature of the polycystic ovary syndrome: A pilot study considering neglected steroid metabolites. <i>PLoS ONE</i> , 2018, 13, e0203903.	2.5	31
799	Assessing C reactive protein/albumin ratio as a new biomarker for polycystic ovary syndrome: a caseâ€“control study of women from Bahraini medical clinics. <i>BMJ Open</i> , 2018, 8, e021860.	1.9	26
800	The Current Description and Future Need for Multidisciplinary PCOS Clinics. <i>Journal of Clinical Medicine</i> , 2018, 7, 395.	2.4	23
801	Assessment of anogenital distance as a diagnostic tool in polycystic ovary syndrome. <i>Reproductive BioMedicine Online</i> , 2018, 37, 741-749.	2.4	21
802	Hormonal and Metabolic Effects of Coenzyme Q10 and/or Vitamin E in Patients with Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 319-327.	3.6	45
803	Integrated Model of Care for Polycystic Ovary Syndrome. <i>Seminars in Reproductive Medicine</i> , 2018, 36, 086-094.	1.1	14
804	Lean Women with Polycystic Ovary Syndrome. , 2018, , .		1
805	Does the Pituitary Gland Volume Change in Polycystic Ovary Syndrome?. <i>Gynecologic and Obstetric Investigation</i> , 2018, 83, 515-519.	1.6	9
806	The association between circulating irisin levels and different phenotypes of polycystic ovary syndrome. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 1401-1407.	3.3	25
807	The diagnosis of PCOS in young infertile women according to different diagnostic criteria: the role of serum anti-M�llerian hormone. <i>Archives of Gynecology and Obstetrics</i> , 2018, 298, 207-215.	1.7	13
808	Clitoromegaly in Childhood and Adolescence: Behind One Clinical Sign, a Clinical Sea. <i>Sexual Development</i> , 2018, 12, 163-174.	2.0	17

#	ARTICLE	IF	CITATIONS
809	Abnormal Uterine Bleeding in Young Women with Blood Disorders. <i>Pediatric Clinics of North America</i> , 2018, 65, 543-560.	1.8	12
810	Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome. <i>The Cochrane Library</i> , 2018, 2018, CD010287.	2.8	88
811	Role of Lipotoxicity and Contribution of the Renin-Angiotensin System in the Development of Polycystic Ovary Syndrome. <i>International Journal of Endocrinology</i> , 2018, 2018, 1-13.	1.5	10
812	Ovarian and extra-ovarian mediators in the development of polycystic ovary syndrome. <i>Journal of Molecular Endocrinology</i> , 2018, 61, R161-R184.	2.5	26
813	Understanding variation in prevalence estimates of polycystic ovary syndrome: a systematic review and meta-analysis. <i>Human Reproduction Update</i> , 2018, 24, 694-709.	10.8	134
815	Maternal androgen excess and obesity induce sexually dimorphic anxiety-like behavior in the offspring. <i>FASEB Journal</i> , 2018, 32, 4158-4171.	0.5	37
816	High-Frequency Electrical Modulation of the Superior Ovarian Nerve as a Treatment of Polycystic Ovary Syndrome in the Rat. <i>Frontiers in Physiology</i> , 2018, 9, 459.	2.8	11
817	Are Psychosocial Consequences of Obesity and Hyperandrogenism Present in Adolescent Girls with Polycystic Ovary Syndrome?. <i>International Journal of Endocrinology</i> , 2018, 2018, 1-10.	1.5	4
818	Gut Microbiota and the Polycystic Ovary Syndrome: Influence of Sex, Sex Hormones, and Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2552-2562.	3.6	201
819	Polycystic Ovary Syndrome. <i>Nursing Clinics of North America</i> , 2018, 53, 407-420.	1.5	103
820	11-oxygenated C19 steroids as circulating androgens in women with polycystic ovary syndrome. <i>Endocrine Journal</i> , 2018, 65, 979-990.	1.6	41
821	Impacts of Air Pollution on Gynecologic Disease: Infertility, Menstrual Irregularity, Uterine Fibroids, and Endometriosis: a Systematic Review and Commentary. <i>Current Epidemiology Reports</i> , 2018, 5, 197-204.	2.4	5
822	Elevated androstenedione in young adult but not early adolescent prenatally androgenized female rats. <i>PLoS ONE</i> , 2018, 13, e0196862.	2.5	8
823	Effectiveness of Laser Acupoints on Women With Polycystic Ovarian Syndrome: A Randomized Controlled Trial. <i>Journal of Lasers in Medical Sciences</i> , 2018, 9, 113-120.	1.2	6
824	The Rise, Fall, and Resurrection of 11-Oxygenated Androgens in Human Physiology and Disease. <i>Hormone Research in Paediatrics</i> , 2018, 89, 284-291.	1.8	40
825	Cumulative live birth rates after IVF in patients with polycystic ovaries: phenotype matters. <i>Reproductive BioMedicine Online</i> , 2018, 37, 163-171.	2.4	47
826	The Polycystic Ovary Syndrome and the Metabolic Syndrome: A Possible Chronobiotic-Cytoprotective Adjuvant Therapy. <i>International Journal of Endocrinology</i> , 2018, 2018, 1-12.	1.5	29
827	Polycystic ovary syndrome in familial partial lipodystrophy type 2 (FPLD2): basic and clinical aspects. <i>Nucleus</i> , 2018, 9, 392-397.	2.2	10

#	ARTICLE	IF	CITATIONS
828	Polycystic ovary syndrome and the risk of cardiometabolic complications in longitudinal studies. Diabetes/Metabolism Research and Reviews, 2018, 34, e3054.	4.0	32
829	Plasma prolidase levels as a biomarker for polycystic ovary syndrome. Biomarkers in Medicine, 2018, 12, 597-606.	1.4	7
830	Long-Term Response of Hirsutism and Other Hyperandrogenic Symptoms to Combination Therapy in Polycystic Ovary Syndrome. Journal of Women's Health, 2018, 27, 892-902.	3.3	14
831	Anti-Müllerian Hormone (AMH) in Adults. , 2019, , 556-566.		0
832	Polycystic Ovary Syndrome and Hyperandrogenic States. , 2019, , 520-555.e13.		11
833	Increased platelet factor 4 and aberrant permeability of follicular fluid in PCOS. Journal of the Formosan Medical Association, 2019, 118, 249-259.	1.7	11
834	Can Polycystic Ovarian Syndrome be cured? Unfolding the Concept of Secondary Polycystic Ovarian Syndrome!. Journal of Obstetrics and Gynecology of India, 2019, 69, 297-302.	0.9	4
835	Diagnostic Value of Anti-Müllerian Hormone as a Biomarker for Polycystic Ovary Syndrome: A Meta-Analysis Update. Endocrine Practice, 2019, 25, 1056-1066.	2.1	10
836	Ovarian and Adrenal Venous Catheterization for Hyperandrogenism. journal of applied laboratory medicine, The, 2019, 4, 439-445.	1.3	1
837	Polycystic Ovary Syndrome (PCOS) and Sexual Dysfunctions. Journal of Psychosexual Health, 2019, 1, 154-158.	0.6	3
838	The impact of polycystic ovary syndrome on women's quality of life: Nursing guidelines for its. Clinical Nursing Studies, 2019, 7, 42.	0.1	3
839	Role of microRNA in the Pathogenesis of Polycystic Ovary Syndrome. DNA and Cell Biology, 2019, 38, 754-762.	1.9	29
840	Phenotypic spectrum of polycystic ovary syndrome and their relationship to the circadian biomarkers, melatonin and cortisol. Endocrinology, Diabetes and Metabolism, 2019, 2, e00047.	2.4	14
841	Insulin gene VNTR class III allele is a risk factor for insulin resistance in Kashmiri women with polycystic ovary syndrome. Meta Gene, 2019, 21, 100597.	0.6	10
842	PCOS. , 2019, , 91-109.		0
843	Opioids and reproduction. Vitamins and Hormones, 2019, 111, 247-279.	1.7	12
845	Polycystic ovary syndrome is a risk factor for sarcopenic obesity: a case control study. BMC Endocrine Disorders, 2019, 19, 70.	2.2	13
846	Polycystic Ovary Syndrome and NC-CAH: Distinct Characteristics and Common Findings. A Systematic Review. Frontiers in Endocrinology, 2019, 10, 388.	3.5	36

#	ARTICLE	IF	CITATIONS
847	Insulin Resistance and Serum Magnesium Concentrations among Women with Polycystic Ovary Syndrome. Current Developments in Nutrition, 2019, 3, nzz108.	0.3	22
848	Prostatic-specific antigen (PSA) levels in patients with polycystic ovary syndrome (PCOS): a meta-analysis. Journal of Ovarian Research, 2019, 12, 94.	3.0	7
849	Toward a standard definition of polycystic ovarian morphology. Fertility and Sterility, 2019, 112, 823-824.	1.0	0
850	Experimental models of polycystic ovary syndrome: An update. Life Sciences, 2019, 237, 116911.	4.3	15
851	Androgen and Anti-Mullerian Hormone Concentrations at Term in Newborns and Their Mothers with and without Polycystic Ovary Syndrome. Journal of Clinical Medicine, 2019, 8, 1817.	2.4	10
852	Inflammatory Stimuli Trigger Increased Androgen Production and Shifts in Gene Expression in Theca-Interstitial Cells. Endocrinology, 2019, 160, 2946-2958.	2.8	38
853	Impact of Testosterone on Aspects of Psychology. , 2019, , 95-120.		0
854	Controversial association between polycystic ovary syndrome and breast cancer. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2019, 243, 125-132.	1.1	19
855	Abdominal Obesity as a Predictive Factor of Nonalcoholic Fatty Liver Disease Assessed by Ultrasonography and Transient Elastography in Polycystic Ovary Syndrome and Healthy Women. BioMed Research International, 2019, 2019, 1-9.	1.9	16
856	PCOS and Hyperprolactinemia: what do we know in 2019?. Clinical Medicine Insights Reproductive Health, 2019, 13, 117955811987192.	3.9	51
857	Polycystic Ovary Syndrome in Adolescents: Challenges in Diagnosis and Treatment. International Journal of Endocrinology and Metabolism, 2019, 17, e91554.	1.0	28
858	Pediatric androgenetic alopecia: A review. Journal of the American Academy of Dermatology, 2021, 85, 1267-1273.	1.2	19
859	Single nucleotide polymorphisms in treatment of polycystic ovary syndrome: a systematic review. Drug Metabolism Reviews, 2019, 51, 612-622.	3.6	6
860	Functional and endocrine-metabolic oligomenorrhea: proposal of a new diagnostic assessment tool for differential diagnosis in adolescence. Journal of Pediatric Endocrinology and Metabolism, 2019, 32, 135-142.	0.9	1
861	Is polycystic ovary syndrome a 20th Century phenomenon?. Medical Hypotheses, 2019, 124, 31-34.	1.5	19
862	Diagnosis of disorders of glucose tolerance in women with polycystic ovary syndrome (PCOS) at a tertiary care center: fasting plasma glucose or oral glucose tolerance test?. Metabolism: Clinical and Experimental, 2019, 93, 86-92.	3.4	18
863	Association of rs6259 polymorphism with SHBG levels and Poly Cystic Ovary Syndrome in Indian population: a case control study. Molecular Biology Reports, 2019, 46, 2131-2138.	2.3	4
864	Independent and Additive Effects of Coenzyme Q10 and Vitamin E on Cardiometabolic Outcomes and Visceral Adiposity in Women With Polycystic Ovary Syndrome. Archives of Medical Research, 2019, 50, 1-10.	3.3	25



#	ARTICLE	IF	CITATIONS
865	Serum ferritin as a candidate diagnostic biomarker of polycystic ovarian syndrome: a meta-analysis. <i>Biomarkers</i> , 2019, 24, 484-491.	1.9	4
866	Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2019, 48, 822-830.	1.9	22
867	Quality of life among infertile PCOS patients. <i>Archives of Gynecology and Obstetrics</i> , 2019, 300, 461-467.	1.7	22
868	Chronic low-grade inflammation in polycystic ovary syndrome: is there a (patho)-physiological role for interleukin-1?. <i>Seminars in Immunopathology</i> , 2019, 41, 447-459.	6.1	37
869	Sexual Function and Socio-Sexual Difficulties in Women with Polycystic Ovary Syndrome (PCOS). <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 498-509.	1.8	18
870	PCOS diagnosis in adolescents: the timeline of a controversy in a systematic review. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2019, 32, 549-559.	0.9	9
871	A robust LC-MS/MS assay with online cleanup for measurement of serum testosterone. <i>Journal of Separation Science</i> , 2019, 42, 2561-2568.	2.5	4
872	Polycystic Ovary Syndrome and Cardiovascular Diseases: Still na Open Door. <i>Arquivos Brasileiros De Cardiologia</i> , 2019, 112, 430-431.	0.8	1
873	The serum level of irisin, but not asprosin, is abnormal in polycystic ovary syndrome patients. <i>Scientific Reports</i> , 2019, 9, 6447.	3.3	38
874	Serum and follicular fluid irisin levels in women with polycystic ovaries undergoing ovarian stimulation: correlation with insulin resistance and lipoprotein lipid profiles. <i>Gynecological Endocrinology</i> , 2019, 35, 803-806.	1.7	9
875	The role of MiRNA in polycystic ovary syndrome (PCOS). <i>Gene</i> , 2019, 706, 91-96.	2.2	102
876	A review of acupuncture in obstetrics and gynaecology. <i>The Obstetrician and Gynaecologist</i> , 2019, 21, 209-214.	0.4	4
877	Serum Prostate-Specific Antigen Level in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis. <i>Hormone and Metabolic Research</i> , 2019, 51, 230-242.	1.5	5
878	Assessment of the Relationship Between Serum High Molecular Weight Adiponectin Hormone Levels and Insulin Resistance in Patients with Polycystic Ovary Syndrome. <i>Hormone and Metabolic Research</i> , 2019, 51, 261-266.	1.5	3
879	Letrozole treatment of adult female mice results in a similar reproductive phenotype but distinct changes in metabolism and the gut microbiome compared to pubertal mice. <i>BMC Microbiology</i> , 2019, 19, 57.	3.3	31
880	Health-related quality of life questionnaire for polycystic ovary syndrome (PCOSQ-50): a psychometric study with the Serbian version. <i>Women and Health</i> , 2019, 59, 1015-1025.	1.0	6
881	Plasma level of peroxiredoxin 3 in patients with polycystic ovarian syndrome. <i>BMC Endocrine Disorders</i> , 2019, 19, 32.	2.2	2
882	Polycystic ovary syndrome. <i>Nurse Practitioner</i> , 2019, 44, 30-35.	0.3	11

#	ARTICLE	IF	CITATIONS
883	Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study. <i>Journal of Ovarian Research</i> , 2019, 12, 25.	3.0	21
884	Polycystic ovary syndrome in adult women. <i>Medicina Clínica (English Edition)</i> , 2019, 152, 450-457.	0.2	12
885	Androgens drive microvascular endothelial dysfunction in women with polycystic ovary syndrome: role of the endothelin B receptor. <i>Journal of Physiology</i> , 2019, 597, 2853-2865.	2.9	44
886	Association Between Vitamin D and Adrenal Parameters with Metabolic and Inflammatory Markers in Polycystic Ovary Syndrome. <i>Scientific Reports</i> , 2019, 9, 3968.	3.3	10
887	Dietary intake and lifestyle behaviour in different phenotypes of polycystic ovarian syndrome: a caseâ€“control study. <i>Journal of Human Nutrition and Dietetics</i> , 2019, 32, 413-421.	2.5	11
888	Improved diagnostic performance for the diagnosis of polycystic ovary syndrome using age-stratified criteria. <i>Fertility and Sterility</i> , 2019, 111, 787-793.e2.	1.0	11
889	Polycystic ovary syndrome in adolescents. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2019, 33, 101272.	4.7	19
890	Molecular Mechanisms in Skeletal Muscle Underlying Insulin Resistance in Women Who Are Lean With Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1841-1854.	3.6	50
891	Polycystic Ovary Syndrome and Insulin Physiology: An Observational Quantitative Serum Proteomics Study in Adolescent, Normalâ€“Weight Females. <i>Proteomics - Clinical Applications</i> , 2019, 13, 1800184.	1.6	11
892	The Role of microRNAs in Ovarian Granulosa Cells in Health and Disease. <i>Frontiers in Endocrinology</i> , 2019, 10, 174.	3.5	75
893	Association of paraoxonase-1 L55M and Q192R polymorphisms with PCOS risk and potential risk factors for atherosclerosis. <i>Biomarkers in Medicine</i> , 2019, 13, 279-289.	1.4	4
894	Urinary volatile metabolomics as a viable alternative diagnostic tool for polycystic ovary syndrome: An exploratory hypothesis. <i>Medical Hypotheses</i> , 2019, 124, 121-124.	1.5	9
895	Familial clustering of metabolic phenotype in brothers of women with polycystic ovary syndrome. <i>Gynecological Endocrinology</i> , 2019, 35, 601-603.	1.7	16
896	Exercise, or exercise and diet for the management of polycystic ovary syndrome: a systematic review and meta-analysis. <i>Systematic Reviews</i> , 2019, 8, 51.	5.3	72
897	Metabolomics of Dynamic Changes in Insulin Resistance Before and After Exercise in PCOS. <i>Frontiers in Endocrinology</i> , 2019, 10, 116.	3.5	29
898	Comprehensive genotyping of Turkish women with hirsutism. <i>Journal of Endocrinological Investigation</i> , 2019, 42, 1077-1087.	3.3	10
899	Hyperandrogenism in polycystic ovarian syndrome and role of CYP gene variants: a review. <i>Egyptian Journal of Medical Human Genetics</i> , 2019, 20, .	1.0	70
900	<p>Genetic Basis of Polycystic Ovary Syndrome (PCOS): Current Perspectives</p>. The Application of Clinical Genetics, 2019, Volume 12, 249-260.	3.0	159

#	ARTICLE	IF	CITATIONS
901	Psychological Aspects of Polycystic Ovary Syndrome. , 2019, , .		1
902	Polycystic Ovary Syndrome: Impact of Lipotoxicity on Metabolic and Reproductive Health. Obstetrical and Gynecological Survey, 2019, 74, 223-231.	0.4	20
903	Roles of different n-3/n-6 PUFA ratios in ovarian cell development and steroidogenesis in PCOS rats. Food and Function, 2019, 10, 7397-7406.	4.6	7
904	Nephrolithiasis and Polycystic Ovary Syndrome: A Case-Control Study Evaluating Testosterone and Urinary Stone Metabolic Panels. Advances in Urology, 2019, 2019, 1-7.	1.3	4
905	Development and Long-Term Evaluation of Ocular Surface Conditions Using Ovariectomized Cynomolgus Monkey. Eye and Contact Lens, 2019, 45, 246-253.	1.6	0
906	Data mining polycystic ovary morphology in electronic medical record ultrasound reports. Fertility Research and Practice, 2019, 5, 13.	4.2	13
907	Polycystic ovary syndrome. Nursing, 2019, 49, 34-40.	0.3	17
908	Screening and Management of the Hyperandrogenic Adolescent. Obstetrics and Gynecology, 2019, 134, e106-e114.	2.4	19
909	Risk of Polycystic Ovary Syndrome in Women Exposed to Fine Air Pollutants and Acidic Gases: A Nationwide Cohort Analysis. International Journal of Environmental Research and Public Health, 2019, 16, 4816.	2.6	20
910	Exploring the Pharmacological Mechanism of Quercetin-Resveratrol Combination for Polycystic Ovary Syndrome: A Systematic Pharmacological Strategy-Based Research. Scientific Reports, 2019, 9, 18420.	3.3	14
911	Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model. American Journal of Physiology - Endocrinology and Metabolism, 2019, 316, E16-E33.	3.5	27
912	The relationship between clinical and biochemical characteristics and quality of life in patients with polycystic ovary syndrome. Clinical Endocrinology, 2019, 90, 129-137.	2.4	19
913	Polymorphisms in vitamin D receptor gene, but not vitamin D levels, are associated with polycystic ovary syndrome in Brazilian women. Gynecological Endocrinology, 2019, 35, 146-149.	1.7	15
914	Dehydroepiandrosterone stimulates inflammation and impairs ovarian functions of polycystic ovary syndrome. Journal of Cellular Physiology, 2019, 234, 7435-7447.	4.1	62
915	S�ndrome de ovario poliqu�stico en la mujer adulta. Medicina Cl�nica, 2019, 152, 450-457.	0.6	22
916	Homocysteine impairs porcine oocyte quality via deregulation of one-carbon metabolism and hypermethylation of mitochondrial DNA�. Biology of Reproduction, 2019, 100, 907-916.	2.7	19
917	Evaluating the association of TNF � promoter haplotype with its serum levels and the risk of PCOS: A case control study. Cytokine, 2019, 114, 86-91.	3.2	15
918	Elevation of antim�llerian hormone in women with polycystic ovary syndrome undergoing assisted reproduction: effect of insulin. Fertility and Sterility, 2019, 111, 157-167.	1.0	20

#	ARTICLE	IF	CITATIONS
919	Active learning with simultaneous subject and variable selections. <i>Neurocomputing</i> , 2019, 329, 495-505.	5.9	2
920	Relationships Between Biochemical Markers of Hyperandrogenism and Metabolic Parameters in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. <i>Hormone and Metabolic Research</i> , 2019, 51, 22-34.	1.5	12
921	Circulating neuregulin-1 levels in polycystic ovary syndrome. <i>Journal of Obstetrics and Gynaecology</i> , 2019, 39, 504-509.	0.9	6
922	Nonpharmacologic Management of Symptoms in Females With Polycystic Ovary Syndrome: A Narrative Review. <i>Journal of Osteopathic Medicine</i> , 2019, 119, 25-39.	0.8	4
923	Development of a novel risk prediction and risk stratification score for polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2019, 90, 162-169.	2.4	13
924	Myoâ€inositol and Dâ€chiroâ€inositol (40:1) reverse histological and functional features of polycystic ovary syndrome in a mouse model. <i>Journal of Cellular Physiology</i> , 2019, 234, 9387-9398.	4.1	54
925	Dehydroepiandrosterone sulfate/free androgen index ratio predicts a favorable metabolic profile in patients with polycystic ovary syndrome. <i>Gynecological Endocrinology</i> , 2019, 35, 128-132.	1.7	3
926	PCOS and Type II Diabetes. , 2019, , 75-90.		0
927	Bidirectional Mendelian randomization to explore the causal relationships between body mass index and polycystic ovary syndrome. <i>Human Reproduction</i> , 2019, 34, 127-136.	0.9	77
928	Serum betatrophin levels are reduced in patients with full-blown polycystic ovary syndrome. <i>Gynecological Endocrinology</i> , 2019, 35, 224-227.	1.7	7
930	Metabolic syndrome in Iranian adolescents with polycystic ovary syndrome. <i>International Journal of Adolescent Medicine and Health</i> , 2019, 31, .	1.3	4
931	Gene expression profile following an oral unsaturated fat load in abdominal obese subjects. <i>European Journal of Nutrition</i> , 2019, 58, 1331-1337.	3.9	4
932	Impact of mitochondrial DNA copy number and displacement loop alterations on polycystic ovary syndrome risk in south Indian women. <i>Mitochondrion</i> , 2019, 44, 35-40.	3.4	35
933	Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. <i>Endocrine</i> , 2020, 67, 1-8.	2.3	150
934	Quality of life and sexual function in women with polycystic ovary syndrome: a comprehensive review. <i>Gynecological Endocrinology</i> , 2020, 36, 96-103.	1.7	23
935	Managing Womenâ€™s Hyperandrogenism. , 2020, , .		0
936	Adiponectin (<i>ADIPOQ</i>) gene variants and haplotypes in Saudi Arabian women with polycystic ovary syndrome (PCOS): a caseâ€“control study. <i>Gynecological Endocrinology</i> , 2020, 36, 66-71.	1.7	10
937	Is the presence of <i>Demodex folliculorum</i> increased with impaired glucose regulation in polycystic ovary syndrome?. <i>Journal of Obstetrics and Gynaecology</i> , 2020, 40, 546-550.	0.9	3

#	ARTICLE	IF	CITATIONS
938	Curtailing PCOS. Pediatric Research, 2020, 87, 353-361.	2.3	53
939	A comparison of the effects of oral contraceptives on the clinical and biochemical manifestations of polycystic ovary syndrome: a crossover randomized controlled trial. Human Reproduction, 2020, 35, 175-186.	0.9	17
940	Discriminating hypothalamic oligomenorrhea/amenorrhea from hyperandrogenic oligomenorrhea/amenorrhea in exercising women. Applied Physiology, Nutrition and Metabolism, 2020, 45, 707-714.	1.9	13
941	Association between circulating zinc- $\alpha$ 2-glycoprotein levels and the different phenotypes of polycystic ovary syndrome. Endocrine Journal, 2020, 67, 249-255.	1.6	2
942	The insulin-sensitizing mechanism of myo-inositol is associated with AMPK activation and GLUT-4 expression in human endometrial cells exposed to a PCOS environment. American Journal of Physiology - Endocrinology and Metabolism, 2020, 318, E237-E248.	3.5	53
943	Altered Ovarian Inositol Ratios May Account for Pathological Steroidogenesis in PCOS. International Journal of Molecular Sciences, 2020, 21, 7157.	4.1	29
944	Mental and personality disorders in infertile women with polycystic ovary: a case-control study. African Health Sciences, 2020, 20, 1241-1249.	0.7	8
945	Metastatin as a Marker for Hyperandrogenemia in Iraqi Women with Polycystic Ovary Syndrome. Obstetrics and Gynecology International, 2020, 2020, 1-6.	1.3	0
946	Association between empirically derived dietary patterns and polycystic ovary syndrome: A case-control study. Nutrition, 2020, 79-80, 110987.	2.4	10
947	Pediatric Gynecology. , 2020, , .		0
948	Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis. Human Reproduction Update, 2020, 26, 942-960.	10.8	180
949	Haptoglobin: From hemoglobin scavenging to human health. Molecular Aspects of Medicine, 2020, 73, 100851.	6.4	62
950	Oncology and Pharmacogenomics Insights in Polycystic Ovary Syndrome: An Integrative Analysis. Frontiers in Endocrinology, 2020, 11, 585130.	3.5	16
951	Neuroendocrine mechanisms of reproduction. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2020, 171, 3-23.	1.8	3
952	Pathophysiological effects of androgens on the female vascular system. Biology of Sex Differences, 2020, 11, 45.	4.1	22
953	Five variants of the superoxide dismutase genes in Turkish women with polycystic ovary syndrome. Free Radical Research, 2020, 54, 467-476.	3.3	4
954	Androgen levels in the fetal cord blood of children born to women with polycystic ovary syndrome: a meta-analysis. Reproductive Biology and Endocrinology, 2020, 18, 81.	3.3	9
955	Increased Skeletal Muscle Fiber Cross-Sectional Area, Muscle Phenotype Shift, and Altered Insulin Signaling in Rat Hindlimb Muscles in a Prenatally Androgenized Rat Model for Polycystic Ovary Syndrome. International Journal of Molecular Sciences, 2020, 21, 7918.	4.1	6

#	ARTICLE	IF	CITATION
956	Mechanisms Underlying Absent Training-Induced Improvement in Insulin Action in Lean, Hyperandrogenic Women With Polycystic Ovary Syndrome. Diabetes, 2020, 69, 2267-2280.	0.6	13
957	Effects of oral contraceptives on the quality of life of women with polycystic ovary syndrome: a crossover randomized controlled trial. Health and Quality of Life Outcomes, 2020, 18, 293.	2.4	8
958	Establishment and Analysis of a Combined Diagnostic Model of Polycystic Ovary Syndrome with Random Forest and Artificial Neural Network. BioMed Research International, 2020, 2020, 1-13.	1.9	34
959	The effects of spinach-derived thylakoid supplementation in combination with calorie restriction on anthropometric parameters and metabolic profiles in obese women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled clinical trial. Nutrition Journal, 2020, 19, 82.	3.4	8
960	Quality of life in adolescent girls with polycystic ovary syndrome. Journal of Paediatrics and Child Health, 2020, 56, 1351-1357.	0.8	12
961	PCOSKBR2: a database of genes, diseases, pathways, and networks associated with polycystic ovary syndrome. Scientific Reports, 2020, 10, 14738.	3.3	16
962	Study of prevalence of insulin resistance and other metabolic abnormalities in various phenotypes of polycystic ovary syndrome in central India. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 2020, 9, 2978.	0.1	0
963	Polycystic ovary syndrome and offspring risk of congenital heart defects: a nationwide cohort study. Human Reproduction, 2020, 35, 2348-2355.	0.9	5
964	Simultaneous quantitation of four androgens and 17 $\alpha$ -hydroxyprogesterone in polycystic ovarian syndrome patients by LC-MS/MS. Journal of Clinical Laboratory Analysis, 2020, 34, e23539.	2.1	12
965	S�ndrome de ov�rios poliqu�sticos. EMC - Ginecolog�a-Obstetricia, 2020, 56, 1-18.	0.0	0
966	Heterogeneity of Endocrinologic and Metabolic Parameters in Reproductive Age Polycystic Ovary Syndrome (PCOS) Women Concerning the Severity of Hyperandrogenemia�� A New Insight on Syndrome Pathogenesis. International Journal of Environmental Research and Public Health, 2020, 17, 9291.	2.6	5
967	The central role of ovulatory disturbances in the etiology of androgenic polycystic ovary syndrome (PCOS)��Evidence for treatment with cyclic progesterone. Drug Discovery Today: Disease Models, 2020, 32, 71-82.	1.2	9
968	Updated adolescent diagnostic criteria for polycystic ovary syndrome: impact on prevalence and longitudinal body mass index trajectories from birth to adulthood. BMC Medicine, 2020, 18, 389.	5.5	41
969	Sex Hormone-Binding Globulin (SHBG) as an Early Biomarker and Therapeutic Target in Polycystic Ovary Syndrome. International Journal of Molecular Sciences, 2020, 21, 8191.	4.1	74
970	Association between Periodontal Diseases and Polycystic Ovary Syndrome: A Systematic Review. Journal of Clinical Medicine, 2020, 9, 1586.	2.4	14
971	Recent Updates in Female Pelvic Ultrasound. Current Radiology Reports, 2020, 8, 1.	1.4	0
972	Anomalous expression of miR-103 in polycystic ovary syndrome influenced by hormonal, and metabolic variables. Experimental and Molecular Pathology, 2020, 116, 104482.	2.1	2
973	Polycystic ovary Syndrome in Adolescents: Pitfalls in Diagnosis and Management. Current Obesity Reports, 2020, 9, 193-203.	8.4	8



#	ARTICLE	IF	CITATIONS
974	A Systematic Review of the Effects of Exercise on Hormones in Women with Polycystic Ovary Syndrome. <i>Journal of Functional Morphology and Kinesiology</i> , 2020, 5, 35.	2.4	36
975	Metformin during Pregnancy: Effects on Offspring Development and Metabolic Function. <i>Frontiers in Pharmacology</i> , 2020, 11, 653.	3.5	20
976	The Relevant Hormonal Levels and Diagnostic Features of Polycystic Ovary Syndrome in Adolescents. <i>Journal of Clinical Medicine</i> , 2020, 9, 1831.	2.4	21
977	Efficacy of sex hormone-binding globulin on predicting metabolic syndrome in newly diagnosed and untreated patients with polycystic ovary syndrome. <i>Hormones</i> , 2020, 19, 439-445.	1.9	3
978	Cutaneous manifestations of polycystic ovary syndrome. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2020, 12, 49-52.	1.4	7
979	Association of estrogen receptor gene variants (ESR1 and ESR2) with polycystic ovary syndrome in Tunisia. <i>Gene</i> , 2020, 741, 144560.	2.2	10
980	Curcumin-loaded super-paramagnetic iron oxide nanoparticle affects on apoptotic factors expression and histological changes in a prepubertal mouse model of polycystic ovary syndrome-induced by dehydroepiandrosterone - A molecular and stereological study. <i>Life Sciences</i> , 2020, 249, 117515.	4.3	20
981	Disorders of the glucose metabolism correlate with the phenotype and the severity in women with polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2020, 93, 44-51.	2.4	5
982	Quercetin modulates granulosa cell mRNA androgen receptor gene expression in dehydroepiandrosterone-induced polycystic ovary in Wistar rats via metabolic and hormonal pathways. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2020, 31, .	1.3	14
983	Adolescent polycystic ovary syndrome according to the international evidence-based guideline. <i>BMC Medicine</i> , 2020, 18, 72.	5.5	142
984	Impact of the newly recommended antral follicle count cutoff for polycystic ovary in adult women with polycystic ovary syndrome. <i>Human Reproduction</i> , 2020, 35, 652-659.	0.9	20
985	Serum adiponectin is a potential biomarker for metabolic syndrome in peri-and postmenopausal women. <i>Gynecological Endocrinology</i> , 2020, 36, 620-625.	1.7	7
986	The role of androgen receptor CAG repeat polymorphism in androgen excess disorder and idiopathic hirsutism. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1271-1281.	3.3	10
987	11-Oxygenated androgens in health and disease. <i>Nature Reviews Endocrinology</i> , 2020, 16, 284-296.	9.6	99
988	Serum Androgens Are Independent Predictors of Insulin Clearance but Not of Insulin Secretion in Women With PCOS. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1981-e1989.	3.6	14
989	The effect of excess body fat on female and male reproduction. <i>Metabolism: Clinical and Experimental</i> , 2020, 107, 154193.	3.4	52
990	GLP-1/GLP-1R Signaling Regulates Ovarian PCOS-Associated Granulosa Cells Proliferation and Antiapoptosis by Modification of Forkhead Box Protein O1 Phosphorylation Sites. <i>International Journal of Endocrinology</i> , 2020, 2020, 1-10.	1.5	11
991	Obesity in adolescence. , 2020, , 15-22.		0



#	ARTICLE	IF	CITATIONS
992	Obesity in polycystic ovary syndrome and infertility. , 2020, , 23-34.		2
993	Implicating androgen excess in propagating metabolic disease in polycystic ovary syndrome. Therapeutic Advances in Endocrinology and Metabolism, 2020, 11, 204201882093431.	3.2	25
994	Disorders of Pubertal Onset. Primary Care - Clinics in Office Practice, 2020, 47, 189-216.	1.6	9
995	Distribution of Body Hair in Young Australian Women and Associations With Serum Androgen Concentrations. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1186-1195.	3.6	10
996	Hyperactive LH Pulses and Elevated Kisspeptin and NKB Gene Expression in the Arcuate Nucleus of a PCOS Mouse Model. Endocrinology, 2020, 161, .	2.8	44
997	Hair, Hormones, and Haunting: Race as a Ghost Variable in Polycystic Ovary Syndrome. Science Technology and Human Values, 2020, 45, 779-803.	3.1	4
998	Sonographic Assessment of Polycystic Ovaries. , 2020, , 87-99.		1
999	Improving the accuracy and efficacy of diagnosing polycystic ovary syndrome by integrating metabolomics with clinical characteristics: study protocol for a randomized controlled trial. Trials, 2020, 21, 169.	1.6	6
1000	Decreased Insulin Resistance by Myo-Inositol Is Associated with Suppressed Interleukin 6/Phospho-STAT3 Signaling in a Rat Polycystic Ovary Syndrome Model. Journal of Medicinal Food, 2020, 23, 375-387.	1.5	18
1001	Cardiovascular health and menopause in aging women with polycystic ovary syndrome. Expert Review of Endocrinology and Metabolism, 2020, 15, 29-39.	2.4	5
1002	Effect of a pulse-based diet and aerobic exercise on bone measures and body composition in women with polycystic ovary syndrome: A randomized controlled trial. Bone Reports, 2020, 12, 100248.	0.4	12
1003	Ovarian mitochondrial dynamics and cell fate regulation in an androgen-induced rat model of polycystic ovarian syndrome. Scientific Reports, 2020, 10, 1021.	3.3	30
1004	Long Noncoding RNA HUPCOS Promotes Follicular Fluid Androgen Excess in PCOS Patients via Aromatase Inhibition. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1086-1097.	3.6	26
1005	Up-regulated FHL2 inhibits ovulation through interacting with androgen receptor and ERK1/2 in polycystic ovary syndrome. EBioMedicine, 2020, 52, 102635.	6.1	26
1006	Polycystic ovary syndrome phenotypes and prevalence: Differential impact of diagnostic criteria and clinical versus unselected population. Current Opinion in Endocrine and Metabolic Research, 2020, 12, 66-71.	1.4	36
1007	Clinical Implications of Polycystic Ovary Syndrome in Adolescents. Nursing for Women's Health, 2020, 24, 115-126.	0.8	5
1008	Metformin and acupuncture for polycystic ovary syndrome. Medicine (United States), 2020, 99, e19683.	1.0	4
1009	Inhibition of autophagy in theca cells induces CYP17A1 and PAI-1 expression via ROS/p38 and JNK signalling during the development of polycystic ovary syndrome. Molecular and Cellular Endocrinology, 2020, 508, 110792.	3.2	24

#	ARTICLE	IF	CITATIONS
1010	Effect of fennel supplementation along with high-protein, low-carbohydrate weight-loss diet on insulin resistance and percentage of fat and muscle mass in overweight/obese women with polycystic ovary syndrome. <i>Journal of Functional Foods</i> , 2020, 67, 103848.	3.4	2
1011	Polycystic Ovary Syndrome: A Brief Review with Recent Updates. <i>Delta Medical College Journal</i> , 2020, 7, 84-99.	0.0	4
1012	Racial and ethnic differences in the metabolic response of polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2020, 93, 163-172.	2.4	21
1013	Efficacy and Safety of Tracnîlâ,¢ Administration in Patients with Dermatological Manifestations of PCOS: An Open-Label Single-Arm Study. <i>Dermatology Research and Practice</i> , 2020, 2020, 1-10.	0.8	3
1014	Effect of a short-term vitamin E supplementation on oxidative stress in infertile PCOS women under ovulation induction: a retrospective cohort study. <i>BMC Women's Health</i> , 2020, 20, 69.	2.0	24
1015	Nicotinamide and its metabolite N1-Methylnicotinamide alleviate endocrine and metabolic abnormalities in adipose and ovarian tissues in rat model of Polycystic Ovary Syndrome. <i>Chemico-Biological Interactions</i> , 2020, 324, 109093.	4.0	32
1016	New insights into anti-MÃ¼llerian hormone role in the hypothalamicâ€“pituitaryâ€“gonadal axis and neuroendocrine development. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 1-16.	5.4	69
1017	Prevalence of metabolic syndrome among women with different PCOS phenotypes â€“ a prospective study. <i>Gynecological Endocrinology</i> , 2021, 37, 21-25.	1.7	12
1018	Associations of Maternal Androgen-Related Conditions With Risk of Autism Spectrum Disorder in Progeny and Mediation by Cardiovascular, Metabolic, and Fertility Factors. <i>American Journal of Epidemiology</i> , 2021, 190, 600-610.	3.4	13
1019	Effects of oral contraceptives on serum concentrations of adipokines and adiposity indices of women with polycystic ovary syndrome: a randomized controlled trial. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 567-580.	3.3	2
1020	Androgens and hirsutism score of overweight women with polycystic ovary syndrome improved after vitamin D treatment: A randomized placebo controlled clinical trial. <i>Clinical Nutrition</i> , 2021, 40, 870-878.	5.0	23
1021	Coronavirus Disease 2019 (SARS-CoV-2) and polycystic ovarian disease: Is there a higher risk for these women?. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2021, 205, 105770.	2.5	23
1022	Gonadotropin-Releasing Hormone Analogue Stimulation Test Versus Venous Sampling in Postmenopausal Hyperandrogenism. <i>Journal of the Endocrine Society</i> , 2021, 5, bvaa172.	0.2	4
1023	A bibliometric analysis of obstetrics and gynecology articles with highest relative citation ratios, 1980 to 2019. <i>American Journal of Obstetrics &amp; Gynecology MFM</i> , 2021, 3, 100293.	2.6	18
1024	Direct impact of gonadotropins on glucose uptake and storage in preovulatory granulosa cells: Implications in the pathogenesis of polycystic ovary syndrome. <i>Metabolism: Clinical and Experimental</i> , 2021, 115, 154458.	3.4	12
1025	In utero exposure to maternal stressful life events and risk of polycystic ovary syndrome in the offspring: The Raine Study. <i>Psychoneuroendocrinology</i> , 2021, 125, 105104.	2.7	0
1026	Comparison of metabolic and obesity biomarkers between adolescent and adult women with polycystic ovary syndrome. <i>Archives of Gynecology and Obstetrics</i> , 2021, 303, 739-749.	1.7	12
1027	Changes of body composition and circulating neopterin, omentinâ€“1, and chemerin in response to thylakoidâ€“rich spinach extract with a hypocaloric diet in obese women with polycystic ovary syndrome: A randomized controlled trial. <i>Phytotherapy Research</i> , 2021, 35, 2594-2606.	5.8	3

#	ARTICLE	IF	CITATIONS
1028	Steroid metabolome profiling of follicular fluid in normo- and hyperandrogenic women with polycystic ovary syndrome. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2021, 206, 105806.	2.5	16
1029	Circulating steroids and mood disorders in patients with polycystic ovary syndrome. <i>Steroids</i> , 2021, 165, 108748.	1.8	6
1030	Effects of Dietary Glycemic Index and Glycemic Load on Cardiometabolic and Reproductive Profiles in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Advances in Nutrition</i> , 2021, 12, 161-178.	6.4	43
1031	Polycystic ovarian syndrome in Nigerian women with epilepsy on carbamazepine/levetiracetam monotherapy. <i>Acta Neurologica Scandinavica</i> , 2021, 143, 146-153.	2.1	7
1032	Characterizing the Clinical and Genetic Spectrum of Polycystic Ovary Syndrome in Electronic Health Records. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 153-167.	3.6	16
1033	Clinical, Metabolic and Hormonal Profiles of Bangladeshi Adolescents with Polycystic Ovary Syndrome. <i>European Endocrinology</i> , 2021, 17, 54.	1.5	7
1034	Adenovirus-36 infection and obesity: A case control study of Turkish women with polycystic ovary syndrome. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 415-418.	3.6	1
1035	Improvement Effect of Metformin on Female and Male Reproduction in Endocrine Pathologies and Its Mechanisms. <i>Pharmaceuticals</i> , 2021, 14, 42.	3.8	33
1036	Clinical, Metabolic and Hormonal Profiles of Bangladeshi Adolescents with Polycystic Ovary Syndrome. <i>European Endocrinology</i> , 2021, 1, 54.	1.5	0
1037	Assessment of Early Markers of Cardiovascular Risk in Polycystic Ovary Syndrome. <i>European Endocrinology</i> , 2021, 1, 37.	1.5	0
1038	Assessment of Early Markers of Cardiovascular Risk in Polycystic Ovary Syndrome. <i>European Endocrinology</i> , 2021, 17, 37.	1.5	7
1039	Association of serum leptin with anthropometric indices of obesity, blood lipids, steroidal hormones, and insulin resistance in polycystic ovarian syndrome. <i>Journal of Human Reproductive Sciences</i> , 2021, 14, 228.	0.9	2
1040	Changes in Ghrelin and Glucagon following a Low Glycemic Load Diet in Women with PCOS. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e2151-e2161.	3.6	14
1041	Cosmetic Endocrinology. <i>Clinical Obstetrics and Gynecology</i> , 2021, 64, 96-101.	1.1	0
1042	Pediatric reproductive disorders. , 2021, , 939-964.		0
1043	Contraceptive Choice in Women with PCOS. <i>Trends in Andrology and Sexual Medicine</i> , 2021, , 249-266.	0.1	0
1044	Prevalence of polycystic ovarian syndrome and its association with circulatory gonadotropins (luteinizing hormone and follicle-stimulating hormone) and prolactin in different reproductive age groups: A brief survey. , 0, 2, 8.		0
1045	Oxidative Stress and Low-Grade Inflammation in Polycystic Ovary Syndrome: Controversies and New Insights. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1667.	4.1	60

#	ARTICLE	IF	CITATIONS
1046	The value of serum free androgen index in the diagnosis of polycystic ovary syndrome: A systematic review and meta-analysis. Journal of Obstetrics and Gynaecology Research, 2021, 47, 1221-1231.	1.3	4
1047	Androgens in premenopausal women and women with premature ovarian insufficiency. Climacteric, 2021, 24, 459-465.	2.4	3
1048	Is polycystic ovary syndrome appropriately diagnosed by obstetricians and gynaecologists across China: a nationwide survey. Journal of Ovarian Research, 2021, 14, 25.	3.0	8
1049	A systematic approach to imaging the pelvis in amenorrhea. Abdominal Radiology, 2021, 46, 3326-3341.	2.1	3
1050	How polycystic ovary syndrome came into its own. F&S Science, 2021, 2, 2-10.	0.9	4
1051	Hyperandrogenic Anovulation. Endocrinology and Metabolism Clinics of North America, 2021, 50, 1-10.	3.2	3
1052	Comparative study of the clinico-trichoscopic response to treatment of hirsutism with long pulsed (1064 nm) Nd:YAG laser in idiopathic hirsutism and polycystic ovarian syndrome patients. Lasers in Medical Science, 2021, , 1.	2.1	5
1053	Characterization of polycystic ovary syndrome among Flo app users around the world. Reproductive Biology and Endocrinology, 2021, 19, 36.	3.3	14
1054	The importance of inflammation markers in polycystic ovary syndrome. Revista Da Associação Médica Brasileira, 2021, 67, 411-417.	0.7	6
1055	Diagnosis of Polycystic Ovary Syndrome. Endocrinology and Metabolism Clinics of North America, 2021, 50, 11-23.	3.2	35
1056	Non-alcoholic fatty liver disease in polycystic ovary syndrome women. Scientific Reports, 2021, 11, 7085.	3.3	21
1057	Postmenopausal Hyperandrogenism. Endocrinology and Metabolism Clinics of North America, 2021, 50, 97-111.	3.2	10
1058	Fertility Issues in Polycystic Ovarian Disease. Endocrinology and Metabolism Clinics of North America, 2021, 50, 43-55.	3.2	5
1059	Absent Exercise-Induced Improvements in Fat Oxidation in Women With Polycystic Ovary Syndrome After High-Intensity Interval Training. Frontiers in Physiology, 2021, 12, 649794.	2.8	13
1060	The Effect of Acupuncture on Glucose Metabolism and Lipid Profiles in Patients with PCOS: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-11.	1.2	16
1061	Dexamethasone suppression test versus selective ovarian and adrenal vein catheterization in identifying virilizing tumors in postmenopausal hyperandrogenism – a systematic review and meta-analysis. Gynecological Endocrinology, 2021, 37, 600-608.	1.7	3
1062	Differential Effects of Various Androgens on Polycystic Ovary Syndrome. Hormone and Metabolic Research, 2021, 53, 341-349.	1.5	4
1063	Multimodal Recruitment to Study Ovulation and Menstruation Health: Internet-Based Survey Pilot Study. Journal of Medical Internet Research, 2021, 23, e24716.	4.3	8

#	ARTICLE	IF	CITATIONS
1064	Polycystic ovary syndrome: clinical and pathogenetic aspects of a multidisciplinary problem. <i>Reproductive Health of Woman</i> , 0, 2, 7-14.	0.2	1
1065	Clinical Practice Guidelines on the Diagnosis and Management of Polycystic Ovary Syndrome: A Systematic Review and Quality Assessment Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 2436-2446.	3.6	44
1066	Beneficial effects of minocycline on the ovary of polycystic ovary syndrome mouse model: Molecular docking analysis and evaluation of TNF- $\alpha$ , TNFR2, TLR-4 gene expression. <i>Journal of Reproductive Immunology</i> , 2021, 144, 103289.	1.9	5
1067	SARS-CoV-2 Viral Entry Proteins in Hyperandrogenemic Female Mice: Implications for Women with PCOS and COVID-19. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4472.	4.1	10
1068	Evaluation of endometrial immune status of polycystic ovary syndrome. <i>Journal of Reproductive Immunology</i> , 2021, 144, 103282.	1.9	18
1069	Polycystic Ovary Syndrome, Affective Symptoms, and Neuroactive Steroids: a Focus on Allopregnanolone. <i>Current Psychiatry Reports</i> , 2021, 23, 36.	4.5	8
1070	Evaluation of the Role of Ghrelin and Leptin as Biochemical Markers in Female with Polycystic Ovarian Syndrome. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , 2021, 20, 373-379.	1.1	3
1071	Use of community-based reference ranges to estimate the prevalence of polycystic ovary syndrome by the recognised diagnostic criteria, a cross-sectional study. <i>Human Reproduction</i> , 2021, 36, 1611-1620.	0.9	10
1072	Age-specific cut-off levels of anti-Müllerian hormone can be used as diagnostic markers for polycystic ovary syndrome. <i>Reproductive Biology and Endocrinology</i> , 2021, 19, 76.	3.3	11
1073	Postmenopausal hyperandrogenism. <i>Climacteric</i> , 2022, 25, 109-117.	2.4	9
1074	The Effects of <i>Salvia miltiorrhiza</i> on Reproduction and Metabolism in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-12.	1.2	5
1075	Insulin-Mediated Substrate Use in Women With Different Phenotypes of PCOS: the Role of Androgens. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3414-e3425.	3.6	12
1076	Effects of antiepileptic drugs on hormones. <i>Neuroscience Letters</i> , 2021, 754, 135800.	2.1	3
1077	Polycystic Ovary Syndrome in Insulin-Resistant Adolescents with Obesity: The Role of Nutrition Therapy and Food Supplements as a Strategy to Protect Fertility. <i>Nutrients</i> , 2021, 13, 1848.	4.1	71
1078	The effectiveness of coenzyme Q10, vitamin E, inositols, and vitamin D in improving the endocrine and metabolic profiles in women with polycystic ovary syndrome: a network Meta-analysis. <i>Gynecological Endocrinology</i> , 2021, 37, 1-9.	1.7	11
1079	Prevalence of at-risk hyperandrogenism by age and race/ethnicity among females in the United States using NHANES III. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 260, 189-197.	1.1	17
1080	Characterization of DNA Methylation and Screening of Epigenetic Markers in Polycystic Ovary Syndrome. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 664843.	3.7	15
1081	High Doses of D-Chiro-Inositol Alone Induce a PCO-Like Syndrome and Other Alterations in Mouse Ovaries. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5691.	4.1	15

#	ARTICLE	IF	CITATIONS
1082	Clinico-investigative attributes of 122 patients with hirsutism: A 5-year retrospective study from India. <i>International Journal of Women's Dermatology</i> , 2021, 7, 237-242.	2.0	5
1083	Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective. <i>Autophagy</i> , 2021, 17, 2706-2733.	9.1	99
1084	PCOS Features and Steroid Profiles Among Young Adult Women with a History of Premature Adrenarche. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3335-e3345.	3.6	8
1085	Does body mass index have an effect on the prevalence of various symptoms of polycystic ovary syndrome and their associated risk factors?. <i>Anthropological Review</i> , 2021, 84, 101-116.	0.3	0
1086	Urinary bisphenol A in women with polycystic ovary syndrome—“a possible suppressive effect on steroidogenesis?”. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2021, 42, 303-309.	0.7	8
1087	Metabolic and hormonal effects of melatonin and/or magnesium supplementation in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. <i>Nutrition and Metabolism</i> , 2021, 18, 57.	3.0	11
1088	Menstrual dysfunction in polycystic ovary syndrome: association with dynamic state insulin resistance rather than hyperandrogenism. <i>Fertility and Sterility</i> , 2021, 115, 1557-1568.	1.0	17
1089	Sexual Function in Chinese Women with Polycystic Ovary Syndrome and Correlation with Clinical and Biochemical Characteristics. <i>Reproductive Sciences</i> , 2021, 28, 3181-3192.	2.5	4
1090	Whey Protein Supplementation Improves the Glycemic Response and May Reduce Non-Alcoholic Fatty Liver Disease Related Biomarkers in Women with Polycystic Ovary Syndrome (PCOS). <i>Nutrients</i> , 2021, 13, 2451.	4.1	4
1091	A high-androgen microenvironment inhibits granulosa cell proliferation and alters cell identity. <i>Molecular and Cellular Endocrinology</i> , 2021, 531, 111288.	3.2	15
1092	Prevalence of idiopathic hirsutism: A systematic review and meta-analysis. <i>Journal of Cosmetic Dermatology</i> , 2021, , .	1.6	6
1094	Depression and anxiety in women with polycystic ovarian syndrome: a literature survey. <i>International Journal of Adolescent Medicine and Health</i> , 2021, 33, 367-373.	1.3	10
1095	Increased pro-inflammatory cytokines in ovary and effect of $\alpha$ -linolenic acid on adipose tissue inflammation in a polycystic ovary syndrome model. <i>Journal of Reproductive Immunology</i> , 2021, 146, 103345.	1.9	5
1096	Sestrin2 and Beclin1 levels in Polycystic Ovary Syndrome. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23957.	2.1	5
1097	Update on polycystic ovary syndrome. <i>Clinical and Experimental Reproductive Medicine</i> , 2021, 48, 194-197.	1.5	4
1098	Cardiac and Renal SARS-CoV-2 Viral Entry Protein Regulation by Androgens and Diet: Implications for Polycystic Ovary Syndrome and COVID-19. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9746.	4.1	3
1099	Effect of l-carnitine supplementation on liver fat content and cardiometabolic indices in overweight/obese women with polycystic ovary syndrome: A randomized controlled trial. <i>Clinical Nutrition ESPEN</i> , 2021, 46, 54-59.	1.2	8
1100	A REVIEW OF PHARMACOLOGICAL SCREENING METHODS FOR EXPERIMENTALLY INDUCED POLYCYSTIC OVARIAN DISEASE (PCOD). <i>Indian Drugs</i> , 2021, 58, 7-21.	0.1	0



#	ARTICLE	IF	CITATIONS
1101	Diagnosis experiences of adolescents with polycystic ovary syndrome: Cross-sectional study. Clinical Endocrinology, 2022, 96, 62-69.	2.4	7
1102	Prevalence of Hirsutism Among Reproductive-Aged African American Women. Journal of Women's Health, 2021, 30, 1580-1587.	3.3	6
1103	The role of polymorphism in various potential genes on polycystic ovary syndrome susceptibility and pathogenesis. Journal of Ovarian Research, 2021, 14, 125.	3.0	32
1104	Metabolic syndrome in obesity: treatment success and adverse pregnancy outcomes with ovulation induction in polycystic ovary syndrome. American Journal of Obstetrics and Gynecology, 2021, 225, 280.e1-280.e11.	1.3	14
1105	Inflammation and Insulin Resistance in a Group of Sub-Saharan African Women with Polycystic Ovary Syndrome. Journal of Inflammation Research, 2021, Volume 14, 4643-4649.	3.5	1
1106	Participation of the Cholinergic System in the Development of Polycystic Ovary Syndrome. Molecules, 2021, 26, 5506.	3.8	7
1107	Quality Improvement in the Evaluation and Diagnosis of Polycystic Ovary Syndrome in Adolescent Girls. Journal of Pediatric and Adolescent Gynecology, 2021, 34, 603-609.	0.7	2
1108	Plasminogenactivator inhibitor-1 polymorphism and risk of polycystic ovary syndrome in Turkish women. Meta Gene, 2021, 30, 100959.	0.6	1
1109	IMPORTANT RISK FACTOR OF HYPERHOMOCYSTEINEMIA IN CARDIOVASCULAR SYSTEM DISEASES AND STATUS OF THE HOMOCYSTEINE LEVELS IN POLYCYSTIC OVARY SYNDROME. Jinekoloji-Obstetrik Ve Neonatoloji Tıp Dergisi, 0, , .	0.5	0
1110	The role of miRNAs in polycystic ovary syndrome with insulin resistance. Journal of Assisted Reproduction and Genetics, 2021, 38, 289-304.	2.5	18
1111	Adolescent disorders. , 2021, , 909-938.		0
1112	Changes in the Lipid Peroxidation-Antioxidant Protection System in Women with Ovarian Hyperandrogenism at Different Periods of Reproductive Age. Bulletin of Experimental Biology and Medicine, 2021, 170, 308-311.	0.8	0
1113	Puberty in the Female and Its Disorders. , 2021, , 528-626.		9
1116	Growth and the Insulin-Like Growth Factor-1 Receptor (IGF1R). , 2012, , 2711-2722.		2
1117	Diagnostic Criteria and Epidemiology of PCOS. , 2014, , 3-10.		7
1118	Ultrasound and PCOS. , 2014, , 75-91.		1
1120	Polycystic Ovarian Syndrome. , 2019, , 31-40.		3
1121	Exercise and Polycystic Ovary Syndrome. Advances in Experimental Medicine and Biology, 2020, 1228, 123-136.	1.6	26



#	ARTICLE	IF	CITATIONS
1122	Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2017, 107, 1380-1386.e1.	1.0	136
1123	Î <sup>3</sup> -Linolenic acid ameliorates DHEA induced pro-inflammatory response in polycystic ovary syndrome via PPAR-Î <sup>3</sup> signaling in rats. <i>Reproductive Biology</i> , 2020, 20, 348-356.	1.9	13
1124	Theoretical and clinical disease and the biostatistical theory. <i>Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences</i> , 2020, 82, 101249.	1.3	8
1125	Endometrium in women with polycystic ovary syndrome during the window of implantation. <i>Revista Da Associação Médica Brasileira</i> , 2011, 57, 688-695.	0.7	11
1127	Removal of DHT can relieve polycystic ovarian but not metabolic abnormalities in DHT-induced hyperandrogenism in mice. <i>Reproduction, Fertility and Development</i> , 2019, 31, 1597.	0.4	3
1128	Polycystic ovary syndrome in adolescent girls. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2017, 24, 56-66.	2.3	12
1130	Defining polycystic ovary syndrome. <i>BMJ: British Medical Journal</i> , 2009, 338, a2968-a2968.	2.3	39
1131	LH Dynamics in Overweight Girls with Premature Adrenarche and Slowly Progressive Sexual Precocity. <i>International Journal of Pediatric Endocrinology (Springer)</i> , 2010, 2010, 724696.	1.6	18
1132	Letter to the Editor Re: Casarini and Brigante, 2014, from Azziz R., et al. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, L22-L23.	3.6	2
1133	Systems Genetics Reveals the Functional Context of PCOS Loci and Identifies Genetic and Molecular Mechanisms of Disease Heterogeneity. <i>PLoS Genetics</i> , 2015, 11, e1005455.	3.5	84
1134	Risk of Psychiatric Disorders following Polycystic Ovary Syndrome: A Nationwide Population-Based Cohort Study. <i>PLoS ONE</i> , 2014, 9, e97041.	2.5	103
1135	Prevalence of Metabolic Syndrome Is Higher among Non-Obese PCOS Women with Hyperandrogenism and Menstrual Irregularity in Korea. <i>PLoS ONE</i> , 2014, 9, e99252.	2.5	31
1136	Of PCOS Symptoms, Hirsutism Has the Most Significant Impact on the Quality of Life of Iranian Women. <i>PLoS ONE</i> , 2015, 10, e0123608.	2.5	56
1137	Should All Women with Polycystic Ovary Syndrome Be Screened for Metabolic Parameters?: A Hospital-Based Observational Study. <i>PLoS ONE</i> , 2016, 11, e0167036.	2.5	17
1138	Bisphenol-A and polycystic ovary syndrome: a review of the literature. <i>Reviews on Environmental Health</i> , 2020, 35, 323-331.	2.4	21
1139	Recent Acupuncture Therapy for Polycystic Ovary Syndromes : Systematic Review. <i>The Journal of Korean Obstetrics and Gynecology</i> , 2014, 27, 71-82.	0.4	4
1140	Sam68 mediates leptin signaling and action in human granulosa cells: possible role in leptin resistance in PCOS. <i>Endocrine Connections</i> , 2020, 9, 479-488.	1.9	12
1141	Androgen excess and diagnostic steroid biomarkers for nonclassic 21-hydroxylase deficiency without cosyntropin stimulation. <i>European Journal of Endocrinology</i> , 2020, 183, 63-71.	3.7	24

#	ARTICLE	IF	CITATIONS
1142	Androgen signaling pathways driving reproductive and metabolic phenotypes in a PCOS mouse model. <i>Journal of Endocrinology</i> , 2020, 245, 381-395.	2.6	42
1143	Female infertility of endocrine origin. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2014, 58, 144-152.	1.3	68
1145	Clinical Efficacy of Low Dose Flutamide plus Diane-35 in the Treatment of Idiopathic Hirsutism and Polycystic Ovary Syndrome. <i>Ginekologia Polska</i> , 2013, 84, 258-62.	0.7	11
1146	The role of insulin and selected adipocytokines in patients with polycystic ovary syndrome (PCOS) – a literature review. <i>Ginekologia Polska</i> , 2015, 86, 300-304.	0.7	8
1147	The role of melatonin in polycystic ovary syndrome: A review. <i>International Journal of Reproductive BioMedicine</i> , 2019, 17, 865-882.	0.9	27
1148	Investigation Trp64Arg polymorphism of the beta 3-adrenergic receptor gene in nonobese women with polycystic ovarian syndrome. <i>International Journal of Reproductive BioMedicine</i> , 2020, 18, 165-174.	0.9	1
1149	Estados hiperandrogénicos: revisión de la literatura. <i>Revista Colombiana De Obstetricia Y Ginecología</i> , 2009, 60, 357-364.	0.3	2
1150	Lipidomics reveals altered biosynthetic pathways of glycerophospholipids and cell signaling as biomarkers of the polycystic ovary syndrome. <i>Oncotarget</i> , 2018, 9, 4522-4536.	1.8	26
1151	Effective treatment of skin and metabolic manifestations of hyperandrogenism: a comprehensive improvement of quality of life. <i>Meditinskiy Sovet</i> , 2019, , 45-50.	0.5	2
1152	Epigenetic Marks in Polycystic Ovary Syndrome. <i>Current Medicinal Chemistry</i> , 2020, 27, 6727-6743.	2.4	5
1153	Translational Insight Into Polycystic Ovary Syndrome (PCOS) From Female Monkeys with PCOS-like Traits. <i>Current Pharmaceutical Design</i> , 2016, 22, 5625-5633.	1.9	34
1154	Medical and Surgical Treatment of Reproductive Outcomes in Polycystic Ovary Syndrome: An Overview of Systematic Reviews. <i>International Journal of Fertility &amp; Sterility</i> , 2020, 13, 257-270.	0.2	14
1155	Criteria, phenotypes and prevalence of polycystic ovary syndrome. <i>Minerva Ginecologica</i> , 2019, 71, 211-223.	0.8	63
1156	The efficacy of gonadotropin-releasing hormone (GnRH) agonist before frozen embryo transfer in improving pregnancy outcome and decreasing miscarriage rate in hyperandrogenic polycystic ovary syndrome women: a randomized clinical trial. <i>Minerva Ginecologica</i> , 2020, 72, 212-218.	0.8	6
1157	Association of leptin and insulin resistance in PCOS: A case-controlled study. <i>International Journal of Reproductive BioMedicine</i> , 2017, 15, 423-428.	0.9	23
1158	Healthy eating index in women with polycystic ovary syndrome: A case-control study. <i>International Journal of Reproductive BioMedicine</i> , 2017, 15, 575-582.	0.9	11
1159	Plasma osteoprotegerin is associated with testosterone levels but unaffected by pioglitazone treatment in patients with polycystic ovary syndrome. <i>Journal of Endocrinological Investigation</i> , 2013, 36, 460-5.	3.3	5
1160	Haplotype TCTG from SNP 45T/G and 276G/T of the adiponectin gene contributes to risk of polycystic ovary syndrome. <i>Journal of Endocrinological Investigation</i> , 2013, 36, 497-502.	3.3	8

#	ARTICLE	IF	CITATIONS
1161	Relationship Between Steroid Hormones and Metabolic Profile in Women With Polycystic Ovary Syndrome. <i>Physiological Research</i> , 2019, 68, 457-465.	0.9	14
1162	Markers of hyperandrogenism in South Asians with polycystic ovary syndrome. <i>Sri Lanka Journal of Diabetes Endocrinology and Metabolism</i> , 2014, 4, 3.	0.1	7
1163	The contribution of hyperinsulinemia to the hyperandrogenism of polycystic ovary syndrome. <i>Journal of Insulin Resistance</i> , 2019, 4, .	1.3	5
1164	Education and self-management for women with polycystic ovary syndrome; a narrative review of literature. <i>Ibnosina Journal of Medicine and Biomedical Sciences</i> , 2015, 7, 1.	0.2	1
1165	Serum leptin level in women with polycystic ovary syndrome: Correlation with adiposity, insulin, and circulating testosterone. <i>Annals of Medical and Health Sciences Research</i> , 2013, 3, 191.	0.8	58
1166	Can anti-Mullerian hormone replace ultrasonographic evaluation in polycystic ovary syndrome? A review of current progress. <i>Indian Journal of Endocrinology and Metabolism</i> , 2015, 19, 731.	0.4	13
1167	Leptin and body mass index in polycystic ovary syndrome. <i>Indian Journal of Endocrinology and Metabolism</i> , 2016, 20, 324.	0.4	23
1168	Comparison of the different PCOS phenotypes based on clinical metabolic, and hormonal profile, and their response to clomiphene. <i>Indian Journal of Endocrinology and Metabolism</i> , 2019, 23, 326.	0.4	50
1169	Polycystic ovary syndrome and periodontal disease: Underlying links- A review. <i>Indian Journal of Endocrinology and Metabolism</i> , 2018, 22, 267.	0.4	19
1170	Comparison of clinical, metabolic, hormonal, and ultrasound parameters among the clomiphene citrate-resistant and clomiphene citrate-sensitive polycystic ovary syndrome women. <i>Journal of Human Reproductive Sciences</i> , 2019, 12, 216.	0.9	7
1171	The Prevalence of Polycystic Ovary Syndrome: A Brief Systematic Review. <i>Journal of Human Reproductive Sciences</i> , 2020, 13, 261.	0.9	209
1172	Polycystic Ovary Syndrome and the Relationship of Cardiovascular Disease Risk. <i>Turkish Journal of Endocrinology and Metabolism</i> , 2013, 17, 33-37.	0.5	1
1173	Therapeutic Effect of Korean Red Ginseng Extract on Infertility Caused by Polycystic Ovaries. <i>Journal of Ginseng Research</i> , 2011, 35, 250-255.	5.7	11
1174	The metabolic effects of drugs used for the treatment of polycystic ovary syndrome. <i>Journal of the Turkish German Gynecology Association</i> , 2013, 14, 168-173.	0.6	2
1175	Metabolic and carbohydrate characteristics of different phenotypes of polycystic ovary syndrome. <i>Journal of the Turkish German Gynecology Association</i> , 2016, 17, 201-208.	0.6	7
1176	Prevalence of anxiety and depression in polycystic ovarian syndrome. <i>International Journal of Medical Science and Public Health</i> , 2016, 5, 681.	0.2	9
1177	Polycystic ovary syndrome and molecular approaches. <i>Turk Hijiyen Ve Deneysel Biyoloji Dergisi Turkish Bulletin of Hygiene and Experimental Biology</i> , 2016, 73, 81-88.	0.2	4
1178	Kompetencje społeczne oraz rolę płciową u nastoletnich dziewcząt z zespołem policystycznych jajników – badanie pilotażowe. <i>Endokrynologia Polska</i> , 2014, 65, 189-194.	1.0	3

#	ARTICLE	IF	CITATIONS
1179	Optimal Cutoff Points for Anthropometric Variables to Predict Insulin Resistance in Polycystic Ovary Syndrome. International Journal of Endocrinology and Metabolism, 2017, In Press, e12353.	1.0	3
1180	Anthropometric and Biochemical Characteristics of Polycystic Ovarian Syndrome in South Indian Women Using AES-2006 Criteria. International Journal of Endocrinology and Metabolism, 2014, 12, e12470.	1.0	36
1181	Association of Mean Platelet Volume With Androgens and Insulin Resistance in Nonobese Patients With Polycystic Ovary Syndrome. International Journal of Endocrinology and Metabolism, 2014, 12, e18642.	1.0	10
1182	Polycystic Ovary Syndrome: An Apparently Simple yet Challenging Diagnosis. International Journal of Endocrinology and Metabolism, 2015, 13, e28557.	1.0	2
1183	Genotype based Risk Predictors for Polycystic Ovary Syndrome in Western Saudi Arabia. Bioinformation, 2019, 15, 812-819.	0.5	11
1184	Assessing the benefits of rosiglitazone in women with polycystic ovary syndrome through its effects on insulin-like growth factor 1, insulin-like growth factor-binding protein-3 and insulin resistance: a pilot study. Clinics, 2012, 67, 283-287.	1.5	17
1185	The expression of small RNAs in exosomes of follicular fluid altered in human polycystic ovarian syndrome. PeerJ, 2020, 8, e8640.	2.0	40
1186	Substituting serum anti-Müllerian hormone for polycystic ovary morphology increases the number of women diagnosed with polycystic ovary syndrome: a community-based cross-sectional study. Human Reproduction, 2021, 37, 109-118.	0.9	11
1187	Impact of Polycystic Ovarian Syndrome, Metabolic Syndrome, and Obesity on Women's Health. ISGE Series, 2021, , 149-160.	0.2	0
1188	Association between biochemical hyperandrogenism parameters and modified Ferriman-Gallwey score in patients with hirsutism in Basrah (Southern Iraq). Postepy Dermatologii I Alergologii, 2021, 38, 603-607.	0.9	2
1189	Prevalance and role of Melatonin on PCOS in its treatment using Herbal Drugs. Research Journal of Pharmacy and Technology, 2021, , 5029-5033.	0.8	3
1190	Implications of environmental toxicants on ovarian follicles: how it can adversely affect the female fertility?. Environmental Science and Pollution Research, 2021, 28, 67925-67939.	5.3	25
1191	Impaired Sexual Function in Young Women with PCOS: The Detrimental Effect of Anovulation. Journal of Sexual Medicine, 2021, 18, 1872-1879.	0.6	9
1192	Effect of the spatial-temporal specific theca cell Cyp17 overexpression on the reproductive phenotype of the novel TC17 mouse. Journal of Translational Medicine, 2021, 19, 428.	4.4	5
1193	Prevalence, Symptomatology and Herbal Management of Polycystic Ovarian Syndrome. , 0, , .		1
1194	Hyperandrogenism, Hirsutism, and Polycystic Ovary Syndrome. , 2010, , 2386-2406.		0
1196	Surgical Management Options for Patients with Infertility and Endometriosis. Current Women's Health Reviews, 2010, 6, 161-166.	0.2	0
1197	Syndrome of hyperandrogenism in girls of pubertal age. Problemy Endokrinologii, 2010, 56, 48-54.	0.8	2

#	ARTICLE	IF	CITATIONS
1204	Clinical focus - Polycystic ovary syndrome. Independent Nurse, 2011, 2011, .	0.1	0
1205	Le syndrome des ovaires polymicrokystiques. , 2012, , 149-160.		0
1206	Excess hair growth. Human Health Handbooks, 2012, , 118-136.	0.1	1
1207	Anti-Mullerian hormone (AMH) in the adolescent girls presenting with hyperandrogenism. Problemy Endokrinologii, 2012, 58, 9-16.	0.8	1
1208	The Polycystic Ovary Syndrome Status - A Risk Factor for Future Cardiovascular Disease. , 0, , .		0
1209	Polycystic Ovary Syndrome: A Review of Management Outcomes in a Low Resource Setting. Journal of Women's Health, Issues & Care, 2013, 02, .	0.1	1
1210	Comparison of vitamin D levels in obese and non obese patients with polycystic ovarian syndrome in a South Indian population. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 0, , 336-343.	0.1	1
1211	The role of insulin sensitizers and calcium plus vitamin D3 preparations in the combined treatment of polycystic ovary syndrome. Problemy Endokrinologii, 2013, 59, 49-56.	0.8	1
1212	Role of Surgery in the Management of PCOS: Rationale and Considerations for Bariatric Surgery. , 2014, , 277-288.		0
1213	PCOS in Adolescence: Diagnostic Dilemmas and Management Considerations. , 2014, , 245-264.		0
1214	Hirsutism and Virilization. , 2014, , 145-157.		0
1215	Androgen Receptor Gene Tagging Single Nucleotide Polymorphisms are not Associated with Polycystic Ovary Syndrome in South Indian Women. IOSR Journal of Pharmacy and Biological Sciences, 2014, 9, 07-11.	0.1	0
1216	Assessment of the Obese Child or Adolescent. , 2014, , 287-304.		1
1218	Relationship of serum fasting insulin with gonadotropins in infertile women. Bangladesh Journal of Physiology and Pharmacology, 2014, 29, 17-24.	0.1	0
1219	Clinical Study for the One Case that Diagnosed Polycystic Ovarian Disease. The Journal of Korean Obstetrics and Gynecology, 2014, 27, 151-157.	0.4	4
1220	A Review on Clinical Studies of Herbal Treatment for Infertility Caused by Polycystic Ovary Syndrome -Focusing on Chinese Clinical Trials-. The Journal of Korean Obstetrics and Gynecology, 2014, 27, 43-56.	0.4	0
1221	Polycystic ovary syndrome: modern view and itâ€™s role in infertility (a review). Russian Journal of Human Reproduction, 2015, 21, 31.	0.3	3
1223	The New Three-dimensional Ultrasound Modes allow a Better Polycystic Ovary Syndrome Ultrasound Diagnosis beyond the Rotterdam Criteria. Donald School Journal of Ultrasound in Obstetrics and Gynecology, 2015, 9, 434-445.	0.3	0

#	ARTICLE	IF	CITATIONS
1225	Polycystic Ovarian Syndrome and Response to Stimulation. , 2015, , 329-345.		0
1226	Association between SHBG (TAAAA)n and AR (CAG)n polymorphisms and PCOS risk: A meta-analysis. World Journal of Meta-analysis, 2015, 3, 72.	0.1	0
1227	Response to letter by Azziz R., et al. Journal of Clinical Endocrinology and Metabolism, 2015, 100, L24-L24.	3.6	0
1228	Metabolic evaluation and measurement of ovarian volume in polycystic ovary syndrome: a cross-sectional observational study. Ąukurova Ąeniversitesi TĄp FakĄltesi Dergisi, 2016, 41, 28.	0.0	0
1229	Glycemic Index and WomenĒ™s Health. , 2016, , 199-218.		0
1230	National consensus on the management of patients with hyperandrogenism (2016). Reproductive Endocrinology, 2016, .	0.3	6
1231	COMMUNITY SCREENING FOR PCOS AMONGST ADOLESCENT GIRLS IN A SEMIURBAN AREA IN WEST BENGAL. Journal of Evidence Based Medicine and Healthcare, 2016, 3, 5540-5544.	0.0	0
1232	Using kisspeptin to assess GnRH function in an unusual case of primary amenorrhoea. Endocrinology, Diabetes and Metabolism Case Reports, 2017, 2017, .	0.5	1
1233	A STUDY ON CLINICAL PROFILE OF PATIENTS WITH HIRSUTISM. Journal of Evolution of Medical and Dental Sciences, 2017, 6, 2726-2729.	0.1	0
1234	Hirsutism, Acne, and Hair Loss: Management of Hyperandrogenic Cutaneous Manifestations of Polycystic Ovary Syndrome. Gynecology Obstetrics & Reproductive Medicine (gorm), 2017, 23, 110-119.	0.3	1
1235	Treatment of infertility in women with polycystic ovary syndrome using assisted reproductive technology. Journal of Obstetrics and Women's Diseases, 2017, 66, 37-45.	0.2	0
1236	New Challenges of Echography in Reproduction. Reproductive Medicine for Clinicians, 2018, , 105-131.	0.2	0
1237	Effect of Metformin on Endometrial Thickness and Subendometrial Flow Patterns in Anovulatory Patients with Polycystic Ovarian Syndrome. Open Journal of Obstetrics and Gynecology, 2018, 08, 1465-1475.	0.2	2
1238	Prevalence of Polycystic Ovary Syndrome in Nigerian Women with Infertility: A Prospective Study of the Three Assessment Criteria. Open Journal of Obstetrics and Gynecology, 2018, 08, 1109-1120.	0.2	3
1239	Effects of orlistat on serum androgen levels among iranian obese women with polycystic ovarian syndrome. Jornal Brasileiro De Reproducao Assistida, 2018, 22, 180-184.	0.7	4
1240	A new look at the polycystic ovary syndrome. Polish Annals of Medicine, 2018, , .	0.3	0
1241	Prostate specific antigen is raised in polycystic ovary syndrome. Endocrinology&Metabolism International Journal, 2018, 6, .	0.1	0
1242	Melatonin in the Clinical Management of Polycystic Ovarian Syndrome. JOJ Nursing & Health Care, 2018, 9, .	0.1	0

#	ARTICLE	IF	CITATIONS
1243	Le syndrome des ovaires polykystiques. , 2019, , 159-177.		0
1244	Investigation of the relationship between insulin resistance and neuropeptide Y levels in polycystic ovary syndrome. Marmara Medical Journal, 0, , 18-46.	0.8	0
1245	Portability of Gwas Results between Ethnic Populations: Genetic Markers for Polycystic Ovary Syndrome (Pcos) in Mediterranean Area. Acta Endocrinologica, 2019, 15, 364-371.	0.3	3
1246	Insulin Resistance, Diabetes, Mood and Binge Eating. , 2019, , 121-139.		0
1247	Introduction to Biological and Psychobiological Aspects of PCOS. , 2019, , 1-34.		1
1248	The Effect of Vitamin D Supplementation on the Androgenic Profile in Patient with Polycystic Ovary Syndrome. The Egyptian Journal of Hospital Medicine, 2019, 75, 2461-2466.	0.1	1
1251	Clinical features of polycystic ovary syndrome phenotypes in women with normogonadotropic anovulation in reproductive age. Journal of Obstetrics and Women's Diseases, 2019, 68, 7-14.	0.2	4
1252	Evaluation of Serum Human Epididymis Protein 4 Levels in Women with Polycystic Ovary Syndrome. Cureus, 2019, 11, e5736.	0.5	1
1255	Causes of Hyperandrogenism. , 2020, , 9-19.		0
1257	Prevalence of hyperandrogenism in Iraqi women with polycystic ovary syndrome. Iraqi Journal of Science, 0, , 2600-2608.	0.3	3
1258	Endocrine Indices of PCOS in Women with Polycystic Ovaries but without Diagnostic Features of PCOS: A Study of an Infertility Clinic Population. Open Journal of Obstetrics and Gynecology, 2020, 10, 275-283.	0.2	0
1259	Identifying Women at Risk for Polycystic Ovary Syndrome Using a Mobile Health App: Virtual Tool Functionality Assessment. JMIR Formative Research, 2020, 4, e15094.	1.4	9
1261	Insertion/deletion of angiotensin-converting enzyme gene polymorphism as a marker of polycystic ovary syndrome (PCOS) development in South Indian cohort women. Asia-Pacific Journal of Molecular Biology and Biotechnology, 0, , 27-31.	0.1	1
1262	PCOS - An Updated Overview and Current Trends in Ultrasound Imaging. Journal of Evidence Based Medicine and Healthcare, 2020, 7, 1255-1260.	0.0	0
1263	Serum levels of inflammatory markers and monocyte to high density lipoprotein ratio in polycystic ovary syndrome. Journal of Health Sciences and Medicine, 2020, 3, 256-261.	0.1	0
1264	Clinical Presentation and Diagnosis of Polycystic Ovarian Syndrome. Clinical Obstetrics and Gynecology, 2021, 64, 3-11.	1.1	10
1265	Comparative Analysis of Machine Learning Algorithms in Diagnosis of Polycystic Ovarian Syndrome. International Journal of Computer Applications, 2020, 175, 42-53.	0.2	9
1266	Association of LH/FSH ratio with menstrual cycle regularity and clinical features of patients with polycystic ovary syndrome. Middle East Fertility Society Journal, 2021, 26, .	1.5	3



#	ARTICLE	IF	CITATIONS
1267	Dietary Modification for Reproductive Health in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. <i>Frontiers in Endocrinology</i> , 2021, 12, 735954.	3.5	12
1268	Metformin effects on zonulin level in polycystic ovarian women. <i>ADMET and DMPK</i> , 2020, 9, 49-55.	2.1	1
1269	Auricular therapy for polycystic ovary syndrome. <i>Medicine (United States)</i> , 2020, 99, e23396.	1.0	3
1270	Divergences in Clinical, Anthropometric, Metabolic, and Hormonal Parameters among Different Phenotypes of Polycystic Ovary Syndrome Presenting at Endocrinology Outpatient Departments: A Multicenter Study from Bangladesh. <i>Journal of Human Reproductive Sciences</i> , 2020, 13, 277.	0.9	3
1271	Polycystic Ovarian Syndrome. , 2020, , 253-274.		0
1272	Thyroid Disorders in Women with Polycystic Ovary Syndrome. <i>Journal of Biosciences and Medicines</i> , 2020, 08, 128-141.	0.2	0
1274	Prevalence of Cutaneous Disorders in Patients with Polycystic Ovary Syndrome. <i>Open Journal of Obstetrics and Gynecology</i> , 2020, 10, 1246-1264.	0.2	0
1276	Resistance to the Insulin and Elevated Level of Androgen: A Major Cause of Polycystic Ovary Syndrome. <i>Frontiers in Endocrinology</i> , 2021, 12, 741764.	3.5	45
1277	The effect of l-carnitine supplementation on insulin resistance, sex hormone-binding globulin and lipid profile in overweight/obese women with polycystic ovary syndrome: a randomized clinical trial. <i>European Journal of Nutrition</i> , 2022, 61, 1199-1207.	3.9	13
1279	Assessment of the Obese Child or Adolescent. , 2014, , 287-304.		0
1280	33. Hypocaloric diets in overweight and obese patients with polycystic ovary syndrome. , 0, , 533-552.		0
1281	Polycystic ovary syndrome and non-alcoholic fatty liver disease: Matched pair or sporadic coexistence?. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2020, 74, 377-381.	0.1	0
1282	Effects of salubrinal on ER stress in an experimental model of polycystic ovary syndrome. <i>Ultrastructural Pathology</i> , 2020, 44, 422-435.	0.9	1
1283	Prevalence of acne vulgaris among women with polycystic ovary syndrome: a systematic review and meta-analysis. <i>Gynecological Endocrinology</i> , 2021, 37, 392-405.	1.7	23
1284	Polycystic ovary syndrome: individualized approach to treatment. Literature review. <i>Reproductive Endocrinology</i> , 2020, .	0.3	1
1286	Is There Any Association Between Clinical and Biochemical Hyperandrogenism in Women With Female Pattern Hair Loss?. <i>Cureus</i> , 2020, 12, e11732.	0.5	2
1287	Obesity and the Risk of Infertility, Gestational Diabetes, and Type 2 Diabetes in Polycystic Ovary Syndrome. <i>Seminars in Reproductive Medicine</i> , 2020, 38, 342-351.	1.1	13
1289	The diagnosis of polycystic ovary syndrome in adolescents. <i>Reviews in Obstetrics and Gynecology</i> , 2011, 4, 45-51.	0.7	41

#	ARTICLE	IF	CITATIONS
1290	Diagnostic value of prostate-specific antigen in women with polycystic ovary syndrome. Journal of Research in Medical Sciences, 2011, 16, 999-1005.	0.9	14
1291	Genetic modeling of ovarian phenotypes in mice for the study of human polycystic ovary syndrome. American Journal of Translational Research (discontinued), 2013, 5, 15-20.	0.0	2
1292	Lack of Association of Vitamin D Receptor FokI (rs10735810) (C/T) and BsmI (rs1544410) (A/G) Genetic Variations with Polycystic Ovary Syndrome Risk: a Case-control Study from Iranian Azeri Turkish Women. MÃdica, 2012, 7, 303-8.	0.1	9
1293	Anti-mullerian and androgens hormones in women with polycystic ovary syndrome undergoing IVF/ICSI. Iranian Journal of Reproductive Medicine, 2013, 11, 883-90.	0.8	6
1294	INSR gene variation is associated with decreased insulin sensitivity in Iraqi women with PCOs. Iranian Journal of Reproductive Medicine, 2014, 12, 499-506.	0.8	8
1295	The polycystic ovary syndrome: an update on metabolic and hormonal mechanisms. Journal of Medicine and Life, 2015, 8, 142-5.	1.3	42
1296	HbA1c in Patients with Polycystic Ovary Syndrome: A Potential Marker of Inflammation. Journal of Reproduction and Infertility, 2015, 16, 203-6.	1.0	3
1297	Association of leptin and insulin resistance in PCOS: A case-controlled study. International Journal of Reproductive BioMedicine, 2017, 15, 423-428.	0.9	16
1299	Clinical, Biochemical, and Hormonal Associations in Female Patients with Acne: A Study and Literature Review. Journal of Clinical and Aesthetic Dermatology, 2017, 10, 18-24.	0.1	18
1300	Healthy eating index in women with polycystic ovary syndrome: A case-control study. International Journal of Reproductive BioMedicine, 2017, 15, 575-582.	0.9	5
1301	2D and 3D Trans-vaginal Sonography to Determine Cut-offs for Ovarian Volume and Follicle Number per Ovary for Diagnosis of Polycystic Ovary Syndrome in Indian Women. Journal of Reproduction and Infertility, 2018, 19, 146-151.	1.0	5
1302	Update on Management of Polycystic Ovarian Syndrome for Dermatologists. Indian Dermatology Online Journal, 2019, 10, 97-105.	0.5	3
1303	Effect of rNA interference on Oatp3a1 gene expression on biological characteristics and immune factors of ovarian granulosa cells in rats with PCOS. American Journal of Translational Research (discontinued), 2020, 12, 4659-4668.	0.0	0
1304	Polycystic Ovary Syndrome and Gender Identity. Yale Journal of Biology and Medicine, 2020, 93, 529-537.	0.2	8
1305	Polycystic ovarian syndrome in adolescents: From diagnostic criteria to therapeutic management. Acta Biomedica, 2020, 91, e2020085.	0.3	0
1306	The Comparative Effect of Hydro-Alcoholic Extract and Metformin on Morphometric Ovarian Follicles Disorders in Estradiol Valerate Induced-Polycystic Ovary Syndrome Rats. Galen, 2018, 7, e1045.	0.6	0
1307	Effect of Nutritional Supplementation on Oxidative Stress and Hormonal and Lipid Profiles in PCOS-Affected Females. Nutrients, 2021, 13, .	4.1	2
1308	The multifarious role of insulin in PCOS: From pathophysiology to therapeutic management. , 2022, , 39-54.		0

#	ARTICLE	IF	CITATIONS
1309	Defining PCOS: A syndrome with an intrinsic heterogeneous nature. , 2022, , 3-13.		4
1310	The pathogenic role of androgen excess in PCOS. , 2022, , 55-71.		0
1311	A landscape analysis of the potential role of polyphenols for the treatment of Polycystic Ovarian Syndrome (PCOS). Phytomedicine Plus, 2022, 2, 100161.	2.0	13
1312	Management of Acne Vulgaris. JAMA - Journal of the American Medical Association, 2021, 326, 2055.	7.4	116
1313	Anti-Müllerian Hormone in Pathogenesis, Diagnostic and Treatment of PCOS. International Journal of Molecular Sciences, 2021, 22, 12507.	4.1	30
1314	<i>Astragalus hamosus</i> Acts as an Insulin Sensitizer in the Treatment of Polycystic Ovary Syndrome Rat Models by Affecting <i>IRS1</i> Expression. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2022, 22, 348-356.	1.2	3
1315	Profile of Daughters and Sisters of Women with Polycystic Ovary Syndrome: The Role of Probandâ€™s Glucose Tolerance. Journal of Clinical Endocrinology and Metabolism, 2021, , .	3.6	4
1319	Prevalence of Polycystic Ovarian Syndrome in Young Adult Unmarried Females Attending Zagazig University Hospital Outpatient Clinic. The Egyptian Journal of Hospital Medicine, 2020, 81, 2152-2159.	0.1	1
1321	Effect of Nutritional Supplementation on Oxidative Stress and Hormonal and Lipid Profiles in PCOS-Affected Females. Nutrients, 2021, 13, 2938.	4.1	27
1322	Dietary Patterns and Polycystic Ovary Syndrome: a Systematic Review. MÃ  dica, 2021, 16, 516-521.	0.1	9
1323	An overview of polycystic ovary syndrome in aging women. Journal of the Turkish German Gynecology Association, 2021, 22, 326-333.	0.6	4
1325	Multomics Analysisâ€™Based Biomarkers in Diagnosis of Polycystic Ovary Syndrome. Reproductive Sciences, 2023, 30, 1-27.	2.5	7
1326	Polycystic Ovary Syndrome Phenotypes and Infertility Treatment. , 0, , .		1
1327	Deconstructing a Syndrome: Genomic Insights Into PCOS Causal Mechanisms and Classification. Endocrine Reviews, 2022, 43, 927-965.	20.1	75
1328	Prevalence of ocular anomalies is increased in women with polycystic ovary syndromeâ€™exploration of association with PAX6 genotype. Ophthalmic Genetics, 2022, 43, 340-343.	1.2	2
1329	Adiponectin levels and its relation with insulin secretion and insulin sensitivity in a group of sub-Saharan African women with polycystic ovary syndrome. BMC Research Notes, 2022, 15, 24.	1.4	0
1330	Does metformin improve reproduction outcomes for non-obese, infertile women with polycystic ovary syndrome? Meta-analysis and systematic review. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2022, 271, 38-62.	1.1	13
1331	Endometrial hyperplasia in asymptomatic subfertile population. Journal of Gynecology Obstetrics and Human Reproduction, 2022, 51, 102337.	1.3	1

[illegible]

#	ARTICLE	IF	CITATIONS
1352	Comparison of health-related quality of life in different polycystic ovary syndrome phenotypes: A cross-sectional study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2022, 271, 189-194.	1.1	2
1353	Effects of clinical and metabolic variables and hormones on the expression of immune protein biomarkers in the endometrium of women with polycystic ovary syndrome and normal-cycling controls. <i>Gynecological Endocrinology</i> , 2022, 38, 508-515.	1.7	5
1354	Reduced cardiovascular risks in women with endometriosis or polycystic ovary syndrome carrying a common functional <i>IGF1R</i> variant. <i>Human Reproduction</i> , 2022, , .	0.9	1
1355	Updated meta-analysis on the diagnostic accuracy of serum anti-Müllerian hormone in polycystic ovary syndrome involving 13 509 subjects. <i>Journal of Obstetrics and Gynaecology Research</i> , 2022, 48, 2162-2174.	1.3	6
1356	Autoimmunity to the Follicle-Stimulating Hormone Receptor (FSHR) and Luteinizing Hormone Receptor (LHR) in Polycystic Ovarian Syndrome. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13667.	4.1	7
1357	Clinical Value of Serum Levels of 11-Oxygenated Metabolites of Testosterone in Women With Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2047-e2055.	3.6	9
1358	The effects of statins on hyperandrogenism in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. <i>Reproductive Biology and Endocrinology</i> , 2021, 19, 189.	3.3	8
1359	Challenges in Establishing a Relevant Model of Polycystic Ovary Syndrome in Rats – A Mini Review. <i>Serbian Journal of Experimental and Clinical Research</i> , 2021, .	0.1	0
1362	Prevalence, incidence and years lived with disability due to polycystic ovary syndrome in 204 countries and territories, 1990–2019. <i>Human Reproduction</i> , 2022, 37, 1919-1931.	0.9	17
1363	Classification of Polycystic Ovary Syndrome Based on Correlation Weight Using Machine Learning. <i>Advances in Medical Technologies and Clinical Practice Book Series</i> , 2022, , 150-176.	0.3	2
1366	Impact of pharmacological interventions on biochemical hyperandrogenemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials. <i>Archives of Gynecology and Obstetrics</i> , 2022, , 1.	1.7	0
1367	Association of FTO gene variant rs9939609 with hyperandrogenemia and fasting glucose levels in South Indian women with polycystic ovarian syndrome. <i>Egyptian Journal of Medical Human Genetics</i> , 2022, 23, .	1.0	1
1374	Sodium-glucose cotransporter-2 inhibitors for improving endocrine and metabolic profiles in overweight and obese individuals with polycystic ovary syndrome: a meta-analysis protocol. <i>BMJ Open</i> , 2022, 12, e058260.	1.9	0
1375	Benefits of using a microencapsulated vitamin D delivery system in women with polycystic ovary syndrome. <i>European Journal of Hospital Pharmacy</i> , 2021, , ejhpharm-2021-002967.	1.1	2
1378	Update on management of polycystic ovarian syndrome for dermatologists. <i>Indian Dermatology Online Journal</i> , 2019, 10, 97.	0.5	23
1379	Exercise interventions in women with Polycystic Ovary Syndrome. , 2022, , 273-286.		0
1381	Diagnosis and management of polycystic ovary syndrome: Perspectives of clinicians in Singapore. <i>Annals of the Academy of Medicine, Singapore</i> , 2022, 51, 204-212.	0.4	3
1382	Correlation of vitamin D with clinical, biochemical and anthropometrical parameters of PCOS patients. <i>International Journal of Health Sciences</i> , 0, , 6608-6617.	0.1	0

#	ARTICLE	IF	CITATIONS
1383	Polycystic ovary syndrome in Singapore. <i>Annals of the Academy of Medicine, Singapore</i> , 2022, 51, 198-200.	0.4	1
1384	Burden of polycystic ovary syndrome in the Middle East and North Africa region, 1990â€“2019. <i>Scientific Reports</i> , 2022, 12, 7039.	3.3	11
1385	Hyperandrogenism and Polycystic ovary syndrome: Effects in pregnancy and offspring development. <i>WIREs Mechanisms of Disease</i> , 2022, 14, e1558.	3.3	8
1386	Insulin resistance and idiopathic hirsutism: a systematic review, meta-analysis, and meta-regression. <i>Journal of Cosmetic Dermatology</i> , 2022, , .	1.6	3
1387	The Classification of Polycystic Ovary Syndrome Informed by the International Guideline 2018. , 2022, , 45-51.		0
1388	The prevalence and phenotypic manifestations of polycystic ovary syndrome (PCOS) among infertile Sudanese women: a cross-sectional study. <i>BMC Women's Health</i> , 2022, 22, 165.	2.0	7
1389	Endocrine Disorders and the Skin. , 2016, , 540-556.e3.		0
1390	Family history of menstrual irregularity or diabetes mellitus enhances the susceptibility to polycystic ovary syndrome among subjects harboring rs7903146 genetic variant of TCF7L2. <i>Journal of Diabetes and Metabolic Disorders</i> , 2022, 21, 769-776.	1.9	2
1391	Challenges in diagnosis and understanding of natural history of polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2022, 97, 165-173.	2.4	13
1392	ComparaÃ§Ã£o do efeito da suplementaÃ§Ã£o de vitamina D e metformina nos sintomas da sÃndrome dos ovÃrios policÃsticos. <i>Research, Society and Development</i> , 2022, 11, e18611729950.	0.1	0
1393	Key Genes Associated With Non-Alcoholic Fatty Liver Disease and Polycystic Ovary Syndrome. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, .	3.5	12
1394	Interplay between PCOS and microbiome: The road less travelled. <i>American Journal of Reproductive Immunology</i> , 2022, 88, .	1.2	5
1395	Spironolactone Versus Oral Contraceptive Pills in the Treatment of Adolescent Polycystic Ovarian Syndrome: A Systematic Review. <i>Cureus</i> , 2022, , .	0.5	1
1396	Serum anti-MÃ¼llerian hormone as a predictor of polycystic ovarian syndrome among women of reproductive age. <i>BMC Women's Health</i> , 2022, 22, .	2.0	8
1397	Polycystic Ovary Syndrome Phenotype D Versus Functional Hypothalamic Amenorrhea With Polycystic Ovarian Morphology: A Retrospective Study About a Frequent Differential Diagnosis. <i>Frontiers in Endocrinology</i> , 2022, 13, .	3.5	9
1398	Female Infertility. , 2022, , 281-301.		1
1399	Divergent Associations Between Serum Androgens and Ovarian Reserve Markers Revealed in Patients With Polycystic Ovary Syndrome. <i>Frontiers in Endocrinology</i> , 0, 13, .	3.5	3
1400	Hair cortisol in polycystic ovary syndrome. <i>Scientific Reports</i> , 2022, 12, .	3.3	2



#	ARTICLE	IF	CITATIONS
1401	High androgen concentrations in follicular fluid of polycystic ovary syndrome women. <i>Reproductive Biology and Endocrinology</i> , 2022, 20, .	3.3	9
1402	Diagnostic value of anti-Mullerian hormone in adolescent girls with polycystic ovary syndrome. <i>MAÄ¼narodnj EndokrinologÄ¼nj Ä½urnal</i> , 2022, 18, 163-168.	0.4	0
1403	Derailed peripheral circadian genes in polycystic ovary syndrome patients alters peripheral conversion of androgens synthesis. <i>Human Reproduction</i> , 0, , .	0.9	8
1404	General infertility workup in times of high assisted reproductive technology efficacy. <i>Fertility and Sterility</i> , 2022, 118, 8-18.	1.0	4
1405	Reconsidering the Polycystic Ovary Syndrome (PCOS). <i>Biomedicines</i> , 2022, 10, 1505.	3.2	15
1406	Updates on Molecular Targets and Epigenetic-Based Therapies for PCOS. <i>Reproductive Sciences</i> , 2023, 30, 772-786.	2.5	6
1407	The stimulation of ovulation and endometrial carcinogenesis: possible relationship and study prospects (literature review). V F Snegirev <i>Archives of Obstetrics and Gynecology</i> , 2022, 9, 73-81.	0.1	0
1408	Dysglycemia screening with oral glucose tolerance test in adolescents with polycystic ovary syndrome and relationship with obesity. <i>BMC Endocrine Disorders</i> , 2022, 22, .	2.2	1
1409	Polycystic Ovary Syndrome Triggers Atrial Conduction Disorders: A Systematic Review and Meta-Analysis. <i>European Journal of Investigation in Health, Psychology and Education</i> , 2022, 12, 802-813.	1.9	1
1410	Implications of endocrine-disrupting chemicalsÄ¼on polycystic ovarian syndrome:Ä¼A comprehensive review. <i>Environmental Science and Pollution Research</i> , 2022, 29, 58484-58513.	5.3	2
1411	Acupuncture for polycystic ovary syndrome â A cross-sectional survey of clinical practice amongst acupuncturists trained in reproductive medicine. <i>European Journal of Integrative Medicine</i> , 2022, 54, 102161.	1.7	0
1412	Biomechanical forces and signals operating in the ovary during folliculogenesis and their dysregulation: implications for fertility. <i>Human Reproduction Update</i> , 2023, 29, 1-23.	10.8	19
1413	Female sexual behavior is disrupted in a preclinical mouse model of PCOS via an attenuated hypothalamic nitric oxide pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	8
1414	Key signalling pathways underlying the aetiology of polycystic ovary syndrome. <i>Journal of Endocrinology</i> , 2022, , .	2.6	3
1415	Discovery of immune-related diagnostic biomarkers and construction of diagnostic model in varies polycystic ovary syndrome. <i>Archives of Gynecology and Obstetrics</i> , 2022, 306, 1607-1615.	1.7	8
1416	Metformin Improves the Hepatic Steatosis Index in Non-Obese Patients with Polycystic Ovary Syndrome. <i>Journal of Clinical Medicine</i> , 2022, 11, 4294.	2.4	3
1417	Abnormal Endometrial Receptivity and Oxidative Stress in Polycystic Ovary Syndrome. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	19
1418	Putative Complementary Compounds to Counteract Insulin-Resistance in PCOS Patients. <i>Biomedicines</i> , 2022, 10, 1924.	3.2	5



#	ARTICLE	IF	CITATIONS
1419	Hirsutism, Normal Androgens and Diagnosis of PCOS. <i>Diagnostics</i> , 2022, 12, 1922.	2.6	11
1421	Criteria for Diagnosis of Polycystic Ovary Syndrome during Adolescence: Literature Review. <i>Diagnostics</i> , 2022, 12, 1931.	2.6	9
1422	Comparative Evaluation of Aldose Reductase Inhibition in Polycystic Ovarian Syndromeâ€œInduced Rats. <i>Reproductive Sciences</i> , 0, , .	2.5	1
1424	Early diagnosis in polycystic ovary syndrome. <i>Nurse Practitioner</i> , 2022, 47, 18-24.	0.3	0
1425	Polycystic Ovarian Syndrome and Increased Risk of Female Cancers. , 2022, , .		1
1426	A study of retinal changes in women with polycystic ovarian syndrome. <i>Indian Journal of Ophthalmology</i> , 2022, 70, 3591.	1.1	0
1427	An update on polycystic ovary syndrome: A review of the current state of knowledge in diagnosis, genetic etiology, and emerging treatment options. <i>Women's Health</i> , 2022, 18, 174550572211179.	1.5	8
1428	A study on changes in hormonal disruption in polycystic ovary syndrome with advancing age and body mass index. <i>Biomedicine (India)</i> , 2022, 42, 461-468.	0.2	0
1429	Decreased Expression of Sam68 Is Associated with Insulin Resistance in Granulosa Cells from PCOS Patients. <i>Cells</i> , 2022, 11, 2821.	4.1	4
1430	Treatment with combined resveratrol and myoinositol ameliorates endocrine, metabolic alterations and perceived stress response in women with PCOS: a double-blind randomized clinical trial. <i>Endocrine</i> , 2023, 79, 208-220.	2.3	7
1431	Do Androgenic Pattern, Insulin State and Growth Hormone Affect Cardiorespiratory Fitness and Strength in Young Women with PCOS?. <i>Biomedicines</i> , 2022, 10, 2176.	3.2	0
1432	IL23 suppresses proliferation and promotes apoptosis of human granulosa-like tumor cell line KGN by targeting the androgen receptor signal pathway. <i>Gynecological Endocrinology</i> , 0, , 1-6.	1.7	1
1433	Communication in non-communicable diseases (NCDs) and role of immunomodulatory nutraceuticals in their management. <i>Frontiers in Nutrition</i> , 0, 9, .	3.7	0
1434	Depression, anxiety, body image scores, and sexual dysfunction in patients with polycystic ovary syndrome according to phenotypes. <i>Gynecological Endocrinology</i> , 2022, 38, 849-855.	1.7	7
1435	Better care for women with polycystic ovary syndrome â€œ a proposal for an international evidence based best practice framework to improve care. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 0, Publish Ahead of Print, .	2.3	1
1436	Distress response in granulosa cells of women affected by PCOS with or without insulin resistance. <i>Endocrine</i> , 2023, 79, 200-207.	2.3	3
1437	Diagnostic Value of Bile Acids and Fibroblast Growth Factor 21 in Women with Polycystic Ovary Syndrome. <i>Women S Health Reports</i> , 2022, 3, 803-812.	0.8	0
1438	Ovarian Volume as an Independent Marker for Metabolic Dysfunction in Women with Suspected Androgen Excess. <i>F&amp;S Reports</i> , 2022, , .	0.7	0

#	ARTICLE	IF	CITATIONS
1439	Therapeutic Investigation of Standardized Aqueous Methanolic Extract of Bitter Melon (Momordica) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Vitro and In Vivo Studies. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-14.	1.2	8
1440	Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome. The Cochrane Library, 2022, 2022, .	2.8	6
1441	Review of the effects of polycystic ovary syndrome on Cognition: Looking beyond the androgen hypothesis. Frontiers in Neuroendocrinology, 2022, 67, 101038.	5.2	3
1442	SÃNDROME DO OVÃRIO POLICÃSTICO ASSOCIADA Ã OBESIDADE: MECANISMOS FISIOPATOLÃ“GICOS E IMPLICAÃ“ES CLÃNICAS â€“ UMA REVISÃfO INTEGRATIVA. Recisatec, 2022, 2, e29188.	0.1	0
1443	Idiopathic hirsutism and metabolic status: A population-based prospective cohort study. Journal of Clinical Endocrinology and Metabolism, 0, , .	3.6	4
1444	A brief insight into the etiology, genetics, and immunology of polycystic ovarian syndrome (PCOS). Journal of Assisted Reproduction and Genetics, 2022, 39, 2439-2473.	2.5	32
1445	Can Red cell distribution width screen for metabolic abnormality in women with Polycystic Ovarian Syndrome?. Journal of Medical Investigation, 2022, 69, 191-195.	0.5	0
1446	Effectiveness of Moringa oleifera Leaves on TNF-Î± Expression, Insulin Levels, Glucose Levels and Follicle Count in Rattus norvegicus PCOS Model. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 0, Volume 15, 3255-3270.	2.4	8
1447	Prevalence of Polycystic Ovary Syndrome in Iranian Adolescent Girls Based on Adults and Adolescentsâ€™ Diagnostic Criteria in Mashhad City. Journal of Reproduction and Infertility, 0, , .	1.0	0
1448	Dual Heterozygous Mutations in CYP21A2 and CYP11B1 in a Case of Nonclassic Congenital Adrenal Hyperplasia. AACE Clinical Case Reports, 2022, 8, 271-274.	1.1	2
1449	Abnormal uterine bleeding patterns determined through menstrual tracking among participants in the Apple Womenâ€™s Health Study. American Journal of Obstetrics and Gynecology, 2023, 228, 213.e1-213.e22.	1.3	1
1450	Screening target genes for the treatment of PCOS via analysis of single-cell sequencing data. Annals of Medicine, 2022, 54, 2975-2989.	3.8	2
1451	CaracterÃsticas clÃnicas, hormonales, bioquÃmicas y prevalencia del SÃndrome de Ovario PoliquÃstico en mujeres del Eje Cafetero, Colombia, 2016-2020. Revista Colombiana De EndocrinologÃa, Diabetes & Metabolismo, 2022, 9, .	0.0	0
1452	Lipidomic biomarkers in polycystic ovary syndrome: An overview. Annales D'Endocrinologie, 2023, 84, 69-80.	1.4	1
1453	Compatible cutâ€off values for luteinizing hormone and the luteinizing hormone/follicleâ€stimulating hormone ratio in diagnostic criteria of the Japan Society of Obstetrics and Gynecology for polycystic ovary syndrome. Journal of Obstetrics and Gynaecology Research, 2023, 49, 253-264.	1.3	2
1454	Female pattern hair loss and polycystic ovarian syndrome: more than just hirsutism. Current Opinion in Endocrinology, Diabetes and Obesity, 2022, 29, 535-540.	2.3	2
1456	Autoimmune regulator (AIRE): Takes a hypoxiaâ€inducing factor 1A (HIF1A) route to regulate FOXP3 expression in PCOS. American Journal of Reproductive Immunology, 2023, 89, .	1.2	1
1458	Acne in Women. , 2022, , 73-119.		0

#	ARTICLE	IF	CITATIONS
1459	Role of C type natriuretic peptide in polycystic ovary syndrome. International Journal of Gynecology and Obstetrics, 0, , .	2.3	0
1460	Propolis protects ovarian follicular reserve and maintains the ovary against polycystic ovary syndrome (PCOS) by attenuating degeneration of zona pellucida and fibrous tissue. Biochemical and Biophysical Research Communications, 2022, 636, 97-103.	2.1	3
1461	Correlations between salivary- and blood-derived gonadal hormone assessments and implications for inclusion of female participants in research studies. American Journal of Physiology - Heart and Circulatory Physiology, 2023, 324, H33-H46.	3.2	2
1462	Polycystic ovary syndrome: Identification of novel and hub biomarkers in the autophagy-associated mRNA-miRNA-lncRNA network. Frontiers in Endocrinology, 0, 13, .	3.5	3
1463	The alterations of circulating mucosal-associated invariant T cells in polycystic ovary syndrome. Frontiers in Endocrinology, 0, 13, .	3.5	1
1465	Polycystic Ovary Syndrome: An Updated Overview Foregrounding Impacts of Ethnicities and Geographic Variations. Life, 2022, 12, 1974.	2.4	5
1467	Comparison of Clinical, Biochemical, and Sonological Parameters in Adolescents with and without Polycystic Ovarian Syndrome. Annals of the National Academy of Medical Sciences (India), 0, , .	0.3	0
1468	Asprosin levels in women with and without the polycystic ovary syndrome: a systematic review and meta-analysis. Gynecological Endocrinology, 2023, 39, .	1.7	2
1470	Squeezing the eggs to grow: The mechanobiology of mammalian folliculogenesis. Frontiers in Cell and Developmental Biology, 0, 10, .	3.7	10
1471	The diagnostic performance of antimullerian hormone for polycystic ovarian syndrome and polycystic ovarian morphology. Archives of Gynecology and Obstetrics, 2023, 307, 1083-1090.	1.7	2
1474	Alpha-Lipoic Acid and Glucose Metabolism: A Comprehensive Update on Biochemical and Therapeutic Features. Nutrients, 2023, 15, 18.	4.1	11
1475	The Burden of Non-Alcoholic Fatty Liver Disease in Adolescents with Polycystic Ovary Syndrome: A Caseâ€“Control Study. Journal of Clinical Medicine, 2023, 12, 557.	2.4	5
1476	Polycystic ovary syndrome and adipose tissue. Annales D'Endocrinologie, 2023, 84, 308-315.	1.4	5
1477	Global trends in polycystic ovary syndrome research: A 10-year bibliometric analysis. Frontiers in Endocrinology, 0, 13, .	3.5	2
1478	Women With Polycystic Ovary Syndrome: A Review of Susceptibility to Type 2 Diabetes. Cureus, 2023, , .	0.5	0
1480	PCONet: A Convolutional Neural Network Architecture to Detect Polycystic Ovary Syndrome (PCOS) from Ovarian Ultrasound Images. , 2022, , .		6
1481	Endocrine Disrupting Chemicals in Polycystic Ovary Syndrome: The Relevant Role of the Theca and Granulosa Cells in the Pathogenesis of the Ovarian Dysfunction. Cells, 2023, 12, 174.	4.1	11
1482	Are Phenotypes of PCOS and Vitamin D Levels Interlinked. Annals of SBV, 2022, 11, 33-35.	0.1	0

#	ARTICLE	IF	CITATIONS
1483	Hormonal and Metabolic Factors Influence the Action of Progesterone on the Endometrium of Women with Polycystic Ovary Syndrome. <i>Diagnostics</i> , 2023, 13, 382.	2.6	5
1484	Modulating Morphological and Redox/Glycative Alterations in the PCOS Uterus: Effects of Carnitines in PCOS Mice. <i>Biomedicines</i> , 2023, 11, 374.	3.2	2
1486	Rotterdam, Androgen Excess Society ve National Institutes of Health Kriterlerine Göre Tanı Alan Polikistik Over Sendromlu Hastaların Biyokimyasal Değerleri ve İnsülin Direncinin Karşılaştırılması. <i>Turk Medical Journal</i> ; 2023, 5, 25-30.	2.0	1
1487	Prevalence of polycystic ovary syndrome under NIH criteria among the tenth-grade Chinese schoolgirls in Guangzhou area: a cross-sectional epidemiological survey. <i>BMC Women's Health</i> , 2023, 23, .	2.0	1
1488	Anti-Mullerian Hormone-Based Phenotyping Identifies Subgroups of Women with Polycystic Ovary Syndrome with Differing Clinical and Biochemical Characteristics. <i>Diagnostics</i> , 2023, 13, 500.	2.6	1
1489	The "Asthma-Polycystic Ovary Overlap Syndrome" and the Therapeutic Role of Myo-Inositol. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6959.	4.1	3
1490	Low-dose spironolactone attenuates metabolic defects in the skeletal muscle of letrozole-induced hyperandrogenic female rats. <i>Nutrire</i> , 2023, 48, .	0.7	0
1491	Validation of circulating microRNAs miR-142-3p and miR-598-3p in women with polycystic ovary syndrome as potential diagnostic markers. <i>Human Reproduction</i> , 2023, 38, 951-960.	0.9	1
1492	The Significance of Plant-Based Foods and Intense Physical Activity on the Metabolic Health of Women with PCOS: A Priori Dietary-Lifestyle Patterns Approach. <i>Applied Sciences (Switzerland)</i> , 2023, 13, 2118.	2.5	2
1493	Prevalence of periodontal disease in patients with polycystic ovary syndrome in a tertiary centre at Kerala: A cross-sectional study. <i>Journal of Datta Meghe Institute of Medical Sciences University</i> , 2022, 17, 898.	0.1	0
1494	Reproduktive Gesundheit. , 2023, , 59-84.		0
1495	Frauengesundheit " Frauenmedizin. , 2023, , e1-e39.		0
1496	Past and present: a bibliometric study on polycystic ovary syndrome. <i>Journal of Ovarian Research</i> , 2023, 16, .	3.0	3
1497	Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome. <i>F&amp;S Reports</i> , 2023, 4, 206-212.	0.7	1
1498	A Distinctive Explainable Machine Learning Framework for Detection of Polycystic Ovary Syndrome. <i>Applied System Innovation</i> , 2023, 6, 32.	4.6	26
1499	Comprehensive Management of Polycystic Ovary Syndrome: Effect of Pharmacotherapy, Lifestyle Modification, and Enhanced Adherence Counseling. <i>Cureus</i> , 2023, , .	0.5	1
1500	Analysis of the effect of hashimoto's thyroiditis and insulin resistance on ovarian volume in patients with polycystic ovary syndrome. <i>BMC Women's Health</i> , 2023, 23, .	2.0	0
1501	Fasting Versus Non-Fasting Total Testosterone Levels in Women During the Childbearing Period. <i>Cureus</i> , 2023, , .	0.5	1

#	ARTICLE	IF	CITATIONS
1502	A prospective cohort study of infertility and cancer incidence. Fertility and Sterility, 2023, , .	1.0	1
1503	Women's Reproductive Milestones and Cardiovascular Disease Risk: A Review of Reports and Opportunities From the CARDIA Study. Journal of the American Heart Association, 2023, 12, .	3.7	5
1504	The Role of Serum Anti-Mullerian Hormone Measurement in the Diagnosis of Polycystic Ovary Syndrome. Diagnostics, 2023, 13, 907.	2.6	4
1505	Effects of androgen excess and body mass index on endothelial function in women with polycystic ovary syndrome. Journal of Applied Physiology, 2023, 134, 868-878.	2.5	4
1506	Recomendaciones para la medici3n de esteroides sexuales en la pr3ctica cl3nica. Documento de posicionamiento SEQC<sup>ML</sup>/SEEN/SEEP. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2023, 4, 61-69.	0.2	0
1507	Executive summary of the position statement of the Spanish Societies SEQCML/SEEN/SEEP. Recommendations for the measurement of sex steroids in clinical practice. Endocrinolog3a Diabetes Y Nutrici3n (English Ed ), 2023, 70, 103-109.	0.2	0
1508	Insight into Bone Metabolism and Skeletal Mass in Polycystic Ovary Syndrome. European Medical Journal Reproductive Health, 0, , 46-53.	1.0	3
1509	Recommendations for the measurement of sexual steroids in clinical practice. A position statement of SEQC<sup>ML</sup>/SEEN/SEEP. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2023, 4, 52-60.	0.2	3
1510	[Commentary] The Polyfollicular Anovulatory Hyperandrogenic Syndrome: A New Label for an Old Syndrome. Qeios, 0, , .	0.0	0
1511	Current Guidelines for Diagnosing PCOS. Diagnostics, 2023, 13, 1113.	2.6	23
1512	Health-related physical fitness in women with polycystic ovary syndrome versus controls: a systematic review and meta-analysis. Archives of Gynecology and Obstetrics, 2024, 309, 17-36.	1.7	0
1513	A Scoping Review of Ayurveda Studies in Women with Polycystic Ovary Syndrome. , 0, , .		2
1514	Polycystic Ovarian Syndrome. ISGE Series, 2023, , 95-121.	0.2	0
1515	A comparative study of insulin levels in lean versus obese polycystic ovarian syndrome patients. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 2023, 12, 893-897.	0.1	1
1516	Microbial composition across body sites in polycystic ovary syndrome: a systematic review and meta-analysis. Reproductive BioMedicine Online, 2023, 47, 129-150.	2.4	5
1517	Childhood, adolescent, and adulthood adiposity are associated with risk of PCOS: a Mendelian randomization study with meta-analysis. Human Reproduction, 2023, 38, 1168-1182.	0.9	9
1518	Diagnostic criteria for polycystic ovary syndrome. , 2024, , 61-74.		0
1519	Polycystic ovary syndrome phenotypes. , 2024, , 6-10.		0

#	ARTICLE	IF	CITATIONS
1520	Management of subfertility in polycystic ovary syndrome. , 2024, , 141-160.		0
1521	Introduction to polycystic ovary syndrome. , 2024, , 1-5.		0
1522	Risk of Gynecological Cancers in Women With Polycystic Ovary Syndrome and the Pathophysiology of Association. Cureus, 2023, , .	0.5	3
1523	Hormones and dry eye disease. Indian Journal of Ophthalmology, 2023, 71, 1276-1284.	1.1	7
1524	The clinical and biochemical significance of 11-oxygenated androgens in human health and disease. European Journal of Endocrinology, 2023, 188, R98-R109.	3.7	8
1525	Polycystic Ovary Syndrome: Pathophysiology and Controversies in Diagnosis. Diagnostics, 2023, 13, 1559.	2.6	2
1526	Practical considerations for diagnosis and treatment of polycystic ovary syndrome in adolescence “distilling guidelines into clinical practice. Current Opinion in Pediatrics, 0, Publish Ahead of Print, .	2.0	1
1527	Benefits of physical activity on reproductive health functions among polycystic ovarian syndrome women: a systematic review. BMC Public Health, 2023, 23, .	2.9	5
1528	Serum HMGB1 levels are independently associated with glucose clamp-derived measures of insulin resistance in women with PCOS. Journal of Endocrinological Investigation, 0, , .	3.3	0
1529	Evaluation of pregnancy and neonatal outcomes according to the phenotypic types of polycystic ovary syndrome: A prospective study. International Journal of Gynecology and Obstetrics, 2023, 163, 894-903.	2.3	1
1530	Sexual function in Chinese women with different clinical phenotypes of polycystic ovary syndrome. Gynecological Endocrinology, 2023, 39, .	1.7	1
1532	Targeting patients for early COVID-19 therapy; Pre-infection metabolic dysfunction, polycystic ovary syndrome and risk of severe disease in patients under 65: A Massachusetts community-based observational study. PLoS ONE, 2023, 18, e0287430.	2.5	0
1533	Testosterone associated blood pressure dysregulation in women with androgen excess polycystic ovary syndrome. American Journal of Physiology - Heart and Circulatory Physiology, 0, , .	3.2	1
1534	Polycystic Ovary Syndrome (PCOS): Clinical Features, Risk Factors, Biomarkers, Treatment, and Therapeutic Strategies. , 2023, , 197-229.		0
1535	Endocrine. , 2023, , 107-203.		0
1536	Factors associated with self-report of polycystic ovary syndrome in the Coronary Artery Risk Development in Young Adults study (CARDIA). BMC Women's Health, 2023, 23, .	2.0	1
1537	Depression and anxiety in adolescents and young women with polycystic ovary syndrome: a systematic review and meta-analysis. International Journal of Adolescent Medicine and Health, 2023, 35, 233-242.	1.3	3
1538	Quality of life improvements after bariatric surgery in reproductive age women with and without PCOS: a cohort study. Minerva Obstetrics and Gynecology, 2023, 75, .	1.0	1

#	ARTICLE	IF	CITATIONS
1539	Pathophysiology and Nutritional Approaches in Polycystic Ovary Syndrome (PCOS): A Comprehensive Review. Current Nutrition Reports, 2023, 12, 527-544.	4.3	4
1540	Clinical Phenotypes of PCOS: a Cross-Sectional Study. Reproductive Sciences, 2023, 30, 3261-3272.	2.5	5
1541	Comparing Literature- and Subreddit-Derived Laboratory Values in Polycystic Ovary Syndrome (PCOS): Validation of Clinical Data Posted on PCOS Reddit Forums. JMIR Formative Research, 0, 7, e44810.	1.4	1
1542	Analysis Of Irregular Menstrual Cycle And Its Consequences. , 2023, , .		0
1543	Serum and follicular fluid levels of soluble receptor for advanced glycation end-products in women with and without polycystic ovary syndrome. Journal of Ovarian Research, 2023, 16, .	3.0	0
1544	Probiotics as Potential Remedy for Restoration of Gut Microbiome and Mitigation of Polycystic Ovarian Syndrome. , 2023, , 1-33.		0
1545	Maternal androgen excess increases the risk of metabolic syndrome in female offspring in their later life: A long-term population-based follow-up study. Archives of Gynecology and Obstetrics, 0, , .	1.7	1
1546	Influence of hsCRP Parameter on the Occurrence of Metabolic Syndrome in Patients with Polycystic Ovary Syndrome. Biomedicines, 2023, 11, 1953.	3.2	2
1547	Myoinositol Versus Metformin in the Treatment of Polycystic Ovarian Syndrome: A Systematic Review. Cureus, 2023, , .	0.5	0
1548	Probiotics and Polycystic Ovary Syndrome: A Perspective for Management in Adolescents with Obesity. Nutrients, 2023, 15, 3144.	4.1	2
1549	The serum steroid signature of PCOS hints at the involvement of novel pathways for excess androgen biosynthesis. Journal of Steroid Biochemistry and Molecular Biology, 2023, 233, 106366.	2.5	3
1550	Individualized lifestyle intervention in PCOS women (IPOS): a study protocol for a multicentric randomized controlled trial for evaluating the effectiveness of an individualized lifestyle intervention in PCOS women who wish to conceive. Trials, 2023, 24, .	1.6	1
1551	Hyperandrogenism and Its Possible Effects on Endometrial Receptivity: A Review. International Journal of Molecular Sciences, 2023, 24, 12026.	4.1	3
1552	Einführung in biologische und psychobiologische Aspekte des PCOS. , 2023, , 1-39.		0
1553	Auswirkungen von Testosteron auf Aspekte der Psychologie. , 2023, , 109-137.		0
1554	Insulinresistenz, Diabetes, schlechte Laune und Essanfälle. , 2023, , 139-159.		0
1556	Interleukin 10 (IL-10) gene variants and haplotypes in Tunisian women with polycystic ovary syndrome (PCOS): a case-control study. Molecular Biology Reports, 0, , .	2.3	0
1557	Hypergonadism. , 2023, , 753-828.		0



#	ARTICLE	IF	CITATIONS
1558	How I Approach Hepatocellular Adenomas in Hormonally Distinct Populations: Time to Think Outside the (Contraceptive Pill) Box. American Journal of Gastroenterology, 2023, , .	0.4	0
1559	Efficacy and safety of anti-androgens in the management of polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials. EClinicalMedicine, 2023, 63, 102162.	7.1	4
1560	Effects of resveratrol on polycystic ovarian syndrome: a systematic review and meta-analysis of randomized controlled trials. Endocrine, 0, , .	2.3	0
1561	Alleviative Effects of Adipose Tissue-derived Stem Cells and Î±-NETA on Metabolic, Biochemical, and Endocrine Parameters in a Letrozole-induced Rat Model of PCOS. Current Pharmaceutical Design, 2023, 29, 1929-1938.	1.9	1
1562	GC-MS analysis and in silico docking of constituents of Cinnamomum malabattrum against CYP450 17Î± and CYP450 19 (Aromatase)- Key targets for hyperandrogenism. Drug Research, 0, , .	1.7	0
1563	Brown adipose tissue in the form of innovative approach for polycystic ovary syndrome treatmentstill long time to reach clinical arena: a narrative review. MOJ Women S Health, 2023, 12, 31-39.	0.2	0
1564	Hyperandrogenism Protects Against High Blood Pressure by Nongenomic Mechanisms and Obesity Causes Hypertension in Females with Polycystic Ovary Syndrome. Endocrine Research, 0, , 1-11.	1.2	0
1565	Prevalence of polycystic ovary syndrome and its clinical and hormonal profile in young females with type 1 diabetes mellitus: experience from a teaching institution of India. Endocrine, 2023, 82, 303-310.	2.3	0
1566	The Effect of HNF1A Gene Polymorphism on the Risk of Polycystic Ovary Syndrome in a Sample of Iraqi Women. Revista Bionatura, 2023, 8, 1-8.	0.4	1
1567	Current Advances in Cellular Approaches for Pathophysiology and Treatment of Polycystic Ovary Syndrome. Cells, 2023, 12, 2189.	4.1	0
1568	Questioning PCOS phenotypes for reclassification and tailored therapy. Trends in Endocrinology and Metabolism, 2023, 34, 694-703.	7.1	7
1569	Polycystic ovary syndrome and thyroid disorder: a comprehensive narrative review of the literature. Frontiers in Endocrinology, 0, 14, .	3.5	4
1570	The Role of Different Methods in Defining Cardiometabolic Risk and Metabolic Syndrome in Women with Polycystic Ovary Syndrome. Life, 2023, 13, 1959.	2.4	1
1571	Hepatokines: the missing link in the development of insulin resistance and hyperandrogenism in PCOS?. Hormones, 2023, 22, 715-724.	1.9	2
1572	Westernâ€style diet in the presence of elevated circulating testosterone induces adipocyte hypertrophy without proinflammatory responses in rhesus macaques. American Journal of Reproductive Immunology, 2023, 90, .	1.2	0
1573	Metabolic Syndrome Rather Than Other Phenotypes in PCOS as a Predictive Indicator for Clinical Outcomes in IVF: Comprehensive Phenotypic Assessment across All PCOS Classifications. Journal of Clinical Medicine, 2023, 12, 5073.	2.4	1
1574	Preâ€polycystic ovary syndrome and polymenorrhoea as new facets of polycystic ovary syndrome (PCOS): Evidences from a single centre data set. Clinical Endocrinology, 2023, 99, 566-578.	2.4	0
1575	Ä°leri Glikasyon Son Ä°erÄ¼nleri (AGE) ve Polikistik Over Sendromu Ä°liÄ¼kisi. Ä°zÄ¼bed Ä°stanbul Sabahattin Zaim Ä°niversitesi Fen Bilimleri EnstitÄ¼sÄ¼ Dergisi, 0, , .	0.6	0

#	ARTICLE	IF	CITATIONS
1576	Clitoromegaly: principles of diagnostics and treatment. <i>Obstetrics, Gynecology and Reproduction</i> , 2023, 17, 462-475.	0.5	0
1577	Endocrinological and Metabolic Heterogeneity Is Low in Japanese Women With Polycystic Ovary Syndrome. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2024, 46, 102217.	0.7	0
1578	Prevalence of Polycystic Ovarian Syndrome and Its Link to Obesity in Adolescent Girls. <i>Cureus</i> , 2023, , .	0.5	0
1579	Knowing About PCOS among Iraqi Females in Some Collage of Tikrit Universities Students. , 2023, , 27-38.		0
1580	Diagnosing and Caring for the Adolescent Patient With Polycystic Ovary Syndrome. <i>Topics in Obstetrics &amp; Gynecology</i> , 2022, 42, 1-7.	0.0	0
1581	Hirsutism and Hypertrichosis. , 2023, , 417-427.		0
1582	Prevalence of polycystic ovary syndrome in a population of women of reproductive age using Rotterdam 2003 criteria (literature review). <i>Acta Biomedica Scientifica</i> , 2023, 8, 59-67.	0.2	0
1583	The Association of Anti-Mullerian Hormone and Infertility Hormonal Imbalance with Polycystic Ovarian Syndrome Among Iraqi Patients. <i>Pakistan Journal of Biological Sciences</i> , 2023, 26, 241-248.	0.5	0
1584	Genetics and Epigenetics of Polycystic Ovary Syndrome. , 0, , .		0
1585	Exercise Interventions for the Management of Polycystic Ovary Syndrome (PCOS): An Update of the Literature. , 0, , .		0
1586	Hirsutism and Polycystic Ovarian Morphology are the Most Frequent Components of Polycystic Ovary Syndrome in Women with Type 1 Diabetes. <i>Archives of Medical Research</i> , 2023, 54, 102895.	3.3	0
1587	Polycystic Ovary Syndrome: A Literature Review With a Focus on Diagnosis, Pathophysiology, and Management. <i>Cureus</i> , 2023, , .	0.5	0
1588	Metabolic dysregulation and gut dysbiosis linked to hyperandrogenism in female mice. <i>Endocrinology, Diabetes and Metabolism</i> , 2024, 7, .	2.4	0
1589	Dehydroepiandrosterone-induced polycystic ovary syndrome mouse model requires continous treatments to maintain reproductive phenotypes. <i>Journal of Ovarian Research</i> , 2023, 16, .	3.0	1
1590	Phytochemical-Based Study of Ethanolic Extract of <i>Saraca asoca</i> in Letrozole-Induced Polycystic Ovarian Syndrome in Female Adult Rats. <i>ACS Omega</i> , 2023, 8, 42586-42597.	3.5	1
1591	Hyperandrogenism drives ovarian inflammation and pyroptosis: A possible pathogenesis of PCOS follicular dysplasia. <i>International Immunopharmacology</i> , 2023, 125, 111141.	3.8	1
1592	Relationship Between Metabolic Syndrome and Polycystic Ovary Syndrome with Special Reference to C-Reactive Protein. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2023, , 102255.	0.7	0
1593	A review of nitric oxide and oxidative stress in typical ovulatory women and in the pathogenesis of ovulatory dysfunction in PCOS. <i>Reproductive Biology and Endocrinology</i> , 2023, 21, .	3.3	2

#	ARTICLE	IF	CITATIONS
1594	Pharmacological investigation of vitamin E with combined oral contraceptives on INHBA gene against PCOS that intricate through melatonin PKC pathway. Systems Biology in Reproductive Medicine, 2023, 69, 450-464.	2.1	0
1595	N6-methyladenosine demethylase FTO related to hyperandrogenism in PCOS via AKT pathway. Gynecological Endocrinology, 2023, 39, .	1.7	1
1596	Anthropometric, Metabolic, and Endocrine Parameters as Predictors of Estimated Average Glucose and Other Biomarkers of Dysglycemia in Women with Different Phenotypes of Polycystic Ovary Syndrome. Hormone and Metabolic Research, 0, , .	1.5	1
1597	Cell-molecular immune mechanisms in the pathogenesis of polycystic ovarian syndrome. , 2023, 19, 6-12.		0
1598	A Comparative Study on Different Machine Learning Algorithms to Detect PCOS. , 2023, , .		0
1599	Establishment and Analysis of an Artificial Neural Network Model for Early Detection of Polycystic Ovary Syndrome Using Machine Learning Techniques. Journal of Inflammation Research, 0, Volume 16, 5667-5676.	3.5	0
1600	The efficacy of <i>Linum usitatissimum</i> seeds to inhibit estrogen receptor as a natural therapy for PCOS: An in silico and in vitro analysis. Cell Biochemistry and Function, 2024, 42, .	2.9	0
1601	Inflammatory perspectives of polycystic ovary syndrome: role of specific mediators and markers. Middle East Fertility Society Journal, 2023, 28, .	1.5	2
1602	Beyond Counting Sheep: Exploring the Link between Polycystic Ovary Syndrome and Sleep Health. Seminars in Reproductive Medicine, 2023, 41, 045-058.	1.1	0
1603	Female sex steroids and epilepsy: Part 1. A review of reciprocal changes in reproductive systems, cycles, and seizures. Epilepsia, 0, , .	5.1	1
1604	Metabolome implies increased fatty acid utilization and histone methylation in the follicles from hyperandrogenic PCOS women. Journal of Nutritional Biochemistry, 2024, 125, 109548.	4.2	0
1605	Glucocorticoid receptor antagonism improves glucose metabolism in a mouse model of polycystic ovary syndrome. Journal of the Endocrine Society, 0, , .	0.2	0
1606	Is There a Difference in Hirsutism Score in Adolescents with Polycystic Ovary Syndrome on the Basis of Ethnicity and Race?. Journal of Pediatric and Adolescent Gynecology, 2023, , .	0.7	0
1607	An updated clinico-investigative approach to diagnosis of cutaneous hyperandrogenism in relation to adult female acne, female pattern alopecia & hirsutism a primer for dermatologists. Expert Review of Endocrinology and Metabolism, 2024, 19, 111-128.	2.4	0
1608	Effects and mechanisms of acupuncture on women related health. Frontiers of Medicine, 0, , .	3.4	0
1609	Polycystic ovary syndrome v.2023: Simplified diagnostic criteria for an East Asian phenotype. Annals of the Academy of Medicine, Singapore, 2023, 52, 669-678.	0.4	1
1610	Experiences of women living with Polycystic Ovary Syndrome: A pilot case-control, single-cycle, daily Menstrual Cycle Diary study during the SARS-CoV-2 pandemic. PLoS ONE, 2023, 18, e0296377.	2.5	0
1611	Causal relationship between PCOS and related sex hormones with oral inflammatory diseases: a bidirectional Mendelian randomization study. Frontiers in Endocrinology, 0, 14, .	3.5	0

#	ARTICLE	IF	CITATIONS
1612	Comparison of physical activity levels and dietary habits between women with polycystic ovarian syndrome and healthy controls of reproductive age: a case-control study. BMC Women's Health, 2024, 24, .	2.0	0
1613	Efficacy of antioxidant supplementation in improving endocrine, hormonal, inflammatory, and metabolic statuses of PCOS: a meta-analysis and systematic review. Food and Function, 2024, 15, 1779-1802.	4.6	0
1615	An Update on the Genetics of Polycystic Ovary Syndrome. Journal of Endocrinology & Reproduction, 0, , 217-240.	0.0	0
1616	Bisphenol A and polycystic ovary syndrome in human: A systematic review. International Journal of Gynecology and Obstetrics, 0, , .	2.3	0
1617	The Role of MicroRNA, Long Non-Coding RNA and Circular RNA in the Pathogenesis of Polycystic Ovary Syndrome: A Literature Review. International Journal of Molecular Sciences, 2024, 25, 903.	4.1	0
1619	Reduction in the Free Androgen Index in Overweight Women After Sixty Days of a Low Glycemic Diet. Experimental and Clinical Endocrinology and Diabetes, 2024, 132, 6-14.	1.2	0
1620	Polycystic ovary syndrome and its management: In view of oxidative stress. Biomolecular Concepts, 2024, 15, .	2.2	0
1621	Resistance and aerobic training increases genome-wide DNA methylation in women with polycystic ovary syndrome. Epigenetics, 2024, 19, .	2.7	0
1622	When one size does not fit all: Reconsidering PCOS etiology, diagnosis, clinical subgroups, and subgroup-specific treatments. Endocrine and Metabolic Science, 2024, 14, 100159.	1.6	0
1623	Predicting polycystic ovary syndrome with machine learning algorithms from electronic health records. Frontiers in Endocrinology, 0, 15, .	3.5	0
1624	The Effects of Myo-Inositol and D-Chiro-Inositol in a Ratio 40:1 on Hormonal and Metabolic Profile in Women with Polycystic Ovary Syndrome Classified as Phenotype A by the Rotterdam Criteria and EMS-Type 1 by the EGOI Criteria. Gynecologic and Obstetric Investigation, 2024, 89, 131-139.	1.6	0
1626	The Effectiveness of Myo-Inositol in Women With Polycystic Ovary Syndrome: A Prospective Clinical Study. Cureus, 2024, , .	0.5	0
1627	Determination of urinary androgens in women with polycystic ovary syndrome using LC-QqQ/MS and the application of thin film solid-phase microextraction (TF-SPME). Journal of Chromatography A, 2024, 1718, 464735.	3.7	0
1628	Is it useful to measure DHEAS levels in PCOS?. Annales D'Endocrinologie, 2024, 85, 95-99.	1.4	0
1629	Berberine alleviates inflammation in polycystic ovary syndrome by inhibiting hyaluronan synthase 2 expression. Phytomedicine, 2024, 128, 155456.	5.3	0
1630	ASSOCIATION OF POLYCYSTIC OVARY SYNDROME AND THYROID DYSFUNCTION AMONG REPRODUCTIVE WOMEN: A CROSS-SECTIONAL STUDY. Asian Journal of Pharmaceutical and Clinical Research, 0, , 149-152.	0.3	0
1631	Metformin versus metformin plus pioglitazone on gonadal and metabolic profiles in normal-weight women with polycystic ovary syndrome: a single-center, open-labeled prospective randomized controlled trial. Journal of Ovarian Research, 2024, 17, .	3.0	0
1632	Letrozole induced a polycystic ovary syndrome model in zebrafish by interfering with the hypothalamic-pituitary-gonadal axis. Environmental Pollution, 2024, 347, 123723.	7.5	0

#	ARTICLE	IF	CITATIONS
1633	Role of the mitophagyâ€apoptosis axis in the pathogenesis of polycystic ovarian syndrome. Journal of Obstetrics and Gynaecology Research, 2024, 50, 775-792.	1.3	0
1634	Prevalence and Diagnosis of PCOS Using Electronic Health Records: A Scoping Review and a Database Analysis. International Journal of Environmental Research and Public Health, 2024, 21, 354.	2.6	0
1635	Psychological symptoms and brain activity alterations in women with PCOS and their relation to the reduced quality of life: a narrative review. Journal of Endocrinological Investigation, 0, , .	3.3	0
1636	Nonhemodynamic Components of EVA: Polycystic Ovary Syndrome (PCOS). , 2024, , 261-276.		0
1637	PCOS phenotype focus: phenotype D under the magnifying glass. Archives of Gynecology and Obstetrics, 0, , .	1.7	0
1638	Immune dysfunction mediated by the competitive endogenous RNA network in fetal side placental tissue of polycystic ovary syndrome. PLoS ONE, 2024, 19, e0300461.	2.5	0
1639	Ovarian Morphology in Non-Hirsute, Normo-Androgenic, Eumenorrhic Premenopausal Women from a Multi-Ethnic Unselected Siberian Population. Diagnostics, 2024, 14, 673.	2.6	0